Determining face, predictive, construct validity and novel receptor targets in a spontaneous compulsive-like mouse model by Mitra, Swarup
DETERMINING FACE, PREDICTIVE, CONSTRUCT VALIDITY AND NOVEL RECEPTOR 
TARGETS IN A SPONTANEOUS COMPULSIVE-LIKE MOUSE MODEL
By
Swarup Mitra, B.S, M.S
A Dissertation Submitted in Partial Fulfillment of the Requirements
for the Degree of
Doctor of Philosophy 
in
Biochemistry and Neuroscience
University of Alaska Fairbanks 
August 2017
APPROVED:
Abel Bult-Ito, Committee Chair 
Kelly Drew, Committee Member 
Lawrence K. Duffy, Committee Member 
Kriya Dunlap, Committee Member 
Thomas Green, Chair
Department of Chemistry and Biochemistry 
Paul Layer, Dean
College of Natural Science and Mathematics 
Michael Castellini,
Dean of the Graduate School
Abstract
Obsessive-compulsive disorder (OCD) is one of the most prevalent neuropsychiatric disorders 
with no known etiology. Genetic variation, sex differences and physiological stages, such as 
pregnancy, postpartum and menopause in females, are important factors that are thought to 
modulate the pathophysiology of the disorder. Deeper understanding of these factors and their 
role in modulating behaviors is essential to unraveling the complex clinical heterogeneity of 
OCD. Using a novel mouse model that exhibits a spontaneous compulsive-like phenotype, I 
investigated the role of strain differences, sex differences, ovarian sex hormones and 
postpartum lactation in influencing compulsive-like and affective behaviors. Due to the lack of 
definite neural substrates and first line therapeutic options for treatment resistant patients, I also 
probed into the role of positive allosteric modulation of nicotinic acetylcholine receptor subtype 
as a therapeutic target for translational prospects. The thesis showed several significant and 
novel findings. Strain and sex comparisons of the compulsive-like mouse strains (BIG1 and 
BIG2) showed that the behavioral outcomes and HPA axis response can be influenced by sex, 
genotype and sex by genotype interactions. Acute ovariectomy and behavioral assessments 
after one week, which mimics surgical menopause in humans, increased the compulsive-like 
behaviors in the BIG strains only. Acute ovariectomy also exacerbated anxiety-like behaviors in 
the compulsive-like BIG strains. This exacerbation of compulsive-like behaviors was restored 
only by estrogen and not progesterone, while estrogen and progesterone both restored anxiety­
like behaviors based on the strain and the type of behavioral assessments. Lactating 
postpartum compulsive-like female mice were protected against compulsive-like behaviors and 
showed enhanced responsiveness to selective serotonin reuptake inhibitors (SSRIs) compared 
to the non-lactating and the nulliparous females. Finally, acute and chronic administration of 
desformylflustrabromine (dFBr), a positive allosteric modulator of a4p2 nicotinic acetylcholine 
receptors, resulted in the attenuation of compulsive-like behaviors in the mouse model, while
iii
not affecting anxiety-like behaviors. The current thesis work therefore provides a foundation for 
further exploration of factors like strain, sex, physiological status and cholinergic receptor 
subtypes in mouse models to understand the neurobiology and behavioral correlates of OCD in 
humans.
iv
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Chapter 1: Overview and Research Aims
1.1 Background
1.1.1 Obsessive-Compulsive Disorder
Obsessive-compulsive disorder (OCD) is a frequently occurring neuropsychiatric 
disorder that impacts almost 2% of the US population (Ruscio et al., 2010) and has a life time 
prevalence of 1-3% making it the fourth most common psychiatric illness (Karno et al., 1988; 
Ruscio et al., 2010). It was first described as a psychiatric condition about 100 years ago (Janet 
and Raymond, 1903). The world health organization has indicated OCD to be the leading global 
cause of non-fatal illness (Ayuso-Mateos, 2006). Previously, OCD has been considered among 
the top 20 causes of years of life spent with disability for patients between 15-44 years old 
(Murray and Lopez, 1996). It has also been estimated that individuals with OCD spend an 
average of 17 years before being diagnosed and treated (Hollander and Weilgus-Kornwasser,
1997). This is mainly because patients are inclined to conceal their symptoms fearing they will 
appear crazy and seek medical attention only when other co-morbid conditions like anxiety and 
depression exacerbate the disorder (Abramowitz et al., 2009; Fullana et al., 2009). Ineffective 
identification of specific symptoms is also one of the reasons for delayed diagnosis (Marazziti et 
al., 2012).
Symptomatically, OCD is characterized by unwanted intrusive thoughts (obsessions) 
and repetitive behaviors (compulsions). Obsessions can be termed as an idea or impulse which 
can be characterized as recurrent, forceful and persistent that does not disappear despite 
attempts to ignore or suppress it. Compulsions on the other hand, are repetitive, perseverant 
and over indulgent acts in response to the obsessions (American Psychiatric Association, 2013; 
Grant, 2014). Compulsions are typically meant to neutralize the obsessive feelings (Grant, 
2014), but provide only transient relief and lead to reinforcement of the behaviors and
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continuation of the obsession compulsion cycle (Pauls et al., 2014). This significantly impacts 
human and social functioning, socio-economic status, family relationships and general quality of 
life (Fontenelle et al., 2010; Hollander et al., 2010). The age of onset ranges from early in 
childhood to adulthood (Pauls et al., 2014). Onset after 30 years of age is highly unusual 
(Jenike, 2004; Ruscio et al., 2010). Approximately 30-50% of the patients have onset of 
symptoms before 10 years of age indicating neurodevelopmental aspects to the disorder (Geller 
et al., 1998; Zohar, 1999; Nakatani et al., 2011). Interestingly, in childhood onset OCD, males 
are more commonly affected than females with a ratio of approximately 2:1 to 3:1 (males: 
females; Kalra and Swedo, 2009). This ratio however shifts to 1:1.4 among patients with onset 
during or after puberty. Though genetic linkage, candidate gene and genome wide association 
studies in humans (Goodman et al., 1990; Abelson et al., 2005; Shugart et al., 2006; Samuels et 
al., 2007; Hanna et al., 2007; Ross et al., 2011; Mathews et al., 2012; Stewart et al., 2013; 
Taylor., 2013) have indicated many genetic associations, the actual causative factor has been 
elusive (Grant, 2014). This could be attributed to the heterogeneous nature of the disorder.
1.1.2 Clinical Heterogeneity of OCD
While obsessions and compulsions are cardinal characteristics of OCD, the specific 
content of these obsessions and compulsions vary widely (Murphy et al., 2010). For example, 
contamination obsessions and subsequent cleaning compulsions are a common type of OCD 
symptoms, but the clinical expression of the contamination fear is broad (Pauls et al., 2014). 
Contamination fears or disgust can range from germs, dirt, events, place or an experience. On 
the other hand, some patients experience obsessions-only symptoms without any compulsive 
ritualistic behaviors. An example is that of fear of causing harm to others or self (Pauls et al., 
2014). Many studies use the Yale-Brown Obsessive Compulsive Scale (Y-BOCS scale) to 
clinically characterize and identify the occurrence and types of obsessive-compulsive symptoms 
(Goodman et al., 1989). The Y-BOCS is an ordinal scale that has a rating of 0-4 to score the
2
clinical severity with 0 being the least time spent on obsessions and compulsions and 4 being 
the most time spent (Pauls et al., 2014). Further enhancements to this scale involve the 
Dimensional Yale-Brown Obsessive Compulsive Scale (DY-BOCS) which categorizes OCD into 
6 distinct dimensions (Rosario-Campos et al., 2006). They are i) aggression/checking, ii) 
sexual/moral/religious, iii) symmetry/ordering/counting, iv) contamination/washing, v) hoarding 
and vi) others (Rosario-Campos et al., 2006; Pauls et al., 2014; Okada et al., 2015). In addition, 
researchers have divided OCD into subgroups based on familiality, gender, age of onset and 
comorbid patterns (Hasler et al., 2005; Miguel et al., 2005; Mataix-cols and van den Heuvel, 
2006; Catapano et al., 2010).
The most common comorbid disorders associated with OCD are depression and anxiety 
(Overbeek et al., 2002; Tukel et al., 2002; Torres et al., 2006; Boileau, 2011). Other less 
frequently observed comorbid symptoms include eating disorders, alcohol abuse, 
tricothillomania (compulsive hair pulling), body dysmorphic disorder, bipolar disorder and 
Tourette syndrome (Ferraro et al., 2009; Mancebo et al., 2009; D'Ambrosio et al., 2010; Murphy 
et al., 2010; Tyagi et al., 2015). Previously, OCD was categorized as an anxiety disorder in the 
DSM-III and DSM-IV manuals (American Psychiatric Association, 1994). However, the current 
version of DSM (DSM-V) declassifies OCD from anxiety disorders. DSM-V designates a new 
category called the OCRD (obsessive-compulsive related disorders) which includes OCD, body 
dysmorphic disorder, hoarding, trichothillomania, excoriation, substance/medication-induced 
OCD and related disorders (American Psychiatric Association, 2013).
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1.1.3 Etiology and Pathophysiology of OCD
1.1.3.1 Environmental and Genetic Factors
Like many other psychiatric disorders, environmental and genetic factors contribute to 
the etiology of OCD. A study (Hudziak et al., 2004) in 7-12 year old twins indicates additive 
genetic factors as the reason for 47-58% of the variance in obsessive-compulsive behaviors. 
The remaining variance is attributed to environmental influences. According to a study (Cath et 
al., 2008), environmental factors explain nearly half of the symptom persistence in boys and two 
third in girls. Some of the critical environmental factors contributing to the obsessive-compulsive 
phenomenology are low socio-economic status, over protected or neglected childhood (Cavedo 
and Parker, 1994) and lack of parental emotional warmth (Alonso et al., 2004). Childhood 
sexual abuse has also been shown to mediate OCD especially in women (Lochner et al., 2002). 
The role of religious beliefs on display and exacerbation of obsessions and compulsions has 
been controversial. Some studies have found a positive correlation (Abramowitz et al., 2004) 
while others have not (Assarian et al., 2006). In addition, perinatal risk factors such as extended 
labor and edema during pregnancy can increase the onset probability of the disorder 
(Vasconcelos et al., 2007). Other notable environmental factors include streptococcus 
infections, which exacerbate obsessive-compulsive symptoms (Boileau, 2011).
Family studies, segregation analysis studies, candidate gene studies and genome wide 
association studies have consistently reported and established heritability and genetic 
mechanisms as one of the important causative factors of OCD. Family studies have 
conclusively shown that early onset OCD has a familial basis (Pauls et al., 1995; Nestadt et al., 
2000). Family studies with adult probands have shown that OCD is familial with increased risk of 
occurrence among relatives of patients with childhood onset OCD (Fyer et al., 2005; Grabe et 
al., 2006; Black et al., 2013). Around 100 candidate gene studies have focused on the genetic 
variants predominantly within neurotransmitter pathways (Pauls et al., 2014). One of these
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candidate gene studies has shown that OCD can be associated with polymorphisms in 
serotonin system related genes such as 5HTTLPR (serotonin-transporter linked polymorphic 
region) and HTR2A (5-hydroxytryptophan receptor 2A) (Taylor et al., 2013). The same study 
also pinpointed genetic variations in monoamine oxidase and catechol-o methyl transferase 
genes only in male patients and dopamine system related genes like DAT-1 (Dopamine active 
transporter 1 gene) and DRD3 (Dopamine receptor D3) (Taylor et al., 2013). In addition, other 
genome wide association studies have found various genes that code for essential 
neurobiological substrates (Schweitzer et al., 2002; Perez-Torrado et al., 2006; Wieczorek et al., 
2010; Stewart et al., 2013), which are essential for neuronal transmission and plasticity, such as 
DLGAP1 (guanylate kinase-associated protein), BTBD3 (BTB domain containing protein 3) etc.
1.1.3.2 Neural Basis: Circuits and Function
A substantial number of neuroimaging, pharmacological and neuropsychological studies 
have facilitated a better understanding of the neural substrates and circuitry implicated in OCD 
(Pauls et al., 2014). One of the most prevailing neurocircuitry models thought to account for the 
pathophysiology of OCD has been the cortico-striato-thalamo-cortico (CSTC) circuit model first 
proposed by Saxena and Rauch (Saxena and Rauch, 2000). The fronto-striatal circuitry 
comprises of direct and indirect pathways. In normal individuals, the excitatory direct pathway is 
counteracted by the inhibitory indirect pathway forming a dynamic balance (Pauls et al., 2014). 
In OCD patients, there is dysregulation of this pathway leading to hyperactivation of the direct 
orbitofrontal-subcortical pathway (Saxena and Rauch, 2000). This seminal finding by Saxena 
and Rauch is based on prior studies that have shown increased activity in orbitofrontal cortex, 
caudate nucleus, globus pallidus and dorsal nucleus of the thalamus of OCD patients (Hoehn- 
Saric et al., 1991; Schwartz et al., 1996; Saxena et al., 1998). Further support for the CSTC 
hypothesis has come from functional connectivity studies that indicate abnormal prefrontal and 
striatal regions in patients (Harrison et al., 2009; Fitzgerald et al., 2011). Moreover, proton
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magnetic resonance spectroscopy studies (Brennan et al., 2013), optogenetic studies in animal 
models (Ahmari et al., 2013; Burguiere et al., 2013) and pharmacological treatment studies 
(Saxena et al., 2009; Freyer et al., 2011) have also corroborated the CSTC model. 
Neuropsychological studies have however provided inconclusive evidence on the target brain 
region (Kuelz et al., 2004; Abramovitch et al., 2012; Abramovitch et al., 2013). One of the 
outcomes of these neuropsychological studies is that, neural circuitries differ among OCD 
patients with symptom dimensions and therefore could have distinct and overlapping neural 
correlates (Van Den Heuvel et al., 2005).
1.1.3.3 Neurochemistry of OCD
Several converging lines of evidence point towards neurobiological mechanisms that 
contribute towards the etiology of OCD. Pharmacological and neurobiological studies on both 
humans and animal models have implicated central neurotransmitters, peptide and steroid 
systems in the pathophysiology of OCD (Pauls et al., 2010). Some of them are as follows:
i) Serotonergic hypothesis: Serotonin (5-HT) is a monoamine neurotransmitter 
biochemically derived from the amino acid tryptophan (Gonzalez-Flores et al., 2011). The B1-B9 
neurons of the raphe nuclei in the brainstem are the principal source of serotonin in the brain 
(Frazer and Hensler, 1999). The axons of these neurons reach out to the central nervous 
system forming a neurotransmitter system called the serotonergic system. The first evidence of 
serotonergic involvement in OCD was found in the 1960s when clomipramine, a tricyclic 
antidepressant with serotonin reuptake blocking properties showed anti-obsessional properties 
(Fernandez and Lopez-Ibor, 1967). Subsequently, many other studies (Goodman et al., 1989; 
Chouinard, 1990; Jenike et al., 1990; Greist et al., 1995; Mundo et al., 2001) corroborated this 
claim. These studies led to exhaustive examination of the serotonin system and its function in 
OCD patients. Studies on 5-HT levels in whole blood (Thoren et al., 1980; Zohar et al., 1987) 
and platelets (Hanna et al., 1991; Hanna et al., 1995) of OCD patients though not definitive,
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indicated serotonergic dysfunction. More evidence has come from pharmacological studies in 
which OCD patients were assessed after treatment with drugs like mCPP (Goodman et al.,
1995), fenfluramine (Hollander et al., 1988), buspirone (Norman et al., 1994), sumatripan (Zohar 
et al., 1996) that stimulate 5-HT transmission. These studies have however also been 
inconclusive since many patients experienced worsening of symptoms. This could be due to 
basal hyperactivity of the serotonergic neurotransmission as a result of either the hypoactivity of 
the presynaptic, or hyperactivity of the post synaptic 5-HT receptors (Blier and Montigny, 1999). 
The efficacy of the chronic SSRI treatment regimen in many OCD patients could be due to the 
desensitization of the 5-HT autoreceptors (Blier and Montigny, 1999). Despite the consistent 
effectiveness of SSRIs in treating a significant subgroup of clinical responders, no agreement 
could be reached on the theory of serotonergic dysfunction as the primary cause of OCD. 
Several studies have refuted the serotonergic abnormality as a probable mechanism of the 
disorder (Berney et al., 2011; Maron et al., 2012). Moreover, 40-60% of the patients do not 
respond to SSRIs reflecting heterogeneity in clinical response to these drugs. Hence, the 
serotonin hypothesis might hold true for a subgroup of patients but not universally for all OCD 
patients.
ii) Dopamine hypothesis: Dopamine (DA) is derived from the amino acid phenylalanine 
and is the simplest neurotransmitter in the catecholamine family (Beaulieu and Gainetdinov, 
2011). Dopamine projections reach to various regions of the brain that control executive 
functions, reward, motivation, reinforcement, motor control, etc. (Dayan and Balleine, 2002; 
Pierce and Kumaresan, 2006). Most important dopaminergic cell bodies with respect to OCD 
are those located in the ventral midbrain and consists of cell bodies A8 through A10. The 
nigrostriatal pathway consists of A9 cell bodies from substantia nigra pars compacta (SNc) to 
dorsal striatum and control voluntary movements (Hegarty et al., 2013). The A8 cell bodies 
project from ventral tegmental area (VTA) to nucleus accumbens in ventral striatum, while A10
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develop from retrobural field (RRF) to the prefrontal cortex (Tzschentke and Schmidt, 2000). 
Both A8 and A10 cell bodies from the mesocorticolimbic system which play an important role in 
emotion and reward (Tzschentke and Schmidt, 2000). Considerable evidence exists about 
certain subtypes of OCD being mediated by dopaminergic systems (Pauls et al., 1995). 
Tourette’s syndrome, a subtype of OCRD, is predominantly caused by dopaminergic 
abnormalities. This can be evidenced by the clinical response of patients to haloperidol and 
other dopamine antagonists (Shapiro et al., 1989). OCD patients with comorbid tic or Tourette’s 
syndrome respond poorly to first line therapies and get more relief from adjuvant treatment with 
dopamine or DA/5-HT blockers (Ravizza et al., 1995; Stein et al., 1997a). Further, results from 
other studies suggest the importance of dopamine in fronto-striatal circuitry (Klanker et al.,
2013), which is implicated in OCD. Deficiency in cognitive flexibility which includes reversal 
learning, task switching and attentional set shifting is often seen in OCD patients and is 
controlled by dopamine signaling (Chamberlain et al., 2006; Pauls et al., 2014). Dopamine 
depletion in brain regions like the caudate nucleus and orbitofrontal cortex leads to impairment 
in reversal learning and impaired extinction, respectively (Walker et al., 2009; Clarke et al.,
2011). Animal studies have also substantiated this claim especially in rodents that exhibit 
excessive self-grooming and anxiety phenotypes (Campbell et al., 1999a; Berridge et al., 2005).
iii) Glutamate abnormality: The glutamate link in OCD was first proposed by Maria 
Carlsson (Carlsson, 2000, 2001). This was based on theoretical reasoning that considered OCD 
symptoms, functions of the CSTC circuitry and glutamate physiology. This theory has garnered 
further support from various studies that involve modulation of the glutamatergic system to look 
for symptom alleviation (Feusner et al., 2009; Haghighi et al., 2013; Rodriguez et al., 2013; 
Poyurovsky et al., 2010; Hussain et al., 2015; Pittenger, 2015). In rodents, knocking out genes 
like DLGAP-3 (Disks large-associated protein 3) (Welch et al., 2007) and SLITRK5 (SlitrK 
proteins) (Shmelkov et al., 2010) have shown abnormality in glutamatergic transmission leading
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to expression of repetitive phenotypes, such as excessive grooming concomitant with anxiety. 
Treatment of these knockout mice with SSRIs has shown attenuation of these excessive 
behaviors indicating a possible relationship between serotonin and glutamate functionality 
(Welch et al., 2007; Shmelkov et al., 2010; Pauls et al., 2014). Excessive self-grooming has also 
been observed in glutamate transporter SLC1A1 knockout mice (Aoyama et al., 2006). Although 
these glutamatergic gene knockout studies suggest a role in OCD-like phenotypes, whether 
normal genetic variability in glutamatergic system plays a direct role remains to be elucidated.
iv) Peptide and steroid involvement: Several studies have pointed towards the involvement 
of hypothalamic peptides, such as oxytocin, vasopression and somatostatin in the 
pathophysiology of OCD (Salzberg and Swedo, 1992; Leckman et al., 1994b). However, further 
replications of these studies are required to understand their specific roles in the disorder 
because of contradictory evidence. One case study reported alleviation of OCD symptoms in 
patients treated with intranasal oxytocin (Ansseau, 1987), while other studies showed no effect 
(Epperson et al., 1996; den Boer and Westernberg, 1992). In addition, elevated levels of 
oxytocin have been seen in cerebrospinal fluid of OCD patients (Leckman et al., 1994a), while 
decreased activity has been hypothesized in autistic patients (Green et al., 2001). More animal 
studies are needed to better understand the role of these peptides in modulating neuronal 
circuitry that drive behavioral expressions seen in OCD.
Earlier onset in males when compared to females (Bogetto et al., 1999), bimodal 
distribution of onset in females and exacerbation of symptoms during various reproductive 
phases (Brandes et al., 2004) point towards the role of steroid hormones in OCD. Sex 
hormones are mainly steroids that are produced by the gonads (Brook, 1999). The most 
relevant are female sex hormones estrogen and progesterone, and the male sex hormone 
testosterone. These hormones regulate and influence global sexual functions like pregnancy, 
pubertal changes, sexual behavior, etc (Barth et al., 2015). Estrogen and progesterone have
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neuromodulation effects in the central nervous system either through intracellular action or via 
neurotransmitter systems (Dreher et al., 2007; Karakaya et al., 2007; Benmansour et al., 2009). 
These sex steroids further metabolize into neurosteroids, which have anti-convulsive (Kokate et 
al., 1994), anti-depressant (Khisti et al., 2000) and anti-anxiety (Barbaccia, 2004) properties 
through modulation of GABA and glutamate receptors (Compagnone and Mellon, 2000).
The emphasis of sex steroids in influencing onset and exacerbation of OCD symptoms 
are more relevant to female OCD patients. This is mainly because women are at risk in 
developing the disorder during various reproductive phases (Alcafache, 2016). Very few studies 
have been conducted which provide contradictory evidence (Vulink et al., 2006). One study has 
shown more prevalence of OCD during menopause (Uguz et al., 2010), while another has 
demonstrated that the symptoms are more related to menarche and decrease during 
menopause (Guglielmi et al., 2014). Further, no literature evidence exists for acute conditions 
like surgical menopause, which is more abrupt and can mimic natural menopause (Rodriguez- 
Landa et al., 2015). Animal studies on the role of sex steroids in compulsive behaviors have 
also been very limited. Anti-compulsive effects of estradiol, allopregnanolone and progesterone 
has been established in handful of studies (Flaisher-Grinberg et al., 2009; Hill et al., 2007; 
Fernandez-Guasti et al., 2006; Umathe et al., 2009).
v) Cholinergic involvement: There is evidence of cholinergic system being involved in 
OCD (Lucey et al., 1993; Yankelevitch-Yahav and Joel, 2013). OCD patients typically report 
less smoking behavior when compared to other neuropsychiatric disorders (Abramovitch et al.,
2014). It has been hypothesized that nicotine further activates the hyperactive fronto-striatal 
circuit resulting in exacerbation of symptoms. This is mainly through glutamate release by 
nicotinic receptor activation (Abramovitch et al., 2015). This theory has however been 
challenged by other studies which have shown significant clinical improvements in OCD patients 
augmented with nicotine (Pasquini et al., 2005). Since cholinergic projections innervate the
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orbitofrontal cortex (Mesulam et al., 1986), which is one of the implicated regions in OCD 
(Menzies et al., 2008; Beucke et al., 2013), further investigation is required to understand the 
modulatory role of cholinergic system in obsessive-compulsive behaviors.
vi) Autoimmune and neuro-inflammatory hypothesis: The autoimmune hypothesis of OCD 
was first proposed by Allen et al. (Allen et al., 1995). This hypothesis was based on the review 
of existing literature sources which resulted in a correlation between infections with group A B- 
hemolytic streptococcus and worsening of OCD symptoms in children. This was followed by the 
characterization of the pediatric autoimmune neuropsychiatric disorders associated with 
streptococcal infections including OCD (Swedo and Sydenham, 1994; Swedo et al., 1998). 
More recent evidence has emerged in this field that corroborates the autoimmune mechanism 
due to infection (Singer et al., 2012; Swedo et al., 2015).
1.1.4 Current Treatment Strategies
1.1.4.1 Pharmacotherapy
i) Monotherapy: The most predominantly used first line treatment for clinical responders 
are the selective serotonin reuptake inhibitors (SSRIs) (Kellner, 2010). SSRIs are a class of 
drugs that are thought to increase the extracellular levels of serotonin in the synaptic cleft by 
limiting its reuptake through the serotonin transporter (SERT) (Blakely and Barker, 1995). 
However, the exact mechanism of these drugs still remains to be elucidated. The concept of 
serotonergic agents in treating OCD gained momentum with the efficacy study of clomipramine 
in 1960s (Fernandez and Lopez-Ibor, 1967; Reynghe de Voxrie, 1968). Clomipramine is a first- 
generation serotonin reuptake inhibitor (SRI). SRIs are less selective than the SSRIs and can 
bind to other transporters such as norepinephrine (Tatsumi et al., 1997). Several studies since 
then have established the clinical effectiveness of clomipramine (Song et al., 1993; Mitchell et 
al., 1997; Anderson et al., 2000) with the most effective dose being 100-300 mg/day
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(Montgomery et al., 1980). The SSRIs were introduced in the 1980s with fluvoxamine as the first 
SSRI that was tested on patients with clinical success (Goodman et al., 1989). Subsequently, 
other SSRIs such as fluoxetine (Montgomery et al., 1993; Tollefson et al., 1994), sertaline 
(Chouinard et al., 1990; Jenike et al., 1990), paroxetine (Weadon et al., 1993; Zohar and Judge,
1996), citalopram (Pallanti et al., 2002) and escitalopram (Stein et al., 2007) have also been 
introduced to treat OCD and have shown effectiveness in various clinical trials. Most of these 
drugs are used at doses of 50-200 mg/day (Chouinard, 1992; Fichter et al., 1996; Hollander et 
al., 2003; Irons, 2005).
In addition to SSRIs, 5-HT-noradrenaline reuptake inhibitors (SNRI) such as Venlafaxine 
have shown promise in clinical studies (Marazziti et al., 2003). Mirtazapine, a tricyclic 
antidepressant which acts on both the noradrenergic and serotonergic systems was found to be 
effective in some studies (Koran et al., 2005). Encouraging data has also emerged from 
phenelzine (monoamine oxidase inhibitor) (Vallejo et al., 1992), inositol (secondary messenger 
modulator) (Fux et al., 1996), cycloserine (glutamatergic agonist) (Storch et al., 2007) and 
morphine (Koran et al., 2005).
ii) Augmenting strategies and combinational treatments: Despite the widespread usage of 
SSRIs in treating OCD, 40-60% of the patients are refractory to the treatment (McDougle et al., 
1993). Complete remission is not achieved and recurrence of symptoms is common (McDougle 
et al., 1993). Moreover, latent response times of 8-12 weeks for SSRIs have been a point of 
concern. Alternative therapeutic strategies like co-administration and augmentation have been 
used for these patients. Combination of SSRIs such as clomipramine with fluoxetine (Simeon et 
al., 1990; Browne et al., 1993) and clomipramine with citalopram (Marazziti et al., 2008) has 
been effective in some cases. Drug resistant patients have shown better response with 
paroxetine and pindolol, a beta blocker (Dannon et al., 2000). Augmentation with antipsychotics
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like haloperidol and risperidone, which targets dopaminergic receptors, has been useful for 
some patients (McDougle et al., 1994; McDougle et al., 2000).
1.1.4.2 Non-Pharmacological Therapies
i) Psychotherapy: Exposure and response prevention (ERP) is a very popular non- 
pharmacological treatment option for OCD patients (Pittenger et al., 2005; Marazziti et al.,
2012). Patients undergoing ERP typically are exposed to conditions that inflict obsessive 
thoughts but they are not allowed to engage in compulsive rituals (Meyer, 1966; Baer and 
Minichiello, 1998). This forced abstinence through repeated trials ultimately results in 
attenuation of engagement in compulsive behaviors. The exposure methods are either in-vivo or 
imaginary (Marazziti et al., 2012). Some of the examples are systemic desensitization, 
satiation/habituation, etc. (Marazziti et al., 2012). Response techniques to exposure stimulus 
include aversive methods or physical obstruction to engagement in overindulgent behaviors 
(Marazziti et al., 2012). This method has yielded results in 70-80% of the patients in clinical 
trials (Perse, 1988). Cognitive therapy has also been used to prevent intrusive thoughts and 
repetitive behaviors. Though based on the premise of ERP, cognitive therapy involves exposure 
and response preventions in the form of behavioral assessments (Freeston et al., 1997). The 
cognitive therapy component aids in improving engagement with reality, while disengaging from 
obsessive thoughts and thereby compulsive behaviors. However, a recent study has shown that 
46% of the patients refused to undergo CBT therapy (Santana et al., 2013). In addition, both 
ERP and CBT are highly demanding and are used for severe cases patients with frequent 
relapses (Feusner et al., 2015).
ii) Deep brain stimulation: Deep brain stimulation is an invasive method which involves 
positioning of electrodes in target brain regions followed by electric stimulation (Gabriels et al., 
2003). DBS is proposed for those patients who have stopped responding to pharmacological 
and behavioral interventions (Sedrak et al., 2013). The therapeutic effect of DBS is attributed to
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its effectiveness in modulating abnormal activities and synaptic connectivity in the orbitofrontal 
cortex, anterior cingulate cortex, and striatum (Lujan et al., 2008). The response to this 
treatment strategy largely varies based on the target brain region for stimulation (Lujan et al., 
2008).
iii) Neurosurgical methods: Most commonly used neurosurgical methods are bilateral 
anterior capsulotomy (Oliver et al., 2003), cingulectomy (Dougherty et al., 2002), lobotomy (Kim 
et al., 2003) and subcaudate tractotomy (Montoya et al., 2002). These ablative surgical 
techniques are predominantly used for very severe cases of OCD that remain resistant to all 
other treatment options (Yaryura-Tobias et al., 2000). Most of these surgeries are aimed at 
CSTC circuit components for remission of symptoms (Marazziti et al., 2012).
1.1.5 Animal Models of OCD
Several animal models have been developed in the past three decades that can provide 
insight into the neurochemical and neuroanatomical substrates of OCD (Alonso et al., 2015). 
Though it is impossible to recapitulate obsessions in animals due to the unique human topics 
that encompass the obsessional thoughts, animal models can provide crucial understanding of 
the phenomenology, such as compulsivity and stereotypical dimensions of the disease (Maio et 
al., 2014). To be considered a successful animal model of a human disorder, there should be 
analogous symptomology between the model and the human disease (face validity) and the 
treatment modalities should effectively reverse the symptoms (predictive validity). In addition, 
there should be similar molecular and physiological mechanisms (construct validity) between 
the animal models and the human disease it represents (McKiney and Bunney, 1969; 
McKinney, 1988). In the field of OCD, a successful animal model exhibits face validity that are 
typically repetitive, excessive and inappropriate behaviors. The predictive validity involves 
alleviation of these abnormal behaviors by treatment with SRIs and SSRIs, which are first line 
treatment options in human patients (Albelda and Joel, 2012). Since the exact neural
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mechanisms of OCD are yet to be elucidated, construct validity of a model involves abnormality 
in CSTC circuitry, ovarian hormones, or the implicated neurotransmitter systems that can 
explain the behavioral correlates (face validity) and treatment response (predictive validity) 
(Albelda and Joel, 2012). Some of the current animal models used for studying OCD are 
discussed as follows:
1.1.5.1 Genetic Models
i) 5-HT2c receptor knockout mouse model: The serotonin receptor type 2c (5-HT2c) 
receptor knockout mouse was generated by Chou-Green et al. (2003). Knocking out the 5-HT2c 
receptor resulted in compulsive-like chewing of nonnutritive clay, patterned chewing of plastic 
mesh screen and reduced habituation or perseveration to the head-dipping task (Chou-Green et 
al., 2003). This organized chewing behavior represents compulsive checking, ordering, 
smoothing or washing behaviors in humans. The head-dipping is considered analogous to 
compulsive checking (Chou-Green et al., 2003). A recent study with this mouse model revealed 
that they increased reversal learning by reducing influence on non-reward associations (Nilsson 
et al., 2013). Despite showing promise in understanding the role of 5-HT2c receptor role in 
driving behavioral outcomes, the model lacks predictive validity.
ii) Hoxb8 mutant mice: The Hoxb8 gene is a member of the mammalian homeo box 
containing complex transcription factor responsible for neural development (Greer and 
Capecchi, 2002). Greer and Capecchi (Greer and Capecchi, 2002) developed the Hoxb8 mutant 
mice which exhibits excessive grooming behavior. This excessive grooming phenotype can be 
compared to trichotillomania and certain OCD subtypes (Frank et al., 2002). Moreover, Hoxb8 is 
predominantly expressed in brain regions implicated in OCD making it a good candidate for 
understanding molecular underpinnings behind abnormal stereotypic behaviors. Unfortunately, 
the predictive validity of this model has not been established (Wang et al., 2009).
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iii) D1CT-7 mutant mice: DICT-7 mice express cholera toxin A1 subunit within a subset of 
dopamine D1-receptor expressing neurons in the cortical-limbic region (Burton et al., 1991; 
Smicun et al., 1999). DICT-7 mice exhibit a constellation of compulsive behaviors such as, 
repetitive episodes of normal behaviors, excessive grooming and biting of siblings and multiple 
episodes of leaping (Smicun et al., 1999). These behaviors provide face validity for compulsive­
like Tourette syndrome (Nordstrom and Burton, 2002). However, the DICT-7 mice also exhibit 
limbic seizures that are not linked to OCD behaviors (Campbell et al., 2000) indicating 
overlapping phenotypes. The predictive validity of this model is also yet to be determined.
iv) Dopamine transporter knockout mice: The dopamine transporter (DAT) knockout 
mouse is a mutant mouse in which the pre-synaptic DAT has been knocked down (Berridge et 
al., 2005). This downregulation of DAT expression results in elevated levels of pre-synaptic 
dopamine (extracellular) which leads to hyperactive and persevarative behaviors such as rigid 
grooming chain patterns (Zhuang et al., 2001; Berridge et al., 2005). This rigid syntactic 
grooming behavior is thought to resemble sequential super-stereotypy in OCD and Tourette 
syndrome (Sheppard et al., 1999). The DAT knockout mice however also exhibit behavioral 
abnormalities that are related to other disorders, such as ADHD and mania (Joel, 2006).
v) Aromatase knockout (ArKO) mice: The aromatase knockout mice were originally 
developed to understand the influence of estradiol in sexual differentiation (Fisher et al., 1998). 
Knocking out aromatase activity causes inhibition of estradiol synthesis from testosterone. This 
specific knockdown of aromatase activity results in excessive wheel running and grooming 
behavior in males but not females and estrogen administration results in attenuation of these 
phenotypes (Hill et al., 2007). The onset of the stereotypical behaviors in ArKO mice is seen 
only at 6 months of age which is complemented by a decline in catechol-o-methytransferase 
(COMT) protein expression in the hypothalamus (Wang et al., 2009). Though reduced function 
of COMT in male OCD patients has been seen in a few studies (Pooley et al., 2007; Schindler
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and Anghelescu, 2007), there are some other potential problems with this mouse model. The 
lack of a compulsive-like phenotype in females and the late onset (6 months), which correspond 
to the early to late adulthood years in humans, questions the predictive validity of the model 
(Wang et al., 2009). Moreover, it is not yet determined if the reductions in COMT levels drive 
the compulsive-like behaviors in the mice. Another potential drawback is the lack of chronic 
treatment studies with first line treatments.
vi) Sapap3-mutant mice: SAP90/PSD95-associated protein-3 (SAPAP-3) is a scaffolding 
protein that is expressed in the postsynaptic membrane of the striatal region. Knocking out 
SAPAP-3 in mice resulted in exaggerated grooming behavior along with anxiety-like behaviors 
in open field and elevated plus maze tests (Welch et al., 2007). The predictive validity of this 
model has also been established through subchronic administration of fluoxetine which 
attenuates the grooming and anxiety-like behaviors. However, the predictive validity of this 
model has been determined through a fluoxetine dose of 5 mg/kg/day for only 6 days. This is a 
substantially low dose when compared to the recommended dose used for humans (Wang et 
al., 2009). It is also noteworthy that in other animal models higher doses (10 to 20 mg/kg/day) 
are required for at least 12-14 days for attenuation of anxiety and depression-like behaviors 
(Dulawa et al., 2004; Yalcin et al., 2008). Also, the role of SAPAP-3 protein in influencing OCD 
in humans is yet to be determined (Wang et al., 2009) and therefore the construct validity 
cannot be substantiated.
vii) Slitrk5 knockout mice: The Slitrk5 gene belongs to a family of integral membrane 
proteins, which regulate neurite outgrowth during developmental phases (Aruga and Mikoshiba, 
2003). Slitrk5 knockout mice exhibit increased neuronal activity in the orbitofrontal cortex and 
striatum. As a result of this abnormal neural activity the mice develop excessive self-grooming, 
increased marble burying and anxiety-like behaviors (Shmelkov et al., 2010). The predictive
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validity of this model has also been verified through repeated fluoxetine treatment, which 
attenuates the compulsive phenotype (Shmelkov et al., 2010).
1.1.5.2 Drug Induced Models
Drug induced models of OCD are based on behavioral alterations due to pharmacological 
manipulations of the neurotransmitter systems that are thought to be implicated in OCD. Two of 
the most widely studied drug induced models are:
i) 8-OH-DPAT-induced spontaneous alternation: The concept of drug induced attenuation 
of normal, sequential and successive exploration of novel places by rats was first proposed by 
Yadin et al. (Yaldin et al., 1991). Based on this concept, rodent models have been established 
that involve acute administration of 8-OH-DPAT, an agonist of the 5-HT1a receptor. This 
treatment with 8-OHDPAT decreases spontaneous alternation in mice and rats (Seibell et al., 
2003; Arora et al., 2013) modeling indecision in humans, which is a specific aspect of OCD 
(Joel, 2006). The 8-OH-DPAT induced reduction in spontaneous alternation is restored by 
repeated fluoxetine or clomipramine treatment but not by tricyclic antidepressant, desipramine 
(Yadin, 1991; Fernandez-guasti et al., 2003) and can also be influenced by ovarian hormones 
(Fernandez-guasti et al., 2003). However, spontaneous alternation is observed in many other 
psychiatric and neurological manifestations such as Parkinson's disease and schizophrenia 
(Albelda and Joel, 2012). Hence, a conclusion cannot be reached as to whether the face validity 
of the model is exclusive to OCD.
ii) Quinpirole-induced compulsive checking: This model was produced by chronic 
treatment (5 weeks) of rats with quinpirole (0.5 mg/kg), a D2/D3 agonist (Szechtman et al., 
1998). Following treatment, the rats are allowed to explore an open field with four small objects 
placed at a fixed location in the field. Quinpirole treated rats typically display two locales in 
which they stop more frequently than others and perform ritualistic motor acts when they stop at
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these objects (Ben-Pazi et al., 2001; Szechtman et al., 1998, 2001). This persistence behavior 
that is dedicated to specific objects and ritual-like motor activity is considered analogous to 
compulsive checking in human patients (Szechtman et al., 2001). This model has also shown 
response to clomipramine treatment which reduces the checking behavior partially or 
momentarily (Szechtman et al., 1998).
1.1.5.3 Spontaneous Models
Spontaneous models use the concept of innately occurring stereotypic behaviors, motor 
behaviors or adjunctive behaviors that are induced through behavioral manipulations (Woods et 
al., 1993; Altemus et al., 1996; Alonso et al., 2015). Some of the most widely studied 
spontaneous models are:
i) Marble burying behavior: The marble burying behavior is one of the most widely studied 
models to assess compulsive-like phenotypes. The concept of marble burying utilizes the 
natural tendency of mice or rats to bury harmless or noxious objects in the bedding provided to 
them (Joel, 2006). Since studies (Njung'e and Handley, 1991; Gyertyan, 1995; Londei et al.,
1998) have shown that rodents typically do not tend to avoid the marbles, marble burying is a 
good indicator of a compulsive-like but not an anxiety-like phenotype (Gyertyan, 1995; Londei et 
al., 1998). The compulsive theory of marble burying is based on the fact that non-reactivity of 
the marbles fails to provide stimuli for ending the investigation leading to frustrated compulsive 
burying (Szechtman and Woody, 2006; Joel, 2006). Marble burying can be mapped to the 
inability to realize the task completion in OCD patients (Szechtman and Woody, 2006), thereby 
establishing its face validity. Several studies have also shown predictive validity of this model 
through SSRI treatment regimens (Takeuchi et al., 2002; Greene-Schloesser et al., 2011). The 
construct validity of this model is moreover supported through studies where ovarian hormones, 
neurosteroids and the estrous cycle have been found to influence the burying behavior 
(Schneider and Popik, 2007; Llaneza and Frye, 2009; Umathe et al., 2009).
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ii) Signal attenuation model: The signal attenuation model is based on the concept of 
deficiency in the feedback of normal goal directed behavior (Gray, 1982; Baxter, 1999; 
Szechtman and Woody, 2006). Using this concept, rats are trained to exhibit compulsive lever 
pressing. This is achieved by trainings rats to lever press for food in the presence of a paired 
stimulus. The stimulus acts as a feedback cue for the rats to press the lever. The rats are then 
presented with an attenuation phase during which repeated stimuli are provided without food. 
Finally, rats are tested for the number of lever press in the extinction phase by presenting the 
stimulus without food (Joel and Avisar, 2001; Joel et al., 2001; Joel and Doljansky, 2003). The 
predictive validity of the model has been assessed using acute doses of paroxetine and 
fluvoxamine which reduced the lever pressing behavior. The tricyclic antidepressants however 
have no effect on the number of lever presses (Joel et al., 2004). The construct validity of the 
model has also been investigated in studies where ovarian hormones have been found to 
modulate lever-pressing (Flaisher-Grinberg et al., 2009). One of the major shortcomings of this 
model is the lack of predictive validity for chronic administration of first line treatments (Alonso et 
al., 2015).
iii) Schedule-induced polydipsia model: In this paradigm, rats are food deprived and 
trained to collect food only after a fixed time interval while having free access to water. Rats 
eventually exhibit polydipsic behavior whereby they consume five to ten times more water than 
control rats not exposed to the training (Woods et al., 1993). This excessive water intake is 
repetitive and can be considered a compulsive-like phenotype (Alonso et al., 2015). Chronic 
administration of SSRIs has also shown to reduce this polydipsia behavior establishing the 
predictive validity of this model (Woods et al., 1993). Neurobiologically, activating 5HT2c 
receptors with agonists reduces the polydipsic behavior indicating serotonergic involvement and 
possible construct validity of the model (Rosenzweig-Lipson et al., 2007).
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iv) Spontaneous stereotypic deer mice model: The deer mice exhibit a unique set of 
stereotypic behaviors such as vertical jumping, backward somersaulting and patterned running 
(Powell et al., 1999). Depending on the frequency of occurrence of these behaviors, deer mice 
are categorized into high, low and non-stereotypic types. These behaviors have been used in 
studies to understand compulsive phenotypes (Wolmarans et al., 2016; Bechard et al., 2017). 
Though chronic administration of fluoxetine decreases these stereotypic behaviors (Korff et al., 
2008), there are some drawbacks with this model. The studies with deer mice have used both 
males and females but the influence of sex in these studies has not been discussed. Also, a 
study with mCPP and quinpirole in these mice has caused attenuation of the stereotypic 
behaviors (Korff et al., 2008). This is puzzling since both mCPP and quinpirole are known to 
exacerbate compulsive-like behaviors in rodents (Erzegovesi et al., 2001; Tsaltas et al., 2005; 
Alonso et al., 2015). Moreover, the predictability of this model is questionable since it does not 
exhibit uniform compulsive-like phenotypes. Only a certain percentage of the offsprings exhibit 
excessive nest-building (Wolmarans et al., 2016b), while marble burying is not an indicator of 
compulsive-like phenotypes in these mice (Wolmarans et al., 2016).
v) Bidirectional selection for nest building behavior: This mouse model was developed 
through bidirectional selection for high and low levels of nest-building from an HS/ibg outbred 
mouse stock population (Lynch, 1980; Bult and Lynch, 2000). The HS/ibg strain was derived 
through crossing of eight house mouse (Mus musculus) inbred strains (A, AKR, BLB/c, C3H/2, 
C57BL, DBA/2, Is/Bi, RIII; McClearn et al 1970; Lynch, 1980). Bidirectional selection resulted in 
three levels of nest-building behavior (with two replicate strains within each level). The 
replicates within each level of nest building were maintained as separate strains, i.e., not 
interbred with the other replicate strains, but subjected to the same selection regime (Lynch, 
1980; Bult and Lynch, 2000). This resulted in two BIG (BIG1 and BIG2) strains that consistently 
display high and excessive levels of nesting with a forty-fold difference in the amount of cotton
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used when compared to the two SMALL strains which display very low levels of nesting. The 
SMALL strains are therefore considered as non-compulsive. The two randomly-bred strains 
serve as a selection Control and show intermediate levels of nesting (Bult and Lynch, 2000). 
The BIG strains also exhibit compulsive-like marble burying behavior (Greene Schloesser et al., 
2011). A prior study has indicated that the BIG1 male strains have face and predictive validity 
for compulsive-like phenotype to study OCD in humans (Greene Schloesser et al., 2011). This 
was established by comparing behavioral responses of the BIG1 strains treated separately with 
fluoxetine, clomipramine and desipramine. There was attenuation of compulsive-like nesting 
and marble burying behavior in the BIG1 males treated with chronic fluoxetine and 
clomipramine. However, desipramine showed no significant differences (Greene Schloesser et 
al., 2011). The current thesis is a continuation of this work that investigates the role of strain and 
sex differences in compulsive-like condition. The research aims at probing into the role of 
ovarian sex steroids and postpartum phases in compulsive-, affective- and cognitive- behaviors. 
The role of cholinergic system in modulating compulsive-like behaviors is also elucidated 
through this thesis work.
1.2 Research Objectives
Sex differences and genetic variations are one of the main contributing factors to the 
complex heterogeneity associated with OCD (Arnold et al., 2006; Labad et al., 2008; Nestadt et 
al., 2010; de Mathis et al., 2011; Grunblatt et al., 2014). Currently, there is a lack of studies that 
emphasize the influence of sex differences on compulsive-like behaviors in model organisms. 
Most of the model systems of OCD discussed above lack sex based comparisons and do not 
consider the role of ovarian steroids in influencing behavioral outcomes. Understanding of onset 
and exacerbation of OCD in females during periods of physiological challenges, such as 
pregnancy, postpartum and menopause, is also very limited (Arnold, 1999; Vulink et al., 2006; 
Guglielmi et al., 2014; Challacombe et al., 2017). Most of these cohort based studies also do
22
not report OCD associated comorbidities and cognitive impairments. This is further 
compounded by genetic variations among patient populations which might result in OCD 
subsets with specific obsessive-compulsive symptoms and co-morbid behaviors (den Braber et 
al., 2016). This heterogeneity also results in drug resistance (Erzegovesi et al., 2001) and the 
current first line therapies available are not effective against clinical non-responders. Most of the 
existing rodent models do not represent the complex heterogeneity associated with OCD. 
Deciphering the phenotypic expressions of compulsions and complementary neurobiological 
mechanisms between compulsive-like mouse strains of opposite sex will be essential for better 
understanding of complex factors that contribute to this heterogeneity. The current research 
therefore aimed at investigating additional face, predictive and construct validity of the 
spontaneous mouse model of OCD first described by Greene-Schloesser et al (Greene- 
Schloesser et al., 2011) with the following aims:
1.2.1 Aim I: Behavioral characterization of a spontaneous compulsive-like mouse model 
based on strain and sex differences to understand clinical heterogeneity associated with OCD. 
This research aimed at establishing the face validity of the mouse model (Greene-Schloesser et 
al., 2011) to study OCD heterogeneity.
There is compelling genetic basis of OCD from clinical studies (Abelson et al., 2005; 
Shugart et al., 2006; Samuels et al., 2007; Hanna et al., 2007; Ross et al., 2011; Mathews et al., 
2012; Goodman et al., 1990; Taylor., 2013; Stewart et al., 2013). In addition, the importance of 
sex differences in influencing onset, symptomology, severity and drug response has also been 
established (Noshirvani et al., 1991; Bogetto et al., 1999; Kalra and Swedo, 2009). However, 
there is lack of understanding whether there is a combined effect of genetic variations and sex 
differences that interact with each other to influence OCD. There is also a lack of understanding 
on how genetic variations and sex differences attribute to the complex heterogeneity of OCD 
including the expression of compulsive and comorbid behaviors and drug response. Previously,
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only one study has been conducted on female mouse strains (C57BL/6J) that were treated with 
quinpirole to induce compulsive-like behaviors (de Haas et al., 2012). The study indicated that 
genetic background is essential in expression of compulsive-like behaviors and strain 
comparisons can provide a better understanding of various forms of compulsivity. However, the 
study used a wildtype strain and looked at the effect of strain differences only in females, but not 
males (de Haas et al., 2012). It also did not account for the associated affective (anxiety-like 
and depression-like) and cognitive (memory function) phenotypes. Considering that OCD is a 
complex heterogeneous disorder which varies based on sex differences and genetic 
background of patient populations I hypothesized that:
Hypothesis: There will be interplay of strain and sex differences in influencing compulsive­
, anxiety-, cognitive- and depression-like behaviors among male and female compulsive-like 
mouse strains. This complex interplay of strain and sex will provide a better understanding of 
the heterogeneity of OCD associated with symptomology and drug response enhancing the face 
and predictive validity of this mouse model.
1.2.2 Aim II: Strain and trait specific attenuation of compulsive-like behavior by 
fluvoxamine in a non-induced mouse model (Greene-Schloesser et al., 2011) of obsessive- 
compulsive disorder. Through this aim I wanted to investigate behavioral responses of two 
different compulsive-like mouse strains in response to a first line treatment, fluvoxamine for 
OCD.
Around 40-60% of OCD patients do not respond to first line treatments (Ravizza et al., 
1995). Even patients who are categorized as clinical responders continue exhibiting residual 
obsessions and compulsions (Lack, 2012). Through animal studies, a better understanding of 
the efficacy of first line treatments on specific compulsive traits is required. This can provide 
answers to such high drug resistant rates among patients. Investigating drug intervention in
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mouse strains exhibiting spontaneous compulsive-like behaviors can be a valuable starting 
point for determining if there is any role of genetic background and compulsive traits in 
influencing drug response. Hence, I tested the hypothesis that:
Hypothesis: There will be a differential response to compulsive-like and anxiety-like 
behaviors in compulsive-like mouse (Greene-Schloesser et al., 2011) strains treated with 
increasing doses of SSRI, fluvoxamine.
1.2.3 Aim III: This aim involved investigating how ovarian sex hormones influence 
compulsive, affective and cognitive functions in a spontaneous mouse model of OCD (Greene- 
Schloesser et al., 2011). Through this aim, I intended to establish the construct validity of the 
mouse model on the premise of sex hormonal regulation of neurobiological mechanisms 
implicated in OCD.
There is currently no understanding as to how acute menopause due to surgical removal 
of ovaries influences compulsive, affective and cognitive behaviors in normal versus OCD 
patients. Moreover, the role of hormone therapy and response to hormone therapy due to 
genetic variations among OCD patient populations is not explored. Clinical and genetic data 
from human and animal studies corroborate the concept of sexual dimorphism in OCD 
(Karayiorgou et al., 1997; Camarena et al., 2001; Enoch et al., 2001; Lochner et al., 2004; 
Denys et al., 2006; Dickel et al., 2007; Hill et al., 2007; Labad et al., 2008; Flaisher-Grinberg et 
al., 2009; Torresan et al., 2009). There is prevalence of certain OCD types among females, 
such as cleaning compulsions, when compared to males (Noshirvani et al., 1991; Bogetto et al.,
1999) and the drug response also varies (Mundo et al., 1999). Females typically experience a 
late onset when compared to males and display a bi-modal distribution with peaks occurring at 
ages that represents puberty and child bearing years (Brandes et al., 2004). These are 
physiological stages during which there are alterations in female sex hormonal levels primarily
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produced by the ovaries. Few research studies have contradictory evidence on onset and 
exacerbation of OCD among females during various physiologically challenging phases like 
postpartum, menarche and menopause (Uguz et al., 2010; Guglielmi et al., 2014). Further, a 
limited number of animal studies has been undertaken to understand the role of ovarian steroids 
in compulsive-like behaviors (Fernandez-Guasti et al., 2006; Hill et al., 2007; Flaisher-Grinberg 
et al., 2009). One study has shown that administration of estradiol to pre-pubertal rats is anti­
compulsive (Flaisher-Grinberg et al., 2009), while another study showed that male mice with 
estrogen deficiency results in compulsive-like grooming (Hill et al., 2007). A study on rats has 
shown a combined effect of estradiol and progesterone in attenuating compulsive behavior 
(Fernandez-Guasti et al., 2006). These studies do not reflect acute ovarian steroid deprivation, 
associated anxiety-like and cognitive-like behaviors in compulsive-like condition, and also do not 
explore the role of strain differences on steroidal influence of these behaviors. Hence using the 
spontaneous mouse model of OCD (Greene-Schloesser et al., 2011), I proposed that:
Hypothesis: Surgical menopause through acute ovariectomy will exacerbate compulsive­
like, anxiety-like and cognitive-like behaviors in the compulsive-like mouse strains. I also 
hypothesized that the ovarian sex hormones estrogen and progesterone will modulate 
compulsive-like, anxiety-like and cognitive-like behaviors and this modulation will vary based on 
strain differences.
1.2.4 Aim IV: Elucidating the neurobiological mechanisms of compulsive-like, anxiety-like 
and depression-like behaviors during post-partum lactation in the spontaneous mouse model of 
OCD (Greene-Schloesser et al., 2011).
The physiology of OCD during post-partum in female patients is poorly understood. This 
is of importance considering that sex differences attribute to the phenotypic expression, 
heterogeneity and drug response variations in OCD (Noshirvani et al., 1991; Bogetto et al.,
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1999; Mundo et al., 1999). Moreover, anxiety and depression, which are prevalent co-morbid 
conditions in OCD (Crino and Andrews, 1996; Goodwin, 2015), are known to precipitate during 
the post-partum phase in females (Smith et al., 2011; Alipour et al., 2012). Serotonergic 
systems are thought to play a critical role in the expression of obsessions and compulsions 
(Zohar et al., 2012; Pauls et al., 2014). In a recent study, lactation in wild-type female C57BL/6 
mice resulted in a decrease of serotonergic neurons in the dorsal raphe nucleus of the brain. 
However, the serum levels of serotonin were higher during lactation (Jury et al., 2015). This 
variation in brain versus serum serotonin correlated with better behavioral responsiveness to 
SSRI treatments in lactating females when compared to nulliparous and postpartum females 
(Jury et al., 2015). Further, dopamine cell bodies (A12) of arcuate nucleus projecting to pituitary 
(Bjorklund and Nobin, 1973) negatively regulate lactation, while oxytocin neurons from 
paraventricular region (PVN) of hypothalamus influence lactation positively (Zingg and Lefebvre, 
1988). This dual regulation of lactation and its impact on behavioral outcomes is not well 
understood. Lactation mediated neurobiological mechanisms during psychiatric disorders such 
as OCD is also poorly understood. Hence, this aim investigated if postpartum lactation has anti­
compulsive, anti-anxiety and anti-depression like effects when compared to non-lactating and 
nulliparous females in compulsive-like mice. Due to the dual regulation of lactation by both 
dopamine and oxytocin, this aim also investigated if lactation-mediated behavioral outcomes in 
compulsive-like mice are mediated by dopamine and/or oxytocin. Through these aims I tested 
the hypothesis that:
Hypothesis: Lactating compulsive-like mice will exhibit less compulsive-, anxiety- and 
depression-like behaviors and will have enhanced responsiveness to SSRI treatments when 
compared to their non-lactating postpartum counterparts and nulliparous controls. These 
behavioral responses in lactation phase will be differentially regulated by dopamine and/or 
oxytocin.
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1.2.5 Aim V: This aim probed the therapeutic role of desformylflustrabromine (dFBr) for 
attenuation of compulsive-like behaviors through positive allosteric modulation of the a4p2 
neuronal nicotinic receptor subtype.
Human and rodent studies have indicated the cholinergic involvement in OCD (Lucey et 
al., 1993; Yankelevitch-Yahav and Joel, 2013). However, the results have been contradictory. 
Some studies have shown that nicotinic activation of already hyperactivated fronto-striatal circuit 
results in exacerbation of OCD symptoms (Abramovitch et al., 2015). On the other hand, one 
study has established nicotine augmentation as a therapeutic option for OCD patients (Pasquini 
et al., 2005). There is lack of understanding on how specific nicotinic receptor subtypes 
influence phenotypic expressions in OCD patients and how their modulation might provide 
further knowledge on their role in influencing compulsive-like behaviors. Considering that a4p2 
subtype of neuronal nicotinic receptor are prevalent in brain regions implicated in OCD, 
addiction and mood disorders (Wise, 2009; Maskos, 2010; Quik et al., 2013), I decided to 
investigate whether modulation of this subtype of receptor with desformylflustrabromine, a novel 
positive allosteric modulator will affect compulsive-like behaviors in the mouse model. Based on 
this premise, I hypothesize that:
Hypothesis: Positive allosteric modulation of a4p2 subtype of nicotinic receptors will 
modulate compulsive-like and anxiety-like behaviors in the spontaneous mouse model.
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Chapter 2: Strain and sex based characterization of behavioral expressions in non-induced
compulsive-like mice.1
2.1 Abstract
There is currently a lack of understanding how genetic background and sex differences 
attribute to the heterogeneity of obsessive-compulsive disorder (OCD). An animal model of 
compulsive-like behaviors has been developed through bidirectional selection of house mice 
(Mus musculus) for high (big cotton nests; BIG mice) and low levels (small nests; SMALL mice) 
of nest-building behavior. The BIG male strains have predictive and face validity as a 
spontaneous animal model of OCD. Here, we evaluated compulsive-, anxiety-, cognitive-, and 
depression-like behaviors among male and proestrus female replicate strains each of BIG 
(BIG1, BIG2) and SMALL (SML1, SML2) nest-builders, and randomly-bred Controls (C1, C2). 
BIG1 and BIG2 males and females had higher nesting scores when compared to SMALL and 
Control strains. Male BIG1 and BIG2 strains showed more compulsive-like nesting than BIG1 
and BIG2 proestrus females, which was not observed among the other strains. Nesting scores 
were also different between BIG replicate male strains. A similar pattern was observed in the 
compulsive-like marble burying behavior with BIG strains burying more marbles than SMALL 
and Control strains. Significant replicate and sex differences were also observed in marble 
burying among the BIG strains. The open field test revealed replicate effects while the BIG 
strains showed less anxiety-like behavior in the elevated plus maze test compared to the 
SMALL strains. For novel object recognition only the Control strains showed replicate and sex 
differences. In the depression-like forced swim test proestrus females demonstrated less 
depression-like behavior than males. BIG and SMALL nest-building strains had a higher 
corticosterone stress response than the Control strains.
1 1Published as S. Mitra, C.P. Bastos, S. Chesworth, C. Frye, A. Bult-Ito, Strain and sex based 
characterization of behavioral expressions in non-induced compulsive-like mice, 2017. Phys & Behav. 
168 103-111
65
Together these results indicate a strong interplay of genetic background and sex in influencing 
expression of behaviors in our compulsive-like mouse model. These results are in congruence 
with the clinical heterogeneity of OCD.
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2.2 Introduction
Obsessive-compulsive disorder (OCD) is a debilitating psychiatric condition 
characterized by invasive and persistent thoughts (obsessions) and repetitive behaviors 
(compulsions) [4]. OCD has an estimated lifetime prevalence of 2.3% in the United States [97]. 
The majority of patients suffering from OCD perform repetitive rituals to mitigate uncomfortable 
feelings of anxiety [32]. Others engage in repetitive behaviors due to subjective sensations also 
called sensory phenomena [79]. Obsessions can be associated with contamination, fear and 
symmetry, while compulsions include hand washing, checking or counting [88]. Such excessive 
ritualistic behaviors become distressing and significantly interfere with daily functioning [4]. OCD 
exhibits a large behavioral repertoire with high rates of repetition and provides an ethological 
basis for studying compulsive-like behaviors in animal models of OCD [11]. Though 
inappropriate for investigating the entire OCD spectrum because obsessions cannot readily be 
assessed, animal models can provide deep insight into various forms of compulsivity [74].
Sex differences in OCD [14,29,63] is thought to contribute to the heterogeneity of OCD 
[59]. Age of onset [14], phenomenology [59] and comorbidity [69] are some of the gender 
related differences that have been observed. Males usually have an earlier onset for most 
symptom dimensions of OCD than females [23,72,82,83]. Clinical studies have indicated that 
sexual, religious and symmetrical obsessions, and compulsive checking and ordering/arranging 
are more frequently seen in males than females, while females tend to exhibit more obsessions 
for contamination and compulsive cleaning than men [30,62,72,108].
In females, ovarian hormones may play a critical role in modulating obsessions and 
compulsions [113]. Fluctuations in the female hormonal cycle may contribute to increased risk of 
onset and exacerbation of OCD symptoms at certain reproductive events, including 
premenstruum phase, menstrual cycle, pregnancy, and postpartum [1,63,73,109,113]. Few 
rodent studies have established that the female sex hormone estrogen can modulate
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compulsive-like behaviors [33,37,58]. The proestrus stage of the estrous cycle in female mice 
has higher circulating levels of estrogen influencing anxiety-, cognitive- and depression-like 
behaviors [106,116] and, therefore, the comparison between males and proestrus females for 
compulsive-like behaviors may provide additional ways to gain important insights using animal 
models of OCD.
Additionally, inbred female mouse strains have shown significant differences in 
expression of drug induced compulsive-like behavior [27], indicating that strain comparisons can 
be valuable for understanding expression of compulsivity. This is important considering the 
compelling genetic basis of OCD from various human studies [25,51,52,56,76,96,105], which 
coupled with the sex differences can provide crucial clues about the complex interactions of 
these two elements in expression of compulsive and affective behaviors.
According to Maio et al. [74], comparing our compulsive-like mouse strains is valuable 
for understanding the disorder. Compulsive-like behavior in our mice is defined as excessive 
and repetitive expression of otherwise normal behaviors, i.e., nest-building and marble burying. 
For example, nest-building in the compulsive-like strains (BIG1 and BIG2) involves rapid and 
repeated movements of the front legs and mouth to pull excessive amount of cotton through the 
cage top metal bars over extended periods of time [50], which shows face validity with repetitive 
behaviors in OCD [79]. This rapid, excessive and repetitive nesting behavior is not observed in 
the Control and SMALL strains. The BIG strains also exhibit predictive validity as a spontaneous 
non-induced model of OCD-like behaviors through attenuation of these compulsive-like 
behaviors with fluoxetine and clomipramine treatment, which are first line treatments for OCD
[50]. In addition, the tricyclic antidepressant desipramine, which is not effective in treating OCD, 
did not change the compulsive-like behaviors in the compulsive-like mice [50]. These strains 
were developed by bidirectional selection for high and low levels of nest-building behavior 
[19,71] using a stock population, i.e., HS/Ibg outbred strain, that was derived from a cross
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among eight inbred house mouse, Mus musculus, strains, i.e., A, AKR, BLB/c, C3H/2, C57BL, 
DBA/2, Is/Bi, and RIII [71,77].
Bidirectional selection resulted in three levels of nest-building behavior (with two 
replicate strains within each level). The replicates within each level of nest building were 
maintained as separate strains, i.e., not interbred with the other replicate, but subjected to the 
same selection regime. Using replicate strains is important to make sure that responses to 
artificial selection are due to selection and not the result of founder effects or random genetic 
drift when comparing the different levels of selection, i.e., selection for building big nests or 
small nests, or randomly bred [17,19]. The two BIG strains consistently display high levels of 
nesting with a forty-fold difference in the amount of cotton used when compared to the two 
SMALL strains which display very low levels of nesting [19,71]. The two randomly-bred strains 
serve as a selection Control and show intermediate levels of nesting [19,71].
Compulsive-like nesting in our mice has a genetic factor with about 30% of the variation 
in behavioral expression among individuals due to additive genetic factors and about 70% of the 
variation due to environmental factors [19,71]. This estimate of heritability of nest building falls 
within the range of heritability estimates of 0.36 [111], 0.37 [26], 0.23-0.58 [60], and similar 
estimates for different types of OCD [16]. In addition, quantitative genetic analyses have 
revealed nesting behavior to be a highly polygenic trait [19,71], which is consistent with OCD in 
humans likely being influenced by many different genes [57,89,101]. Considering the 
heterogeneity and sex factors in OCD and the behavioral and genetic characteristics of our 
mouse model of OCD, we aimed to investigate the effects of genetic background and sex on the 
compulsive-, anxiety-, cognitive- and depression-like behaviors for a better understanding of 
factors influencing compulsivity.
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2.3 Methods
The University of Alaska Fairbanks Institutional Animal Care and Use Committee 
approved the animal care and experimental procedures (IACUC assurance number 497513).
2.3.1 Mice
2.3.1.1 Husbandry
Mice were housed in polypropylene cages (27 * 17 * 12 cm) with wood shavings in a 
temperature (22 ± 1 °C) and humidity (60-80%) controlled room of the Biological Research and 
Diagnostics (BiRD) Facility vivarium on a 12:12 h light-dark cycle. Pups were weaned at 19­
21 days of age and housed with same-sex and same-strain littermates until the end of all 
experiments. Food (Purina Mills, Lab Diet Mouse Diet #5015, St. Louis, MO) and water were 
available ad libitum.
2.3.1.2 Mouse strains
Randomly-bred Control strains (C1, C2), BIG strains selected to build big nests (BIG1, 
BIG2) and SMALL strains selected to build small nests (SML1, SML2) [17,18,19] were used. 
The BIG strains express higher levels of compulsive-like behaviors, i.e., nest building and 
marble burying, when compared to the SMALL strains [50], while the Control strains are 
intermediate [19,71]. Male and female mice (Mus musculus) of these six different mouse strains 
were used for the behavioral experiments (C1 males n = 20; C1 females n = 21; C2 males n = 
20; C2 females n = 17; BIG1 males n = 21; BIG1 females n = 22; BIG2 males n = 20; BIG2 
females n = 14; SML1 males n = 19; SML1 females n = 21; SML2 males n = 19; SML2 females 
n = 20).
2.3.2. Estrous cycle
Female mice in proestrus were used for the study. The proestrus stage was determined 
daily by both visual and vaginal cytology methods [20]. All females from all the strains were
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visually inspected daily. Vaginal cytology was performed on those females that showed visual 
signs of proestrus. The females for which proestrus was confirmed through cytology were 
subjected to behavioral testing the same day. This procedure was conducted daily until desired 
sample sizes were achieved for a specific test. When the females cycled to their next proestrus, 
which was typically on the 4th or the 5th day, they were subjected to the next behavioral test in 
the schedule and this cycle was continued until all behavioral tests were completed.
2.3.3 Experimental design
All mice were at least 60 days old at the start of the experiment. All behavioral tests were 
done in the light phase of the light-dark cycle. All males underwent behavioral tests once in 
every 5 days consisting of nest building (on day 1), marble burying (on day 6), open field (on 
day 11), elevated plus maze (on day 16), novel object recognition (on day 21) and forced swim 
test (on day 26). For females, behavioral tests were conducted every 4-5 days depending on 
their proestrus stage. Males and females were tested on this schedule until desired sample 
sizes were achieved. A gap of 4 days for males and 3-4 days for females between each 
behavioral test minimized the behaviors interfering with each other.
For nest-building, animals were housed individually in cages and, therefore, following 
data collection after 24 h, they were returned to home cages with their littermates and kept for 4 
days to negate any isolation effects that could influence performance in subsequent tests [55]. 
For marble burying, open field, elevated plus maze, and novel object recognition the mice were 
singly housed just before testing. After testing they were returned to their home cage with their 
littermates. Upon reintroduction to their littermates, some fighting was observed within the first 
hour, which was similar to fighting observed after a normal cage change, which should not have 
interfered with the subsequent behavioral assessment considering a 3-4 day gap between 
tests. Immediately after the forced swim test, trunk blood was collected to determine stress-
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induced plasma corticosterone levels. An observer blind to the conditions of experimental 
animals and the hypothesized outcome of the study collected all data.
2.3.4 Measuring compulsive-like behavior
2.3.4.1 Nest-building test
Nest-building behavior was used as a measure of the compulsive-like phenotype of the 
mice [50]. Male and female mice of all the strains were singly housed and provided with a pre­
weighed cotton roll in the cage-top food hopper. After 24 h, the cotton roll was removed and 
weighed [17,18,19,71]. The total nesting score was defined as the amount of cotton used over 
the 24-h period. Generally, all the mice incorporated the cotton into their nest. The more cotton 
was used, the more elaborate the nest was, which progressed from cotton on the bottom of the 
nest, to a bowl nest, and finally to a dome nest.
2.3.4.2 Marble burying test
Nest-building behavior was used as a measure of the compulsive-like phenotype of the 
mice [50]. Male and female mice of all the strains were singly housed and provided with a pre­
weighed cotton roll in the cage-top food hopper. After 24 h, the cotton roll was removed and 
weighed [17,18,19,71]. The total nesting score was defined as the amount of cotton used over 
the 24-h period. Generally, all the mice incorporated the cotton into their nest. The more cotton 
was used, the more elaborate the nest was, which progressed from cotton on the bottom of the 
nest, to a bowl nest, and finally to a dome nest.
2.3.5 Measuring anxiety-like behaviors
2.3.5.1 Open field test
Open field behavior was used to assess anxiety-like behavior of the mice [92]. BIG, 
SMALL and Control male and female mice were transported in their home cages, singly housed 
and placed on a rack outside the testing room just prior to testing. The open field apparatus
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consisted of an open field arena (40 * 40 * 30 cm) with 16 10 * 10 cm squares marked on its 
floor. For testing, mice were placed in the central 4 squares of the field and allowed to explore 
the arena for 5 min. Entries into the central (20 * 20 cm) and peripheral squares were recorded
[40] by the ANYMaze video-tracking program (Stoelting Co., IL, USA). The apparatus was 
cleaned before each test.
2.3.5.2 Elevated plus maze
Assessment of anxiety-like behavior was also determined with the elevated plus maze 
test [114]. The plus maze consisted of two open arms (5 * 40 cm) and two closed arms (5 * 40 
* 20 cm) at right angles to each other. Each mouse was placed in the central square facing an 
open arm, and was allowed to explore the maze for 5 min. The time spent on the open arms 
was determined [115] by the ANYMaze video tracking program (Stoelting Co., IL, USA). An 
entry was defined as all four paws being on the arm. The maze was cleaned before each test.
2.3.6 Measuring novel object recognition behavior
The novel object recognition test was performed to measure object recognition memory 
[8]. During day 1, mice were habituated to the open field arena (40 * 40 * 30 cm) for 3 min. 
Twenty-four hours later on day 2, the time spent on investigating two identical objects (plastic 
toys) within a 5 cm distance in the open field arena was recorded for 3 min with the ANYMaze 
video tracking program (Stoelting.co). Mice were then taken out of the arena and returned to 
their home cages for 4 h. After 4 h one of the objects was replaced with a novel object of 
different shape and size and animals were then reintroduced into the arena and allowed to 
explore the objects for 3 min. Time spent exploring the familiar and novel objects were 
recorded. The preference of one object over another was assessed through the Recognition 
Index (RI) which is the time spent on the novel object relative to the time spent on both novel 
and familiar objects: [RI = TN/(TN + TF)] where TN is time spent on the novel object and TF is 
time spent on the familiar object) [38,67].
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2.3.7 Measuring depression-like behavior
Time spent immobile in the forced swim test was used as a measure of depression-like 
behavior [41,90,91], where immobility is defined as the absence of no active behaviors like 
swimming, jumping or diving [12,41,91]. Mice were introduced in a glass cylinder, 20.5 cm in 
diameter and 21.5 cm in depth, which was filled with 18 cm of water maintained at 25-27 °C for 
10 min [44].
2.3.8 Corticosterone ELISA
Mice were euthanized after the forced swim test through cervical dislocation to measure 
stress induced corticosterone levels. Trunk blood was collected randomly from each strain and 
sex (C1 males n = 4; C1 females n = 5; C2 males n = 6; C2 females n = 6; BIG1 males n = 4; 
BIG1 females n = 4; BIG2 males n = 7; BIG2 females n = 5; SML1 males n = 5; SML1 females n 
= 5; SML2 males n = 6; SML2 females n = 6) in chilled heparinized tubes and stored at -80 °C. 
After thawing the blood was centrifuged at 1000 *g for 20 min. The plasma was extracted and 
placed in fresh tubes and stored at -80 °C. The corticosterone levels were determined using a 
corticosterone ELISA kit from Cayman Chemicals (Catalogue ID: 500,655) as per the 
manufacturer's instructions and as previously described [42]. The detection limit (80% B/B0) of 
the assay is approximately 80 pg/mL (Cayman) with inter- and intra-assay coefficient of 
variation of 2.2% and 8.9%, respectively
2.3.9 Statistical analyses
All measurement values are expressed in mean ± standard error of the mean (SEM). 
Statistical Analysis System (SAS Version 9.4, Cary, NC) software was used for statistical 
analyses. All behavioral and biochemical measures were tested in a general linear model (GLM) 
analysis of variance (ANOVA) for effects of strain (BIG, SMALL, Control), sex (female, males), 
replicate (1, 2) nested within strain, and strain x sex interaction. If significant effects were found, 
appropriate post hoc pair-wise comparisons were conducted using the Tukey's Studentized
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Range. If the replicate effect was significant, the strain effect was tested over the replicate 
effect. If the replicate effect was not significant, the strain effect was tested over the error term. 
The total nesting score was square root transformed to obtain a more normal distribution [17, 
18,19], while the data are presented as non-transformed nesting scores. Significant correlations 
between behaviors within strains were determined through linear regression.
2.4 Results
2.4.1 Behavioral data
2.4.1.1 Strain, replicate and sex differences in nest building
Significant strain (F2,3 = 175.41, p < 0.001), replicate (F3,226 = 3.71, p < 0.02) and sex 
(F1 ,226 = 15.61, p < 0.0001) effects were observed for compulsive-like nest building. Both male 
and female big nest builders (BIG1 and BIG2) used more cotton to build a nest than the Control 
mice (C1 and C2) and the SMALL mice (SML1 and SML2), and the Control mice built bigger 
nests than the SMALL mice. Most SML2 male mice did not use any cotton. The replicate effect 
was due to significant differences between the BIG1 and BIG2 males and C1 and C2 females. 
Sex differences were attributed to BIG1 and BIG2 males using more cotton than proestrus 
females for nesting (Fig 2.1). The significant interaction between strain and sex (F2,226 = 16.68, 
p < 0.0001) was due to females and males not being different in total nesting scores in the C1 
and C2, and SML1 and SML2 strains, while the BIG strains showed large differences.
2.4.1.2 Replicate and sex differences in marble burying
For compulsive-like marble burying, the strain differences were marginally significant 
(F23 = 9.02, p < 0.054), predominantly due to the significant replicate effect (F3,226 = 10.21, 
p < 0.0001), although the general trend of BIG mice burying more marbles than SMALL mice 
with Control mice having intermediate values was in line with previously found significant strain 
differences [50]. The replicate effect was predominantly due to C1 females burying more
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marbles than C2 females. The significant sex effect (F^226 = 11.03, p < 0.002) resulted from C2 
and BIG1 males burying more marbles than their female counterparts (Fig 2.2). The significant 
sex by strain interaction effect (F2,226 = 4.07, p < 0.02) was due to the SMALL strains not 
showing sex or replicate effects while the other strains did.
2.4.1.3 Replicate differences in open field behavior
There were no significant strain (F23 = 1.16, p > 0.40), sex (F1 226 = 1.73, p > 0.15) and 
strain by sex interaction (F2,226 = 2.54, p = 0.08) effects on anxiety-like behavior in the open field, 
as measured by the number of central entries. Significant replicate effects (F3,226 = 17.87,
p < 0.0001) were due to female and male C2 mice making more central entries than C1 mice.
Replicate effects were also due to female and male SML1 mice making more central entries 
than SML2 mice (Fig 2.3).
2.4.1.4 Strain differences in elevated plus maze behavior
In the elevated plus maze test, anxiety-like behavior, as measured by the time spent on 
the open arms, was significantly influenced by strain (F2,226 = 22.1 1, p < 0.0001) without a 
significant replicate effect (F3,226 = 1.1 1, p > 0.30). The strain differences were due to BIG2 
males spending more time on the open arms than C2, SML1 and SML2 males and the BIG1 
and C1 males spending more time on the open arms than the SML2 males. For females, the 
C1, C2, SML1 and SML2 strains spent less time on open arms than the BIG1 and BIG2 
females. No significant sex (F1226 = 0.75, p > 0.30) and strain by sex interaction (F2,226 = 0.74, 
p > 0.40) effects were found (Fig 2.4).
2.4.1.5 Sex and replicate differences in novel-object recognition memory
No significant strain (F23 = 5.33, p > 0.09) and strain by sex interaction (F2,226 = 2.80,
p > 0.05) effects were found for novel object recognition. The significant effects of sex
(F1226 = 6.87, p < 0.01) on novel object recognition was mostly due to female C1 mice showing
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better performance than their male counterparts (Fig 2.5). A significant replicate effect was 
found (F3,226 = 3.44, p < 0.01), which was predominantly due to differences between C1 and C2 
males.
2.4.1.6 Sex and replicate differences in the forced swim test
In the forced swim test, depression-like behavior, as measured by duration of immobility, 
revealed no significant strain (F2,3 = 1.78, p > 0.25) and strain by sex interaction (F2,226 = 1 82, 
p > 0.15) effects. The significant sex (F1226 = 5.67, p < 0.05) effect was due to proestrus females 
demonstrating less depression-like immobility behavior than did males, especially SML1, BIG1, 
C1, but not SML2 strains (Fig 2.6). The significant replicate effect (F3,226 = 8.64, p < 0.0001) was 
due to differences between the SML1 and SML2 males and the C1 and C2 females.
2.4.2 Strain differences in corticosterone plasma levels
Plasma corticosterone levels were significantly influenced by strain (F252 = 12.17, 
p < 0.0001) without a replicate effect (F352 = 2.53, p > 0.05). The BIG and SMALL nest-building 
strains generally mounted a higher corticosterone response to forced swim followed by 
euthanasia. Corticosterone levels in male BIG1 and SML1 strains were significantly higher than 
the C2 strain (Fig 2.7). Also, BIG1 males had higher corticosterone levels than C1 males. In 
females, both the BIG and SMALL strains had higher corticosterone levels when compared to 
the Control strains. No significant sex (F352 = 3.68, p > 0.05) and strain by sex interaction 
(F2,52 = 1.54, p > 0.20) effects were observed.
2.5 Discussion
In this study we report for the first time that females of both the BIG strains displayed 
face validity as a non-induced compulsive-like model by using more cotton for nest building and 
burying more marbles compared to the females of the SMALL strains. For nest-building 
behavior, the female Control strains were intermediate but closer to the SMALL strains, while for
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marble burying one of the Control strains was similar to the BIG strains and the other Control 
strain was similar to the SMALL strains. BIG1 and BIG2 females had less compulsive-like 
nesting (48% and 28%, respectively), when compared to BIG1 and BIG2 males establishing a 
sex difference, which was specific to the compulsive-like mice because the SMALL and Control 
strains did not show differences between males and females. We hypothesize that this 
difference was due to using proestrus females in this study with higher estrogen levels. For 
marble burying a similar sex difference was also observed for the BIG1 strain, but not the BIG2 
strain although the trend was in the same direction.
Prior studies have shown that compulsive-like behaviors were enhanced in the absence 
of estrogen, such as estrogen-deficient male mice that showed development of compulsive-like 
wheel running and grooming behavior. These behaviors were considerably reduced with 
estrogen replacement [58]. Estrogen administration in ovariectomized rats with 8-OH-DPAT 
induced compulsive-like traits caused significant reduction in the compulsive-like behavior [33]. 
Females in proestrus have high physiological circulating estrogen levels [22,99], but whether 
estrogen played a direct role in reducing compulsive-like behaviors in proestrus female 
compared to male compulsive-like mice remains to be elucidated. Cohort based clinical studies 
have found that overall males have higher vulnerability to obsessions and compulsions when 
compared to females [14,53]. Although obsessions are difficult to model in animals, the severity 
of compulsions can be a suitable measure of it [34]. Therefore, the higher levels of compulsive­
like behaviors in BIG males compared to BIG females may further add face validity to the 
mouse model for understanding sex differences that attribute to the complexity of OCD.
Open field and elevated plus maze tests were used to assess anxiety-like behavior in 
males and females of BIG, SMALL and Control strains. No significant strain effects were found 
for the number of central entries in the open field, which indicates that this measure of anxiety­
like behavior did not correlate with the level of compulsive-like behavior. However, significant
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strain differences were observed in elevated plus maze tests for both males and females. 
Generally the BIG strains showed less anxiety-like behavior in the elevated plus maze test when 
compared to the SMALL strains, which is consistent with our previous findings [50], and the 
females showed this general pattern most clearly. The responses of the six strains in the open 
field and elevated plus maze varied, which may be due to these tests measuring different 
aspects of emotionality associated with anxiety [6,93].
Although BIG mice overall were less anxious than the SMALL mice in the elevated plus 
maze, within each BIG strain the correlations were generally opposite. Elevated plus maze 
exploration had a negative correlation with levels of compulsive-like nesting (r = -0.708, p b 
0.005) and marble burying (r = -0.562, p b 0.05) behavior in BIG2 females indicating that an 
increase in compulsive-like behavior was associated with more anxiety (less exploration of the 
open arms). A negative correlation was also found between marble burying (but not nesting) 
with open arm exploration in BIG1 males (r = -0.817, p b 0.0001). This result could be due to a 
changing genetic correlation structure as selection progressed, similar to what we found in 
these mice for the relationship between food consumption and nest building previously [19]. 
Alternatively, genetic drift and founder effects [17,19] might be responsible for the correlations 
observed in just the BIG2 females and the BIG1 males.
The association of OCD with general anxiety is deemed controversial [103]. Studies 
have shown that the ego-dystonic and intrusive nature of obsessions differ largely from general 
anxiety [64,65]. There is also large heterogeneity and variability of anxiety in OCD, though 
general anxiety is a common comorbid psychiatric condition associated with the disorder [5,84]. 
This makes it an ambiguous indicator for the disorder [85]. General anxiety and panic disorders 
have a late onset when compared to OCD, which has a very early onset [95]. In addition, 
neurocircuitry models proposed for anxiety and OCD differ. While anxiety and panic disorders 
have been linked to dysregulation of amygdala-ventromedial prefrontal cortex-hippocampus
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circuitry [98], OCD is thought to occur due to abnormal fronto-striatal circuitry [36,49,88,94]. 
Consequently, findings from the current study will allow the BIG2 female and BIG1 male strains 
to be used for studying association between various forms of compulsivity and anxiety. The 
BIG1 females and BIG2 males on the other hand can provide understanding of various forms of 
compulsivity and how they vary based on sex and genetic background.
In the depression-like forced swim test, no significant relationship was found between 
the level of compulsive-like behavior and immobility times as the strain effect was not 
significant. However, significant sex differences were observed with the females generally 
showing less depression-like behavior than males. Rodent studies have shown sex and strain 
differences in depression-like behavior in the forced swim task [13,102]. Proestrus female mice 
and rats with higher circulating estrogen have been found to be less immobile in forced swim 
task when compared to the male counterparts [43,44,47], which is similar to our findings. 
Depression is a common comorbidity associated with OCD [5, 87,104], but has been found to 
vary considerably among studies [3]. Human studies have shown that anxiety and depressions 
are influenced by factors like race/ethnicity and gender differences [78]. Hence, an effect of 
genetic background coupled with sex differences could influence the comorbid depression 
disorders in OCD and present a complex set of interactions, also reflected in our six mouse 
strains with different compulsive-like phenotypes.
The novel object recognition test revealed no significant strain effects, although the 
Control strains tended to outperform the BIG and SMALL strains. Females significantly 
outperformed the males, mostly due to the Control strains and less so due to the SMALL 
strains. The novel object recognition task is useful for studying working memory [38,46,100]. 
Several clinical studies have reported deficits in working memory among OCD patients 
[75,81,110], while others have reported no significant difference [85,86]. Our findings in the mice 
may be due to the fact that differences in working memory capacity among OCD patients are
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linked to intrusive thoughts or obsessions [15], which simply cannot be assessed in animals. 
Alternatively, novel object recognition memory may not be equivalent to the working memory 
deficits measured in OCD patients
The female Control mice had significantly lower plasma corticosterone levels than the 
BIG or SMALL strain females. This general pattern was also observed in the males, but to a 
lesser degree. Previous studies have shown that female rodents secrete higher levels of 
corticosterone than males [10,21,66], which the BIG1, BIG2, and SML2 mice tended to show as 
well, although the overall sex effect was not significant. Additionally, in proestrus, corticosterone 
levels in response to stress are higher [9,21,35,112]. Coping with stress is promoted by the 
hypothalamic-pituitary-adrenal (HPA) axis [28,106] and corticosterone is a primary end point of 
HPA axis activation in mice [54]. OCD is known to be stress responsive since symptoms not 
only increase during periods of stress but stressful events can also precede the onset of 
obsessive-compulsive symptoms [80]. Our results show that selection to behavioral extremes, 
both in the high and low direction of nesting, resulted in enhanced activation of the HPA axis 
due to stress imparted by the forced swim test. OCD patients have higher baseline urine [45] 
and blood [61] cortisol levels than healthy matched controls, which can be compared to the 
higher stress-induced corticosterone levels in the BIG strains compared to the Control strains.
Significant replicate effects nested within strain were found for nest building, marble 
burying, open field behavior, novel object recognition memory, and the forced swim test. These 
replicate effects were most likely due to differences in genetic background as a result of random 
genetic drift and founder effects within each strain [17,19]. Of special interest are the replicate 
effects between the BIG strains as they represent the compulsive-like phenotype and may 
correspond to subtypes of compulsive-like phenotypes as seen in human OCD patients 
[39,48,68]. The male BIG1 strain nested more than the BIG2 strain, while the BIG2 strain 
showed more anxiety-like behavior in the elevated plus maze than the BIG1 strain. However,
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the females were not different from each other for either trait indicating a potential sex by 
genotype interaction. Further, sex differences in only the BIG1 but not the BIG2 strains in 
marble burying add heterogeneity based on specific compulsive-like traits that might 
significantly vary depending on the sex and genotype.
2.6 Conclusion
In the current study, we confirmed that females of the compulsive-like BIG strains also 
have face validity as a mouse model of OCD, enhancing our earlier findings in males [50]. 
Proestrus females also showed lower levels of compulsive-like behaviors than males, which 
suggest that physiological changes in females related to the estrous cycle might influence 
compulsive-like behavioral expression. A differential response was observed in anxiety-like 
behaviors with replicate effects in the open field and strain differences in the elevated plus 
maze. Sex differences were seen for depression-like behavior with an elevated HPA axis 
response in females compared to males. Overall, our mouse strains can be used to better 
understand how genetic and sex factors and behavioral correlates contribute to the compulsive­
like phenotype. Replicate effects in compulsive-like expression also indicate symptom 
heterogeneity that is strongly associated with OCD making it a complex neuropsychiatric 
disorder. Future studies will aim at investigating sex and strain differences in first line therapy 
responses and the neurobiological mechanisms in the mouse model that could broaden the 
understanding of heterogeneity and drug unresponsiveness in certain OCD subtypes when 
compared to others.
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2.8 Figures
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Fig 2.1 Nest-building behavior.
Mean (± SEM) total nesting scores of male and female BIG, SMALL and Control replicate 
strains. BIG1 and BIG2 males had higher nesting score than C1 (t = 15.28 p < 0.001 and 
t = 12.95 p < 0.001), C2 (t = 17.20 p < 0.001 and t = 14.86 p < 0.001), SML1 (t = 20.47 
p < 0.001 and t = 18.16 p < 0.001) and SML2 (t = 22.72 p < 0.001 and t = 20.42 p < 0.001) 
males. BIG1 males had higher nesting score than BIG2 males (t = 2.365 p < 0.05). BIG1 and 
BIG2 females had higher nesting score than C1 (t = 9.564 p < 0.001 and t = 9.364 p < 0.001), 
C2 (t = 11.81 p < 0.001 and t = 11.43 p < 0.001), SML1 (t = 15.19 p < 0.001 and t = 14.34 
p < 0.001) and SML2 (t = 14.20 p < 0.001 and t = 13.49 p < 0.001) females. BIG1 and BIG2 
males had higher nesting score than BIG1 and BIG2 females (t = 6.682 p < 0.001 and t = 2.886 
p < 0.05).
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Fig 2.2 Marble burying behavior.
Mean (± SEM) number of marbles buried in male and female BIG, SMALL and Control replicate 
strains. Replicate effect was due to C1 females burying more marbles than C2 females 
(t = 5.850 p < 0.001). BIG1 and C2 males buried more marbles than BIG1 (t = 3.132 p < 0.05) 
and C2 (t = 4.201 p < 0.001) females, contributing to the sex differences and strain by sex 
interactions.
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Fig 2.3 Open field behavior.
Mean (± SEM) number of central entries in male and female BIG, SMALL and Control replicate 
strains. C2 males and females had more central entries than C1 males (t = 3.739 p < 0.001) and 
females (t = 3.903 p < 0.001), respectively. SML1 males and females had more central entries 
than SML2 males (t = 3.624 p < 0.001) and females (t = 3.903 p < 0.01), respectively.
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Fig 2.4 Elevated plus maze behavior.
Mean (± SEM) time spent on open arms of male and female BIG, SMALL and Control replicate 
strains. Significant strain differences were observed in time spent on open arms between male 
BIG2 with C2 (t = 3.881, p < 0.001), SML1 (t = 3.807, p < 0.001) and SML2 strains (t = 4.899, 
p < 0.001). The C1, C2, SML1 and SML2 females spent less time on open arms when 
compared to BIG1 females (t = 3.836, p < 0.001; t = 2.627, p < 0.05; t = 4.041, p < 0.001; 
t = 3.923, p < 0.001, respectively). The C1, SML1 and SML2 females spent less time on open 
arms when compared to BIG2 females (t = 2.904, p < 0.01; t = 3.085, p < 0.01; t = 2.994, 
p < 0.01, respectively).
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Fig 2.5 Novel object recognition behavior.
Mean (± SEM) recognition index of male and female BIG, SMALL and Control replicate strains. 
The C2 males had higher RI values when compared to C1 males (t = 3.340, p < 0.01). The C1 
females had higher RI when compared to C1 males (t = 3.921, p < 0.001).
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Fig 2.6 Forced swim test.
Mean (± SEM) immobility time of male and female BIG, SMALL and Control replicate strains. 
SML1 males had higher immobility times than SML2 males (t = 5.796, p < 0.001) while C2 
females had higher immobility times than C1 females (t = 4.229, p < 0.001). BIG1, C1 and 
SML1 males had higher immobility times when compared to BIG1 (t = 3.063, p < 0.05), C1 
(t = 3.778, p < 0.01) and SML1 (t = 3.083, p < 0.01) females. In the SML2 strain, females had 
higher immobility time than the males (t = 3.827, p < 0.01).
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Fig 2.7 Plasma corticosterone levels.
Mean (± SEM) corticosterone levels as a measure of HPA axis stress response of male and 
female BIG, SMALL and Control replicate strains. Levels in male BIG1 and SML1 strains were 
significantly higher than the Control C2 strain (t = 3.773, p < 0.001 and t = 4.385, p < 0.001, 
respectively). BIG1 (t = 2.455, p < 0.05) and SML1 (t = 2.916, p < 0.05) males had higher 
corticosterone levels than C1 males. Female BIG1, BIG2, SML1 and SML2 also had higher 
corticosterone levels than female C1 (t = 3.90, p < 0.001; t = 3.73, p < 0.001; t = 2.91, p < 0.05 
and t = 4.91, p < 0.001, respectively) and C2 (t = 4.95, p < 0.001; t = 4.85, p < 0.001; t = 3.99, 
p < 0.001 and t = 5.30, p < 0.001, respectively).
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Chapter 3: Strain and trait specific attenuation of compulsive-like behavior by fluvoxamine in a 
non-induced mouse model of obsessive-compulsive disorder.2
3.1 Abstract
The influence of genetic background on efficacy of drug treatment in OCD is poorly 
understood. The current study evaluates the role of strain and compulsive trait differences in 
response to fluvoxamine, a common OCD drug, in two different mouse strains (BIG1 and BIG2) 
exhibiting a spontaneous compulsive-like phenotype. For compulsive-like nest-building 
behavior, dose-dependent attenuation of nesting was observed for BIG1 compulsive-like strain 
following one hour of administration. No significant differences were observed for BIG2 strain 
after one hour. Fluvoxamine dose dependently decreased the number of marbles buried in both 
strains one hour after administration. For anxiety-like behaviors in the open field no significant 
drug effects were found for the latency to leave the center and the number of line crossings. The 
10 mg/kg fluvoxamine dose increased time in the center for the BIG2 strain compared to the 0 
mg/kg control group. Taken together these results suggest a strong role of strain and specific 
compulsive traits in influencing efficacy of fluvoxamine. The results also indicate better 
effectiveness of intermediate but not high doses of fluvoxamine in mitigating certain anxiety-like 
behaviors in the compulsive-like condition.The data from this study corroborates the differential 
treatment responses in human OCD patients, further validating the use of our compulsive-like 
mouse strains for understanding the neurobiology associated with the clinical heterogeneity in 
OCD.
2 2Submitted as Mitra S, Bult-Ito A. Strain and trait specific attenuation of compulsive-like behavior by 
fluvoxamine in a non-induced mouse model of obsessive-compulsive disorder. Journal of Behavioral 
Pharmacology.
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3.2 Introduction
Obsessive-compulsive disorder (OCD) is an intricate heterogeneous disorder 
characterized by persistent obsessions (thoughts) and compulsions (repetitive behaviors) 
(Karno et al., 1988; Albert et al., 2013). In the United States OCD has an estimated lifetime 
occurrence of about 2.3% (Ruscio et al., 2010). The social functioning, relationships, quality of 
life and socio-economic status of patients suffering from OCD are significantly impacted 
(Fontenelle et al., 2010; Hollander et al., 2010).
The most common forms of first line treatments for OCD are selective serotonin 
reuptake inhibitors (SSRI) and cognitive behavioral therapy (Kellner, 2010; Pittenger et al., 
2005; Bandelow et al., 2012). Fluvoxamine is a first generation SSRI widely used for treatment 
of OCD (Irons, 2005). It is a potent inhibitor of serotonin reuptake at the synapses and has no 
effect on reuptake of dopamine and nor-epinephrine (Goodman et al., 1997). Many clinical 
studies have shown efficacy of fluvoxamine in treating OCD (Goodman et al., 1989, Mallya et 
al., 1992; Milanfranchi et al., 1997; Mundo et al., 2001). However, 40-60% of the OCD patients 
are refractory to the first line treatments (Nakamae, 2013). Even patients categorized as clinical 
responders continue exhibiting impairments from their residual obsessions and compulsions 
(Lack, 2012). Considering such high drug resistant rates among patients, a better understanding 
of the efficacy of first line treatments on specific compulsive traits in OCD subjects of different 
genetic backgrounds is needed.
Investigating drug intervention in mouse strains exhibiting spontaneous compulsive-like 
behaviors can be a valuable starting point for determining if there is any role of genetic 
background and compulsive traits in influencing drug response. OCD has a strong genetic 
connection which has been established in both human and rodent studies (Hettema et al., 2001; 
Pato et al., 2002; Welch et al., 2007; Wang et al.,2010; Ting and Feng, 2011; Taylor, 2013). 
According to Maio et al. (2014), comparing our compulsive-like strains can be useful for
108
understanding the disease mechanism during the OCD condition. As per our knowledge, no 
studies have been undertaken to elucidate the efficacy of a first line OCD treatment on two 
different spontaneously compulsive-like mouse strains for compulsive- and anxiety-like 
behaviors. Hence, in the current study we aim to investigate the efficacy of fluvoxamine in 
attenuating two separate compulsive-like behaviors (marble burying and nest-building) exhibited 
by the compulsive-like BIG mice (Greene-Schloesser et al., 2011) and anxiety-like behavior 
(open field).
The current mouse model was developed by bidirectionally selecting house mice, Mus 
musculus, for nest-building behavior (Lynch, 1980; Bult and Lynch, 2000). The stock population 
for the original selection experiment (Lynch, 1980) was a cross among eight inbred strains 
yielding the HS/Ibg outbred strain (McClearn et al., 1970; Lynch, 1980). Nest-building behavior, 
which is homologous to hoarding in humans with OCD (Warneke, 1993), is considered a 
measure of compulsive-like behavior in mice (Greene- Schloesser et al., 2011). Bidirectional 
selection resulted in three main strains of mice exhibiting three different levels of nesting 
behavior. The BIG strains consistently display high levels of nesting with a forty-fold difference 
in the amount of cotton used (typically the BIG1 and BIG2 mice nest on an average 8 grams of 
cotton in 24-hour period which is in contrast to 0.20 grams for non-compulsive SMALL and 0.70 
grams for Control mice) when compared to the SMALL strains which display very low levels of 
nesting. The randomly-bred Control strains serve as a selection control and show intermediate 
levels of nesting (Bult and Lynch, 2000). Each of these BIG, SMALL and Control strains has two 
replicate strains (BIG1 and BIG2, SML1 and SML2, and C1 and C2). The BIG strains of mice 
exhibit compulsive-like behavior (nest-building and marble burying) without gene manipulations, 
behavioral inductions, or administration of psychostimulants, which makes them a novel non­
induced model of OCD (Greene- Schloesser et al., 2011). Further, consistent differences in 
compulsive- and anxiety-like behaviors have also been observed between the two BIG strains
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(BIG1 and BIG2) making them ideal for investigating the role of strain differences in influencing 
drug effectiveness.
3.3 Methods
3.3.1 Animals
Intact compulsive-like BIG male house mouse (Mus musculus) strains (BIG1, BIG2) 
were used for the study (BIG1 n= 36: BIG2 n= 38). A total of 12 animals per group per strain 
was initially considered but 12 mice from BIG1 and 10 mice from BIG2 strain was euthanized 
due to skin scabbing). Mice were raised in polypropylene cages (27^17^12 cm) with wood 
shavings under a 12-12 light-dark cycle at 22±1°C. Food (Purina Mills, Lab Diet Mouse Diet 
#5015, St. Louis, MO) and water were provided ad libitum. Pups were weaned at 19-21 days of 
age and housed with same-sex littermates. All animals were approximately 60 days old at the 
start of the experiment.
3.3.2 Drug administration
Fluvoxamine maleate (Sigma Aldrich) was dissolved in physiological saline (pH=7.4) to 
yield final doses of 10 mg/kg, 20 mg/kg and 40 mg/kg (pH 7-7.4). Saline served as a vehicle (0 
mg/kg) control. All male compulsive-like mice were divided into four treatment groups (starting 
at 12 animals per group) comprising vehicle (sterile saline with pH adjusted to 7.4), 10 mg/kg, 
20 mg/kg and 40 mg/kg fluvoxamine. Animals in each group received subcutaneous injections 
of fluvoxamine/vehicle daily for 17 days.
3.3.3 Experimental design
All Animals underwent behavioral testing consecutively consisting of nest building on 
day 15, marble burying on day 16 and open field on day 17 of the 17-day fluvoxamine treatment 
regimen. The sequence of behavioral tests, i.e., doing the anxiety-like tests before the
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compulsive-like tests or vice versa, does not affect the performance in any of these behaviors in 
our mouse strains (data not shown).
For nest-building, data was collected during the first hour after fluvoxamine 
administration. Marble burying and open field were performed one hour after drug 
administration. Marble burying was performed for 15 minutes and open field for 3 minutes 
(Greene-Schloesser et al., 2011). Testing was performed in the light phase of the light-dark 
cycle and the University of Alaska Fairbanks Institutional Animal Care and Use Committee 
approved the animal care and experimental procedures (IACUC assurance number 718349).
3.3.4 Compulsive-like nest-building behavior
Nest-building behavior was used as a measure of the compulsive-like phenotype of the 
mice (Greene-Schloesser et al., 2011). Male mice of both the BIG strains (BIG1 andBIG2) were 
singly housed and provided with a pre-weighed cotton roll in the cage-top food hopper. The 
cotton roll was removed and weighed (Bult and Lynch, 1996; Bult and Lynch, 1997; Bult and 
Lynch, 2000) after 1 hour of fluvoxamine administration. The total nesting score was defined as 
the amount of cotton used over a 1 -hour period.
3.3.5 Compulsive-like marble burying behavior
The marble-burying test was also used for determining compulsive-like behavior
(Takeuchi et al., 2002; Thomas et al., 2009; Greene-Schloesser et al., 2011; Angoa-Perez et al., 
2013). One hour after fluvoxamine administration, compulsive-like male mice were individually 
introduced into a polypropylene cage (37^21^14 cm) containing 2 0  glass marbles ( 1 0  mm in 
diameter) spaced evenly on wood chip bedding 5 cm deep without access to food or water for 
15 min (Greene-Schloesser et al., 2011). Testing was carried out in the testing room separate 
from the housing room. The total number of marbles buried at least 2/3 in the 15-min period was
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quantified as compulsive-like digging behavior. After the 15-min test, the animals were returned 
to their home cages.
3.3.6 Anxiety-like open field behavior
Anxiety-like behavior in the mice was evaluated through open field test (Simon et al., 
1994; Prut and Belzung, 2003). BIG1 and BIG2 males were transported in their home cages, 
singly housed and placed on a rack outside the testing room just prior to beginning testing. The 
open field apparatus consisted of an open field arena (40 x 40 x 30 cm) with 16 10 x 10 cm 
squares on its floor. For testing, animals were placed in the center of the field and allowed to 
explore the arena for 3 minutes. Latency to leave the central square (20 x 20 cm) initially and
entries into the central zone (2 0  x 2 0  cm) after leaving it initially were recorded to quantify
anxiety like behaviors. The total number of line crossings was recorded as a measure of
locomotor activity (Frye et al., 2006; Nosek et al., 2008; Greene-Schloesser et al., 2011). The
apparatus was cleaned before each test.
3.3.7 Statistical analysis
Values from all behavioral assessments were expressed in mean ± standard error of the 
mean (SEM). Statistical Analysis System Software (Version 9.4, Cary, NC) was used for 
statistical analyses. All behavioral measures were tested in a general linear model (GLM) 
analysis of variance (ANOVA) for effects of strain, drug and strain x drug interaction effects. If 
significant effects were found, appropriate post-hoc pair-wise comparisons were conducted 
using the Tukey's Studentized Range test. The total nesting score was square-root transformed 
to obtain a more normal distribution (Bult and Lynch, 2000), while the data are presented as 
non-transformed nesting scores.
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3.4 Results
3.4.1 Strain dependent attenuation of compulsive-like nesting behavior by fluvoxamine
After 1 hour of fluvoxamine administration there was a significant drug effect (F3,74 = 
11.73, p<0.0001). 20 and 40 mg/kg doses significantly attenuated the nesting scores for BIG1 
strain when compared to vehicle (0 mg/kg). There was no significant effect of fluvoxamine on 
nesting in the compulsive-like BIG2 strain (Fig 3.1).
3.4.2 Dose-dependent attenuation of compulsive-like marble burying behavior by fluvoxamine in 
both the BIG strains.
A significant dose-dependent drug effect (F3,74 = 13.08, p<0.0001) was observed in the 
number of marbles buried. The 20 and 40 mg/kg doses showed significant attenuation of marble 
burying when compared to vehicle in both the BIG1 and BIG2 strains. No significant strain (F174 
= 1.99, p>0.16) and drug by strain interaction (F3,74 = 0.88, p>0.45) effects were found (Fig 3.2).
3.4.3 Significant strain differences in anxiety-like open field behavior
For anxiety-like open field test a significant strain effect (F174 = 39.83 p<0.0001) for the 
latency to leave the central square was found with the BIG1 strain taking less time when 
compared to the BIG2 strain. The drug (F3,74 = 2.21, p>0.09) and drug by strain interaction (F3,74 
= 0.76, p>0.451) effects were not significant (Fig 3.3a). For the time spent in the central square 
the strain effect was marginally significant (F174 = 3.73, p>0.05) with the BIG1 mice tending to 
spend more time in the central square compared to the BIG2 mice. The significant drug effect 
(F3,74 = 5.12, p<0.003) was primarily due to the 10 mg/kg dose which increased the time spent in 
the central zone for BIG2 strains compared to the vehicle (Fig 3.3b). The drug by strain 
interaction effect was not significant (F3,74 = 0.47, p>0.70). For the number of line crossings 
there was a significant strain effect (F174 = 19.61,p<0.0001), which was due to the BIG1 strains
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having more line crossings when compared to the BIG2 strains (Fig 3.3c). No significant drug 
(F3,74 = 0.77, p>0.51) or drug by strain interaction (F3,74 = 0.19, p>0.89) effects were found.
3.5 Discussion
Our results showed that a fluvoxamine treatment regimen for 15-17 days resulted in 
significant dose-dependent attenuation of compulsive-like nesting in BIG1 but not BIG2 male 
mice. This effect was observed following one hour of drug administration on the day of testing. 
Marble burying behavior on the other hand was dose-dependently reduced by fluvoxamine in 
both BIG1 and BIG2 strains. The dose response is in congruence with human studies where 
high doses of fluvoxamine have been found to be more effective for compulsive behaviors when 
compared to low doses (Fontenelle et al., 2007; Ordacgi et al., 2009; Koran et al., 2010). 
Previous study with the BIG mice has shown that a two week (14 days) fluoxetine (SSRI) 
treatment significantly attenuates nesting and marble burying behavior (Greene-Schloesser et 
al., 2011) in the BIG1 strain. This is the first time we used both the BIG strains (BIG1 & BIG2) 
for comparing the compulsive-like behavioral response to a first line treatment, fluvoxamine. The 
results support both nesting and marble burying behavior for compulsive-like assessment in our 
model. This is in contrast to the compulsive-like deer mouse model with spontaneous 
stereotypy, in which marble burying behavior was not associated with stereotypy and did not 
respond to oral escitalopram treatment (Wolmarans et al., 2016b). So for deer mice, marble 
burying behavior did not appear to be a compulsive-like behavior. Interestingly, stereotypy and 
nest-building behavior also did not correlate, but 30% of the deer mice, irrespective of these two 
behaviors, showed unusually large nest building behavior, which was attenuated by 
escitalopram (Wolmarans et al., 2016a). So individual deer mice show different compulsive-like 
behaviors, i.e., stereotypy or nest building, but these were not correlated, while our BIG nest 
builders have a predictable compulsive-like phenotype showing both compulsive-like nesting 
and marble burying that can be attenuated with drugs used in OCD (Greene-Schloesser et al.,
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2011) as shown in this study. Therefore, it appears that compulsive-like behaviors are specific 
and that not all compulsive-like behaviors are genetically correlated or affected by the 
environment in similar ways.
Locomotor activity was measured in the open field test (Hale et al., 2008) and was not 
affected by fluvoxamine. This result replicates another study with fluvoxamine in mice in which 
repeated fluvoxamine administration attenuated marble burying but not locomotion or 
exploratory behavior (Ichimaru et al., 1995). Overall, BIG2 mice showed larger levels of anxiety­
like behaviors than BIG1 mice measured as time to leave the central square in the open field. 
This replicates earlier findings in these compulsive-like strains. For time spent in center in the 
BIG2 mice the 10 mg/kg group showed anxiolytic behavior when compared to the 0 mg/kg 
group, and the BIG1 strain showed the same trend. This effect was however not observed for 
the higher doses (20 and 40 mg/kg) for both the BIG1 strains, showing that fluvoxamine only 
had a moderate effect overall. This is an interesting finding since a prior study with mice has 
shown that fluvoxamine had no anxiolytic effects on different anxiety tests (Ichimaru et al., 
1995). Our results show that behavioral response to fluvoxamine in our compulsive-like mice for 
anxiety-like measures could be very specific to assessed parameters (line crossings, time in 
center, latency to leave the center) and can vary between strains. While, fluvoxamine is well 
tolerated and used widely in the treatment of general anxiety disorder and OCD (Freeman et al., 
1994; Irons, 2005; Mundo et al., 2000), not many studies have focused on looking at the effect 
of fluvoxamine in treating co-morbid anxiety in complex neuropsychiatric disorders (Nadeau et 
al., 2011). A study on the efficacy of fluvoxamine in treating autism spectrum disorder (ASD) 
and associated anxiety resulted in a poor response to treatment (Martin et al., 2003). The ego- 
dystonic and intrusive nature of obsessions differs largely from general anxiety (Langlois et al., 
2000, 2000a). In addition to large heterogeneity and variability of anxiety in OCD, this makes it a 
non-significant indicator for the disorder (Nutt and Malizia, 2006). General anxiety disorders and
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panic disorders have a late onset when compared to OCD, which has a very early onset 
(Rosenbaum et al., 1997). In addition, neurocircuitry models proposed for anxiety and OCD 
differ. While anxiety and panic disorders have been linked to dysregulation of amygdala- 
ventromedial prefrontal cortex-hippocampus circuitry (Rauch et al., 2006; Shin and Liberzon, 
2010), OCD is thought to occur due to abnormal fronto-striatal circuitry (Fitzgerald et al., 2005; 
Rauch et al., 2007; Greenberg et al., 2010). A study from our lab on compulsive-like (BIG) and 
non-compulsive-like (SMALL) mice indicated that general anxiety appears to be separate from 
anxiety pertaining to compulsions (Greene-Schloesser et al., 2011). This is corroborated by 
other studies where association of OCD with general anxiety is deemed controversial (Stein et 
al., 2 0 1 0 ).
There is currently a lack of consensus on the best treatment option for OCD patients 
(Pittenger et al., 2005). Significant relapse rates have been reported in clinical studies with 
SSRI's (Abramowitz et al., 2009). Medication differences have also been observed with these 
first line treatments. One such example is that of comorbid tics in children with OCD which 
reduces efficacy of SSRI (March et al., 2007). It is however unclear if the same effect is 
persistent in adults (Lack, 2012). Among various factors, compulsive traits and associated co­
morbid symptoms can result in non responsiveness to treatments in the OCD condition (Koran, 
2004). Studies have attributed strong genetic link to the etiological heterogeneity of OCD 
(Nestadt et al., 2000; Pauls, 2010). These genes have also been thought to contribute to the 
disease severity and treatment resistance (Ozaki et al., 2003; Wendland et al., 2008). 
Quantitative genetic analysis has indicated that nesting behavior is a highly polygenic trait (Bult 
and Lynch, 2000) which is consistent with OCD in humans likely influenced by many candidate 
genes (Pauls et al., 1999; Hettema et al., 2001; Stein, 2002; Smoller., 2009). Hence, our mouse 
model selected for varied levels of compulsive-like behavior, i.e., nest-building, provides a
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critical insight into the role of genetic background and trait in influencing first line treatment 
efficacy.
3.6 Conclusion
This study adds predictive validity to our mouse model for investigating trait specific drug 
resistance OCD subtypes and the role of compulsive trait and genetic background in influencing 
drug action. Fluvoxamine commonly used to treat OCD, dose-dependently decreased nest 
building behavior in one compulsive-like strain and dose-dependently attenuated marble burying 
in both compulsive-like strains. This behavior and strain specific response, coupled with one of 
the compulsive-like strains being more anxious than the other, adds heterogeneity to our mouse 
model, similar to the heterogeneity seen in OCD. Future studies will involve probing into the 
mechanisms of trait specific drug resistance in the compulsive-like mouse strains.
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3.8 Figures
Fig 3.1 Compulsive-like nest-building behavior of the BIG1 and BIG2 strains.
The data represent the mean (± SEM) for the nesting score in grams for the 0-1 hour period. 
***(p<0.0001) indicates significant drug effect between 20 and 40 mg/kg with vehicle (0 mg/kg) 
in BIG1 strain. 0 mg/kg, n=11 and n=11; 10 mg/kg, n=7 and n=12; 20 mg/kg, n=10 and n=8 ; 40 
mg/kg, n= 6  and n=9 for BIG1 and BIG2, respectively.
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Fig 3.2 Compulsive-like marble burying behavior of the BIG1 and BIG2 strains.
The data represent the mean (± SEM) for total number of marbles buried. ***(p<0.0001) 
indicates significant drug effect between 20 and 40 mg/kg with vehicle (0 mg/kg) in both BIG1 
and BIG2 strains. 0 mg/kg, n=11 and n=11; 10 mg/kg, n=7 and n=12; 20 mg/kg, n=10 and n=8 ; 
40 mg/kg, n= 6  and n=9 for BIG1 and BIG2, respectively.
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Fig 3.3 Anxiety-like open field behavior of the BIG1 and BIG2 strains.
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Fig 3.3 continued: The data represent the mean (± SEM) for (a) latency to leave the central 
square, *(p<0.05) indicates significant strain differences between BIG1 and BIG2 males in each 
treatment group, (b) the time spent in the central square, *(p<0.05) indicates significant drug 
effect between 10 mg/kg with vehicle (0 mg/kg) in BIG2 strain, and (c) the total number of line 
crossings, *(p<0.05) indicates strain differences between BIG1 and BIG2 for the 10 and 20 
mg/kg treatment groups. 0 mg/kg, n=11 and n=11; 10 mg/kg, n=7 and n=12; 20 mg/kg, n=10 
and n=8 ; 40 mg/kg, n= 6  and n=9 for BIG1 and BIG2, respectively.
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Chapter 4: Ovarian Sex Hormones Modulate Compulsive, Affective and Cognitive Functions in 
A Non-Induced Mouse Model of Obsessive-Compulsive Disorder.3
4.1 Abstract
There is currently a lack of understanding of how surgical menopause can influence 
obsessions, compulsions and associated affective and cognitive functions in female obsessive- 
compulsive disorder (OCD) patients. Early menopause in women due to surgical removal of 
ovaries not only causes dramatic hormonal changes, but also may induce affective and 
cognitive disorders. Here, we tested if surgical removal of ovaries (ovariectomy, OVX), which 
mimics surgical menopause in humans, would result in exacerbation of compulsive, affective 
and cognitive behaviors in mice strains that exhibit a spontaneous compulsive-like phenotype. 
Female mice from compulsive-like BIG, non-compulsive SMALL and randomly-bred Control 
strains were subjected to OVX or sham-surgery. After 7 days animals were tested for nest 
building and marble burying to measure compulsive-like behavior. The elevated plus maze and 
open field tests measured anxiety-like behaviors, while memory was assessed by the novel 
object recognition. Acute OVX resulted in exacerbation of compulsive-like and anxiety-like 
behaviors in compulsive-like BIG mice. No significant effects of OVX were observed for the non­
compulsive SMALL and Control strains. Object recognition memory was impaired in 
compulsive-like BIG female mice compared to the Control mice, without an effect of OVX on the 
BIG mice. We also tested whether 17 p-estradiol (E2) or progesterone (P4) could reverse the 
effects of OVX. E2, but not P4, attenuated the compulsive-like behaviors in compulsive-like BIG 
OVX female mice. The actions of the sex steroids on anxiety-like behaviors in OVX females 
were strain and behavioral test dependent. Altogether, our results indicate that already existing
3 Published as 3Mitra, S., Bastos, C. P., Bates, K., Pereira, G. S., & Bult-Ito, A. (2016a). Ovarian Sex 
Hormones Modulate Compulsive, Affective and Cognitive Functions in A Non-Induced Mouse Model of 
Obsessive-Compulsive Disorder. Frontiers in Behavioral Neuroscience, 10, 215.
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compulsions can be worsened during acute ovarian deprivation concomitant with exacerbation 
of affective behaviors and responses to hormonal intervention in OVX female mice can be 
influenced by genetic background.
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4.2 Introduction
Obsessive-compulsive disorder (OCD) is characterized by intrusive thoughts 
(obsessions) and/or repetitive behaviors (compulsive rituals) in response to the obsessions 
(American Psychiatric Association, 2013). OCD has a lifetime prevalence of around 2.3% in the 
United States (Ruscio et al., 2010) and it has been listed as a common mental disorder in adults 
(Eaton et al., 2008). The obsessive beliefs lead to compulsive symptoms among patients. For 
example, contamination obsessions can result in compulsive cleaning (Wheaton et al., 2010). 
Moreover, OCD can negatively impact cognitive and affective functions in humans. Human 
studies involving neurocognitive tests and image analysis showed impairments in non-verbal 
(Kashyap et al., 2013), spatial working (Van der Wee et al., 2007; Nakao et al., 2009) and visual 
memories (Dirson et al., 1995). Associated comorbidities like depression (Peris et al., 2010; 
Remijnse et al., 2013) and anxiety disorders (Nestadt et al., 2001) are also very common in the 
OCD condition.
Clinical and genetic data for OCD corroborate the hypothesis of sexual dimorphism, 
which reveals differences in clinical manifestations between males and females (Labad et 
al., 2008; Torresan et al., 2009). Obsessions for cleaning and compulsive contamination are 
more prevalent in females than males, while males have higher rates of symmetrical and sexual 
obsessions when compared to females (Noshirvani et al., 1991; Lensi et al., 1996; Bogetto et 
al., 1999; de Mathis et al., 2008; Labad et al., 2008). There is also a sex difference to treatment 
response (Mundo et al., 1999). Women typically have a later onset when compared to men and 
display a bi-modal distribution with the first peak occurring between 13-16 years of age and the 
second peak around 22-32 years. These are puberty and child bearing stages in a women’s 
life, respectively (Brandes et al., 2004) when sex hormone (estrogen and progesterone, P4) 
levels are known to fluctuate.
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It is well established that a plausible cause of OCD is abnormal cortical-striatal-thalamic 
circuitry activation (Ahmari et al., 2013) and altered serotonergic (Schilman et al., 2010), 
glutamatergic (Arnold et al., 2004; Egashira et al., 2013; Porton et al., 2013) and GABAergic 
(Egashira et al., 2013) systems. Interestingly, female hormones, such as estrogen and P4, 
regulate various neurotransmitter signaling pathways in brain regions implicated in OCD (Dreher 
et al., 2007; Karakaya et al., 2007; Benmansour et al., 2009; Alonso et al., 2011; Quinlan et 
al., 2013; Barth et al., 2015). During the estrous phase, circulating estrogen levels are higher 
and serotonin release is lower in striatal neurons (Yang et al., 2015), while in the frontal cortex, 
estrogen depletion by ovariectomy (OVX) decreases 5-HT2A receptor density and mRNA levels 
(Cyr et al., 1998). On the other hand, P4 increases dopamine release mediated by NMDA 
receptor activation in striatal neurons (Cabrera and Bregonzio, 1996) and decreases NMDA 
binding density in the frontal cortex after OVX (Cyr et al., 2000). Therefore, ovarian sex 
hormones may account for the sex differences observed in OCD.
Women are subjected to hormonal fluctuations during their entire life span, which may 
lead to significant alterations in mood and cognition (Soares and Zitek, 2008). However, 
remarkable challenges are encountered during the menopause transition due to the natural 
decline in ovarian function, the primary source of estrogen and P4 (Luine, 2014). Natural 
menopause is also associated with cognitive deficits and mood disorders (Weber et al., 2012; 
Dumas et al., 2013). Such dysfunction in mood and cognitive functions has also been reported 
in women with surgical menopause (Chen et al., 2013; Faubion et al., 2015). Physiological 
challenges during surgical menopause are much more drastic due to a sudden depletion of 
ovarian sex steroids as compared to progressive menopause which follows fluctuating patterns 
of steroid levels (Bachmann, 2001; Rodriguez and Shoupe, 2015; Rodrlguez-Landa et 
al., 2015). This results in greater predisposition to mood and anxiety disorders when compared 
to natural menopause (Rodrlguez-Landa et al., 2015).
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The impact of acute ovarian dysfunction during surgical menopause on compulsive 
behaviors and comorbid affective behaviors in females are currently poorly understood. In 
addition to younger women, one out of eight women after the age of 55 undergoes bilateral 
oophorectomy (surgical removal of ovaries) before reaching natural menopause due to benign 
diseases, prophylaxis against cancer and autoimmune disorders (Shuster et al., 2010; Erekson 
et al., 2013; Cox and Liu, 2014). Existing studies have investigated obsessions and 
compulsions only during and after progressive menopause with contradictory evidence (Vulink 
et al., 2006). One such study showed that, OCD is not a rare comorbidity during post 
menopause (Uguz et al., 2010), while another study demonstrated that the symptoms are more 
related with menarche and decreases during menopause (Guglielmi et al., 2014).
In animal studies, acute administration of estradiol (E2) in pre-pubertal female rats 
exerted an anti-compulsive-like effect (Flaisher-Grinberg et al., 2009), while male mice with 
estrogen deficiency (aromatase enzyme knockout) displayed compulsive-like behavior (Hill et 
al., 2007). In OVX rats, concurrent administration of E2 and P4 was able to reduce compulsive­
like lever pressing behavior (Fernandez-Guasti et al., 2006). Most of these studies were 
conducted on induced (drug or gene knockouts) models and did not investigate the associated 
comorbidities like anxiety and cognitive impairments, while only one study looked at the effect of 
P4 and E2 in the ovariectomized condition (Fernandez-Guasti et al., 2006). Moreover, though 
OCD has a compelling genetic basis (Nestadt et al., 2010) the role of genetic background in 
influencing steroid actions in OCD condition during menopause has never been explored.
How do already existing compulsions in females get affected during acute sex hormone 
deprived conditions when compared to non-compulsive females are not clearly known. The co 
morbid anxiety and cognitive functions associated with OCD during such a physiological state 
and the role of genetic background in influencing steroid actions demands investigation. 
According to Maio et al. (2014), our mice developed through selective breeding for phenotypes
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of increased or decreased amounts of compulsive-like behavior can be a heuristic tool for 
studying OCD, especially the replicate BIG strains (BIG1 and BIG2). An unpublished study from 
our lab has shown that there is variation in compulsive-like and affective behaviors between the 
two replicate BIG strains that mimics heterogeneity as seen in subgroups of OCD patients. This 
study however did not look into hormonal deprivation and manipulations. We therefore 
investigated the hypothesis that acute deprivation of estrogen and P4 through OVX for 7 days 
will increase the compulsive-and anxiety-like behavior and impair novel object recognition 
memory in compulsive-like mouse strains. We also hypothesized that the administration of 
estrogen (E2) and P4 will attenuate the exacerbation in compulsive-like, anxiety-like and 
cognitive behaviors in compulsive-like strains. Though rodents do not have menopause, surgical 
removal of the ovaries can cause depletion of E4 and P4 (Kato et al., 2013). We therefore used 
bilateral OVX as the sex hormone deprived surgical menopause model to achieve the 
experimental endpoints in this study.
4.3 Materials and Methods
The University of Alaska Fairbanks Institutional Animal Care and Use Committee 
approved the animal care and experimental procedures (IACUC assurance numbers 568518 
and 631126).
4.3.1 Mouse Husbandry
All mice were raised in polypropylene cages (27 cm * 17 cm * 12 cm) and provided with 
wood shavings under a 12:12 light-dark cycle at 22 ± 1°C. Weaning of the pups was conducted 
at 19-21 days of age. All mice were housed with same-sex and same-strain littermates until the 
end of all the experiments. All mice were singly housed just before the behavioral assessments 
and were returned to their home cages with their littermates following each test. Food (Masuri 
Rodent Diet #5663, Purina Mills, LLC, St. Louis, MO, USA) and water were available ad libitum.
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4.3.2 Experimental Subjects
The mouse model of OCD used for this study was developed from house mouse (Mus 
musculus) strains bidirectionally selected for nest-building behavior (Lynch, 1980; Bult and 
Lynch, 2000). The stock population for the original selection experiment (Lynch, 1980) was a 
cross among eight inbred strains, i.e., A, AKR, BLB/c, C3H/2, C57BL, DBA/2, Is/Bi, and RIII, to 
yield the HS/Ibg outbred strain (McClearn et al., 1970; Lynch, 1980). This resulted in two BIG 
strains (BIG1 and BIG2) that use a forty-fold larger amount of cotton for their nest than the two 
SMALL strains (SML1 and SML2) and two randomly-bred control strains (C1 and C2) that show 
intermediate levels of nesting (Lynch, 1980; Bult and Lynch, 2000). The BIG strains engage in 
excessive and repetitive nest building (considered to be homologous to hoarding in humans; 
Warneke, 1993) and marble burying behavior which is dose-dependently attenuated by 
fluoxetine and clomipramine, but not desipramine, treatment, making the BIG mice a novel non­
induced model for OCD (Greene-Schloesser et al., 2011).
For the OVX study, female mice (Mus musculus) of six different mouse strains i.e., two 
each of compulsive-like strains (BIG1 and BIG2), randomly-bred Control strains (C1, C2) and 
SMALL (SML1, SML2) strains, were used. For the hormone replacement studies in OVX 
females, only compulsive-like BIG1 and BIG2 female strains were used. All mice were 80-90 
days of age during testing. All data were collected by an individual blinded to the outcome of the 
study.
4.3.3 Surgical Procedure
For the OVX study, animals were divided into two groups for each strain. One group was 
sham operated while the other group was OVX (removal of ovaries). All animals in the hormone 
replacement studies were OVX. For the surgical procedures, females were exposed to 
isofluroane (4% induction and flow rate of 1.5-2 L/min) anesthesia. Abdominal incisions were 
made longitudinally and bilaterally in the region below the last lumbar vertebra. The ovary,
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oviduct and top of the fallopian tubes were tied and removed in the OVX group. For the sham- 
operated mice, the procedure remained the same except that the ovaries were not removed but 
only identified (Fonseca et al., 2013). The abdominal wall and the skin were sutured as 
described by Capettini et al. (2011). All animals were provided ibuprofen in the drinking water 24 
h prior to surgery and maintained for 3-4 days post surgery as needed for pain management.
4.3.4 Hormone Administration
4.3.4.1 E2 Administration
For the E2 administration study, BIG1 and BIG2 females were subdivided into two 
treatment groups: vehicle and E2 (n = 12 females per group). Seven days after OVX, the 
vehicle group received a single subcutaneous injection of corn oil while the E2 group received 
0.1 mg/kg (acute dosage of E2 produces comparable proestrus levels (Walf et al., 2006)) of E2 
(Sigma, St. Louis, MO, USA) in corn oil 44 h before behavioral assessments (compulsive and 
anxiety tasks; Walf et al., 2008b). For the object recognition task, the mice were injected 
immediately after the training session and were tested 4 h later (Walf et al., 2008a). A total gap 
of 5 days between each behavior was employed.
4.3.4.2 P4Administration
For the P4 administration study, BIG1 and BIG2 females were subdivided into vehicle 
and P4 groups (n = 9 females per group). Following 7 days of OVX, the vehicle group received 
corn oil while the P4 group received 4 mg/kg of P4 1 h before behavioral testing. For the object 
recognition task, the mice were injected immediately after the training session and the test was 
performed 4 h later (Walf et al., 2008a). A gap of 3 days between the end of each behavioral 
test and the next injection was employed. An acute dosage of P4 used in this study 
approximates circulating and central P4 levels observed during the proestrus phase (Walf et 
al., 2006).
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4.3.5 Plasma Steroid Levels
To establish that acute OVX leads to depletion of E2 and P4 plasma E2 and P4 levels 
were determined in plasma samples (n = 5-7 per group) of OVX and sham operated 
compulsive-like BIG female strains (BIG1 and BIG2). All samples were assayed in duplicates 
using Cayman ELISA kits (Ann Arbor, MI, USA) as per the manufacturer’s instructions. Data 
collection was accomplished with a Biotek EL808 spectrophotometric plate reader and analyzed 
by Prism software.
4.3.6 Compulsive-Like Behaviors
4.3.6.1 Nest-Building
Nest-building behavior was used to assess the compulsive-like phenotype of the female 
mice (Greene-Schloesser et al., 2011). All mice were housed individually and were allowed to 
access a pre-weighed cotton roll placed in the cage top food hopper. The amount of cotton used 
by the mice after 24 h was determined by weighing the cotton roll. As all other behavioral 
assessments in the P4 administration experiment were performed after 1 h of P4 administration, 
nest building was measured for 1 h and 24 h of cotton availability, starting 1 h after the injection, 
to be able to capture the short-term effects of P4 and also to be able to compare this behavior to 
the 24-h nesting score of the E2 administration experiment.
4.3.6.2 Marble Burying
The marble-burying test was also used to measure compulsive-like behavior (Takeuchi 
et al., 2002; Thomas et al., 2009; Greene-Schloesser et al., 2011; Angoa-Perez et al., 2013). All 
mice were individually introduced to a polypropylene cage (37 cm * 21 cm * 14 cm) containing 
20 glass marbles (10 mm in diameter) evenly spaced on 5 cm deep wood shavings firmly 
pressed into a bedding without access to food or water for 20 min. The total number of marbles 
buried at least 2/3 in the 20-min period was quantified as compulsive-like digging behavior
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(Greene-Schloesser et al., 2011). After the 20-min test, the animals were returned to their home 
cages with littermates.
4.3.7 Anxiety-Like Behaviors
4.3.7.1 Open Field
The open field test was performed to evaluate anxiety-like behavior in female mice 
(Crawley, 1985; Meerlo et al., 1999). Female mice were singly housed outside the testing room 
just prior to testing. The open field apparatus consisted of an open field arena (40 cm * 40 cm * 
30 cm). For testing, animals were placed in the center of the field and allowed to explore the 
arena for 3 min. Entries into the central square (20 cm * 20 cm) (Greene-Schloesser et 
al., 2011) were recorded by ANYMaze video tracking system (Stoelting Co., Wood Dale, IL, 
USA). Total number of line crossings was also assessed for sham and OVX strains. The 
apparatus was cleaned before each test.
4.3.7.2 Elevated Plus Maze
Anxiety-like behavior was further substantiated by the elevated plus maze test. The plus 
maze apparatus consisted of two open arms (5 cm * 40 cm) and two closed arms (5 cm * 40 
cm * 20 cm) at right angles to each other. Each mouse was placed in the central square facing 
an open arm and was allowed to explore the maze for 5-min duration (Frye et al., 2008). The 
time spent on the open arms was determined by the ANYMaze video tracking program 
(Stoelting Co., Wood Dale, IL, USA). The maze was cleaned before each test.
4.3.8 Novel Object Recognition Test
The novel object recognition test was performed to measure object recognition memory 
(Antunes and Biala, 2012). Mice were allowed to explore the open field arena (40 cm * 40 cm * 
30 cm) without any objects for 3 min during the habituation phase on day 1. Twenty-four hours 
later on day 2 , the training session was performed and mice were introduced to two similar
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objects (plastic toys) within a 5 cm distance in the open field arena for 3 min. Mice were then 
taken out of the arena and returned to their home cages. After 4 h, one of the objects was 
replaced with a novel object of different shape and size. Animals were then reintroduced into the 
arena and allowed to explore the objects for 3 min in the testing phase. Time spent exploring 
the familiar and novel objects was recorded with ANYMaze video tracking software (Stoelting 
Co., Wood Dale, IL, USA). The preference of one object over another was assessed through the 
Recognition Index (RI: time spent on novel object divided by the time spent on novel and 
familiar object together; Fonseca et al., 2013).
4.3.9 Statistical Analysis
All data were analyzed using Statistical Analysis System (SAS) software. A general 
linear model (GLM) repeated analysis of variance (ANOVA), with strain (BIG, SMALL, Control), 
replicate nested within strain (1, 2), treatment (OVX, sham), and strain by treatment interaction 
effects was used to statistically evaluate the effects of OVX on nest building behavior (grams of 
cotton), marble burying behavior (number of marbles buried), open field behavior (time in 
seconds in center), elevated plus maze behavior (time in seconds on open arms), and novel 
object recognition memory (RI). If the replicate nested within strain effect was significant, the 
strain effect was tested over the replicate effect. If the replicate effect was not significant, the 
strain effect was tested over the error term.
A GLM ANOVA, with treatment (OVX, sham), strain (BIG1, BIG2), and replicate by 
treatment interaction effects, was used to statistically evaluate the effects of OVX on E2 (pg/mL) 
and P4 (ng/mL) plasma levels.
A GLM ANOVA, with treatment (E2, vehicle or P4, vehicle), strain (BIG1, BIG2), and 
strain by treatment interaction effects, was used to statistically evaluate the effects of females, 
sex hormone replacement in compulsive-like OVX females on nest building behavior (1 and 24
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h nesting scores), marble burying behavior, open field behavior, elevated plus maze behavior 
and novel object recognition memory.
When significance was found appropriate pairwise comparisons were performed using 
the studentized range test. The nesting scores were square root transformed to obtain a more 
normal distribution (Bult and Lynch, 1996, 1997, 2000), while the data are presented as non­
transformed nesting scores.
4.4 Results
4.4.1 Acute OVX Increased Compulsive-Like Behavior in Compulsive-Like BIG Strains
4.4.1.1 Compulsive-Like Nesting
Acute OVX in compulsive-like BIG1 (post hoc t(22) = 8.983, p < 0.0001) and BIG2 (post 
hoc t(22) = 11.51, p < 0.0001) females resulted in significant increases of nesting behavior when 
compared to the sham operated ones (F(1,134) = 77.60, p < 0.0001). No significant increases of 
compulsive-like nesting were observed in the SMALL (SML1: post hoc t(2i) = 0.0045, p > 0.99; 
SML2: post hoc t(22) = 0.794, p > 0.43) and Control (C1: post hoc t(22) = 0.270, p > 0.78; C2: post 
hoc t(22) = 0.0150, p > 0.98) OVX strains when compared to their sham operated controls (Figure 
4.1A), which explains the significant strain by treatment interaction effect (F(2,134) = 65.91, p < 
0.0001). The BIG strains built bigger nests than the SMALL and Control mice (F(2,3) = 70.84, p < 
0.0001). The replicate nested within strain effect was also significant (F(3134) = 10.59, p < 
0.0001), predominantly due to the BIG1 females building bigger nests than the BIG2 females 
(sham: post hoc t(22) = 5.188, p < 0.0001; OVX: post hoc t(22) = 2.666, p < 0.05).
4.4.1.2 Compulsive-Like Marble Burying
Acute OVX resulted in more marbles buried in BIG1 (post hoc t(22) = 3.248, p < 0.004) 
and BIG2 (post hoc t(22) = 3.193, p < 0.005) females when compared to the sham operated 
groups (F(1134) = 18.15, p < 0.0001). No significant differences were observed between OVX and
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sham operated SMALL (SML1: post hoc t(21) = 0.525, p > 0.60; SML2: post hoc t(22) = 1.028, p > 
0.31) and Control (C1: post hoc t(22) = 1.732, p > 0.09; C2: post hoc t(22) = 0.650, p > 0.52) 
strains (Figure 4.1B), which explains the significant strain by treatment interaction effect 
(F(2,134) = 3.49; p < 0.034). BIG females buried more marbles than the SMALL females, with the 
Control mice showing intermediate values (F(23) = 24.24, p < 0.015). The replicate nested within 
strain effect was also significant (F(3134) = 5.56, p < 0.0013), predominantly due to the SML1 
females burying fewer marbles than the SML2 females (sham: post hoc t(21)= 2.324, p < 0.05; 
OVX: post hoc t(22) = 2.922, p < 0.008).
4.4.2 Acute OVX Increased Anxiety-Like Behavior in Compulsive-Like BIG Strains
4.4.2.1 Anxiety-Like Open Field Behavior
In the anxiety-like open field test, the BIG1 (post hoc t(22) = 5.697, p < 0.0001), BIG2 
(post hoc t(22) = 5.008, p < 0.0001), C1 (post hoc t(22) = 6.272, p < 0.0001), C2 (post hoc t(22) = 
5.927, p < 0.0001), and SML1 (post hoc t(21) = 2.296, p < 0.032) OVX females spent significantly 
less time in the center when compared to the sham groups (F(1134) = 119.24, p < 0.0001). No 
significant difference was observed between OVX and sham groups in SML2 (post hoc t(22) = 
1.286, p > 0.21) females for the time spent in the center (Figure 4.2A), which explains the 
significant strain by treatment interaction effect (F(2134) = 10.55; p < 0.0015). No significant strain 
effect was found (F(23) = 6.51, p > 0.08), although the Control strains tended to be the least 
anxious and the SMALL strains the most, while the BIG strains tended to be intermediate. The 
replicate nested within strain effect was significant (F(3134) = 22.87, p < 0.0001), predominantly 
due to the C1 females spending less time in the center than the C2 females (sham: post 
hoc t(22) = 5.582, p < 0.0001; OVX: post hoc t(22) = 5.927, p < 0.0001). For total number of line 
crossings, as a measure of locomotor activity (Figure 4.2B), no differences were observed 
among the strains (F(23) = 0.10, p > 0.90) and between sham and OVX groups (F(1134) = 
0.03, p > 0.80).
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4.4.2.2 Anxiety-Like Elevated Plus Maze Behavior
Acute OVX resulted in less time spent on the open arms in the elevated plus maze test 
for BIG1 (t(22) = 6.320, p < 0.0001) and BIG2 (t(22) = 4.934, p < 0.0001) females when compared 
to the sham groups (F(1,134) = 30.14, p < 0.0001). No significant differences were observed in 
Control (C1: post hoc t(22) = 0.0676, p > 0.94 and C2: post hoc t(22) = 1.403, p > 0.17) and 
SMALL (SML1: post hoc t(21) = 0.1833, p > 0.85 and SML2: post hoc t(22) = 0.4394, p > 0.66) 
OVX strains when compared to the sham operated mice (Figure 4.2C), which explains the 
significant strain by treatment interaction effect (F(2,134) = 17.50, p < 0.0001). The BIG females 
spent the most time on the open arms, followed by the Control females, and the SMALL mice 
showed the highest level of anxiety-like behavior (F(2,134) = 26.84; p < 0.0001). The replicate 
nested within strain effect was not significant (F(3134) = 0.86, p > 0.46).
4.4.3 Acute OVX Did Not Affect Recognition Index (RI) for Compulsive-Like BIG Strains in Novel 
Object Recognition
The RI was significantly reduced in OVX females compared to sham operated mice 
(F(1,134) = 3.94; p < 0.05; Figure 4.3) with the C2 OVX females having a significantly lower RI 
than the sham operated C2 mice (post hoc t(22) = 2.569, p < 0.05), while the other strains did not 
show significant differences (BIG1: post hoc t(22) = 0.02763, p > 0.97; BIG2: post hoc t(22) = 
0.2579, p > 0.78; C1: post hoc t(22) = 0.4236, p > 0.66; SML1: post hoc t(21) = 0.6280, p > 0.52; 
SML2: post hoc t(22) = 0.9393, p > 0.34). The Control females had significantly higher RIs than 
the BIG and SMALL mice (F(2,134) = 37.70; p < 0.0001). The replicate nested within strain 
(F(3,134) = 0.53, p > 0 .6 6 ) and the strain by treatment interaction (F(2,134) = 0.92, p > 0.40) effects 
were not significant.
4.4.4 Plasma E2 and P4 Levels Declined in BIG Strains Following Acute OVX
Plasma E2 levels in acute OVX BIG1 (post hoc t(9) = 5.501 p < 0.0001) and BIG2 (post 
hoc t(10) = 6.948 p < 0.0001) mice were significantly and similarly (strain: F(119) = 0.00; p > 0.99;
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strain by treatment interaction: F(119) = 2.99; p > 0.10) reduced when compared to the sham 
females (treatment: F(119) = 63.23; p < 0.0001; Figure 4.4A). P4 levels were significantly reduced 
in the BIG2 (post hoc t(12) = 8.665 p < 0.0001) but not in BIG1 (post hoc t(10) = 1.993 p > 0.058) 
OVX females when compared to their sham counterparts (F(119) = 61.17; p < 0.0001; Figure 
4.4B), which explains the significant strain (F(119) = 17.30; p < 0.0005) and strain by treatment 
interaction (F(119) = 18.93; p < 0.0004) effects.
4.4.5 Acute E2 and P4 Administration in OVX Female Mice
4.4.5.1 Compulsive-Like Nesting Was Attenuated by E2 But Not P4 Administration
Acute E2 administration resulted in a significant and similar (strain by treatment 
interaction: F(1,43) = 0.00, p > 0.94) decline of nesting scores in the BIG1 (post hoc t(22) = 
3.000, p < 0.007) and BIG2 (post hoc t(22) = 3.814, p < 0.001) OVX females when compared to 
the vehicle controls (F(1,43) = 19.51; p < 0.0001; Figure 4.5A). The BIG1 females used more 
cotton for their nest compared to the BIG2 mice (F(1,43) = 5.69, p < 0.022), which replicated the 
results in Figure 4.1A. No significant differences were observed in the 1 h (F(132) = 0.96; p > 
0.33) and 24 h (F(132) = 3.47; p > 0.05) nesting scores of acute P4 treated BIG1 and BIG2 OVX 
females when compared to the vehicle treated controls (Figures 4.6A,B). For 1 h and 24 h 
nesting scores, the strain (F(1,32) = 0.37; p > 0.54; F(1,32) = 1.05; p > 0.31, respectively) and strain 
by treatment interaction (F(132) = 2.06; p > 0.16; F(132) = 0.00; p > 0.95, respectively) effects 
were not significant.
4.4.5.2 Compulsive-Like Marble Burying was Attenuated by E2 But Not P4 Administration
BIG1 (post hoc t(22) = 6.447, p < 0.0001) and BIG2 (post hoc t(22) = 7.606, p < 0.0001) 
OVX females buried significantly less marbles in the acute E2 treatment group when compared 
to the vehicle groups (F(1,43) = 85.67, p < 0.0001; Figure 4.5B). The strain (F(1,43) = 0.79, p > 
0.37) and strain by treatment interaction (F(1,43) = 1.24, p > 0.27) effects were not significant,
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indicating that the BIG1 and BIG2 OVX females had similar marble burying scores and 
responses to E2.
P4 administration did not cause significant changes in the number of marbles buried by 
BIG1 and BIG2 OVX females when compared to the vehicle control mice (F(1,32) = 2.64; p > 
0.11; Figure 4.6C). The strain (F(132) = 3.22, p > 0.08) and strain by treatment interaction 
(F (1,32) = 1 64, p > 0 .2 0 ) effects were also not significant.
4.4.5.3 E2 and P4 Treatment Showed Strain Dependent Decreases in Anxiety-Like Behavior in 
the Open Field
In the acute E2 administration group, the BIG1 OVX females (post hoc t(22) = 4.245, p < 
0.0005) spent more time in the center when compared to the vehicle group (F(1,43) = 16.70, p < 
0.0002; Figure 4.5C). No significant difference in the time spent in the center was observed 
between E2 and vehicle groups in BIG2 OVX females (post hoc t(22) = 1.564 p > 0.13). The 
significant strain effect (F(1,43) = 17.05; p < 0.0003) was due to BIG1 E2 administered females 
performing better than the BIG2 E2 administered females (post hoc t(22) = 4.178, p < 0.0005). 
The strain by treatment interaction effect was not significant (F(1,43) = 3.77, P > 0.058), which 
showed that the BIG2 females responded to E2 in a similar direction as the BIG1 females.
P4 administered groups in both BIG1 (post hoc t(16) = 4.311, p < 0.0005) and BIG2 (post 
hoc t(16) = 3.904, p < 0.001) OVX females spent significantly more time in the center when 
compared to their respective vehicle control groups (F(132) = 33.75; p < 0.0001; Figure 4.6D). 
The strain (F(132) = 2.17, p > 0.15) and strain by treatment interaction (F(132) = 0.08, p > 0.77) 
effects were not significant, indicating that the BIG1 and BIG2 OVX females spent similar times 
in the center and responded similarly to P4.
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4.4.5.4 P4, But Not E2, Treatment Had an Effect on Anxiety-Like Elevated Plus Maze Behavior
No significant differences in the time spent on the open arm in the elevated plus maze
test was observed between E2 and vehicle groups of BIG1 and BIG2 OVX females (F(1,43) =
1.81; p > 0.18; Figure 4.5D). In addition, the strain (F(1,43) = 0.22, p > 0.63) and strain by 
treatment interaction (F(1,43) = 0.39, p > 0.53) effects were also not significant.
Overall, P4 administration significantly increased the time spent on the open arms 
compared to the vehicle groups (F(1,32) = 8.20, p < 0.0073; Figure 4.6E), which was significant 
when comparing the BIG2 P4 treated to the BIG2 vehicle OVX females (post hoc t(16) = 
2.692, p < 0.014). Although the trend was in the same direction as the BIG2 OVX females, no 
significant difference was observed between P4 and vehicle groups of BIG1 OVX females (post 
hoc t(16) = 1.358, p > 0.18). The strain (F(132) = 0.63, p > 0.43) and strain by treatment interaction 
(F (1,32) = 0.89, p > 0.35) effects were not significant, indicating that the BIG1 and BIG2 OVX 
females spent similar times on the open arms, and the BIG1 females responded to P4 in a 
similar direction as the BIG2 females.
4.4.5.5 E2 and P4 Improved Recognition Index (RI) in Object Recognition Memory With a 
Replicate Effect Seen in E2 Treatment
Overall, E2 administration significantly increased performance in the novel object 
recognition test compared to the vehicle treated OVX females (F(1,43) = 26.95, p < 0.0001; Figure 
4.5E), which was significant for the BIG2 OVX females compared to their vehicle treated 
counterparts (post hoc t(22) = 5.358, p < 0.0001). Although the trend was in the same direction 
as the BIG2 OVX females, no significant difference was observed in the RI of E2 treated BIG1 
OVX females compared to vehicle treated females (post hoc t(22) = 1.946, p > 0.06), which 
explains the significant strain by treatment interaction effect (F(1,43) = 5.55, p < 0.024). The strain 
effect was not significant (F(1,43) = 1.93, p > 0.17), which indicates that the BIG1 and BIG2 
females had overall similar memory scores.
147
P4 administration enhanced the performance in the novel object recognition test for both 
the BIG1 (post hoc t(16) = 3.855, p < 0.001) and the BIG2 (post hoc t(16) = 4.726, p < 0.0001) 
OVX females compared to their vehicle control groups (F(1,32) = 114.3; p < 0.0001; Figure 4.6F). 
The BIG1 OVX females had higher RIs compared to the BIG2 OVX females (strain: F(132) = 
7.32; p < 0.011, irrespective of treatment group (strain by treatment interaction: F(132) = 0.36; p > 
0.55)).
4.5 Discussion
In the current study we showed that acute OVX for 7 days resulted in a significant 
increase in the compulsive-like nesting and marble burying behaviors of BIG1 and BIG2 female 
mice. No increase in nesting and marble burying was observed for the Control and SMALL 
strains, which shows the specificity of the OVX effects for the compulsive-like condition. The 
exacerbations in compulsive-like behaviors in BIG mice were attenuated by acute subcutaneous 
administration of E2, but not P4. Human studies have shown that gonadal steroids trigger or 
precipitate mood disorders in women with a history of an already existing disease condition 
when compared to women without it (Hay et al., 1994; Schmidt et al., 1998; Clayton and 
Ninan, 2010). Onset and exacerbation of OCD associated with pregnancy and postpartum has 
been shown in human studies (Neziroglu et al., 1992; Williams and Koran, 1997; Labad et 
al., 2005; Uguz et al., 2007; Forray et al., 2010) establishing a strong link between reproductive 
events and OCD. However, there is lack of literature on how obsessions and compulsions and 
associated affective and cognitive behaviors vary during induced menopause. According to a 
review (Forray et al., 2010) a large variation exists in human studies on onset and exacerbation 
of OCD during reproductive events and one of the contributing factors could be innate 
differences in patient populations. In congruence with this we found that BIG1 sham females 
had higher nesting scores when compared to BIG2 sham females. This variation in compulsive­
like nesting behavior was also seen post acute OVX but was abolished in the E2 treatment
148
regimen. What is more intriguing is the fact that BIG1 and BIG2 females did not exhibit variation 
in compulsive-like marble burying. This is an interesting finding indicating heterogeneity in the 
BIG strains based on compulsive-like traits and genetic background as often seen in subgroups 
of OCD patients (Fontenelle et al., 2005; Grados and Riddle, 2008; Leckman et al., 2009). 
Whether E2 might be more effective compared to P4 in reducing OCD symptoms in 
postmenopausal females, as seen in our OVX compulsive-like mice, remains to be elucidated.
A prior study has shown that acute E2 administration along with P4 to OVX rats reduced 
compulsive perseverance in the T-maze (Fernandez-Guasti et al., 2006). This is similar to our 
findings in the compulsive-like mice though, E2 alone had an attenuating effect in the OVX 
state. Interestingly, previous findings show that acute P4 administration reduced compulsive-like 
marble burying behavior in male rats (Umathe et al., 2009). However, in the current study we 
did not see an anti-compulsive effect of P4 treatment in BIG mice. This could be due to various 
factors, including using mouse strains and females in our study compared to male rats in the 
(Umathe et al., 2009) study.
In the anxiety-like measures, the OVX BIG strains spent less time in the center of the 
open field and also explored the open arm less in elevated plus maze when compared to the 
sham groups. The SMALL and the Control OVX strains showed no significant changes in open 
field and elevated plus maze when compared to their sham counterparts. Therefore, OVX 
worsened anxiety-like behaviors in compulsive-like condition specifically. Acute administration of 
E2 resulted in increased time spent in the central square of the open field in BIG1, but not BIG2 
strains, indicating a strain dependent effect in the E2 treatment response. The acute dosage 
and the time frame of administration of E2 in our study previously also showed anxiolytic effects 
in the open field in acutely OVX mice (Walf et al., 2008b) and rats (Walf and Frye, 2009). In the 
plus maze no significant effect of E2 was observed in the compulsive-like mice, which could be
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due to the fact that the open field and the elevated plus maze tests measure different aspects of 
emotionality associated with anxiety (Ramos, 2008; Anchan et al., 2014).
P4 treatment, on the other hand, decreased anxiety-like behavior in open field for both 
BIG1 and BIG2 strains. For the elevated plus maze, however, P4 was effective only in the BIG2 
and not the BIG1 strain. These results indicate a strain specific response to anxiety-like 
behavior due to P4 administration. Strain specific effects of E2 and P4 on behavioral responses 
have been sparsely explored in rodent studies. Only one study has shown significant strain 
specific effects of E2 on depressive-like forced swim behavior (Koss et al., 2012). Behavioral 
responses to alterations in gonadal steroids have been found to vary in women with and without 
premenstrual syndrome (Schmidt et al., 1998), which might be similar to the differences in 
behavioral responses to E2 and P4 in the BIG1 and BIG2 strains.
The association of memory impairment with OCD is not clear. Many clinical studies have 
failed to find any evidence that OCD is associated with memory deficits (McDonald, 1991; 
Dirson et al., 1995; Radomsky and Rachman, 1999). In addition, no impairment in declarative 
and short-term memory has been found in OCD patients compared to normal controls (Roth et 
al., 2004; Demeter et al., 2013). However, many others have reported working memory 
impairments in patients (Martin et al., 1995; Nakao et al., 2009). Our BIG mice showed a larger 
object recognition memory deficit than the Control mice, both in the sham and OVX groups. 
However, the SMALL mice also showed a similar memory deficit and, therefore, whether this 
memory deficit in the BIG mice was due to a genetic correlation between compulsive-like 
behaviors and object recognition memory, or was due to genetic differences between the two 
strains caused by founder effects or random drift (Bult and Lynch, 1996, 2000), remains to be 
elucidated. Also as the BIG and SMALL strains had a RI below 0.5 they appeared to avoid the 
new object, while the control mice had an index above 0.5 and appeared to favor the new 
object.
150
Acute OVX did not result in significant object recognition memory impairment in the 
compulsive-like condition. Contradictory evidence exists as to whether acute OVX leads to 
object recognition memory impairment in normal mice (c57 strain). While few studies have 
shown memory loss during acute OVX (Gresack and Frick, 2006; Rhodes and Frye, 2006), 
others show the opposite (Willard et al., 2011; Fonseca et al., 2013; Bastos et al., 2015). 
However, chronic OVX has consistently caused poor performance in the novel object 
recognition test (Fonseca et al., 2013; Bastos et al., 2015). Though there was no overall effect 
in novel object recognition memory among sham and OVX strains, E2 treatment improved the 
RI in only the BIG2 but not the BIG1 strain. P4 treatment however improved the RI in both the 
strains. In the current context of investigation object recognition was performed to evaluate short 
term or working memory impairments associated with OCD in the mouse strains. However, 
object recognition encompasses just one aspect of assessing otherwise very complex memory 
consolidation and cognition process in rodents. In future studies we aim to include a more 
robust assessment of both short-term and spatial memory components.
The current study supports a complex interplay of genetic background and sex steroids 
during acute ovarian dysfunction in the compulsive-like condition. We report exacerbation of 
compulsive-like behaviors with trait specific intra-strain variation during acute ovarian failure in 
the spontaneously compulsive-like mouse strains only, which was restored by E2 and not P4. 
This effect was similar for the spontaneously compulsive-like BIG1 and BIG2 strains, unlike the 
associated anxiety-like and cognitive-like behaviors, which displayed differences between the 
BIG1 and BIG2 strains for both E2 and P4 effects on these behaviors. We therefore hypothesize 
that the associated comorbidities in the surgical menopause state in the OCD condition might 
vary among individuals because of genetic differences. Future studies will focus on investigating 
effects of E2 and P4 on the chronic OVX state and also the potential signaling pathways in the 
brain of compulsive-like mice. Overall, the results presented here strengthen the face, predictive
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and construct validities of the mouse model for investigating heterogeneity associated with OCD 
during ovarian failures in females.
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4.7 Figures
Fig 4.1 Compulsive-like behavior in BIG, SMALL and Control strains.
The data represent the mean (± SEM) for (A) nesting score in grams between 0-24 h in nest- 
building test and (B) number of marbles buried in marble burying test of the two replicates of the 
BIG, SMALL and Control strains. *(p < 0.05), **(p < 0.001) and ***(p < 0.0001) indicates 
significant differences between sham and ovariectomy (OVX) groups. #(p < 0.05), ##(p < 0.001) 
and ###(p < 0 .0 0 0 1 ) indicate significant differences between replicate strains.
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Fig 4.2 Anxiety-like behavior in BIG, SMALL and Control strains.
The data represent the mean (± SEM) for (A) time spent on center in open field and (B) total 
number of line crossings and (C) time spent on open arm in elevated plus maze of the two 
replicates of the BIG, SMALL and Control strains. ***(p < 0.0001) and *(p < 0.05) indicates 
significant differences between sham and OVX groups. ###(p < 0.0001) indicate significant 
differences between replicate strains.
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Fig 4.3 Novel object recognition in BIG, SMALL and Control strains.
The data represent the mean (± SEM) for the recognition index (RI) in the novel object 
recognition test between sham and OVX groups of the two replicates of the BIG, SMALL and 
Control strains. *(p < 0.05) indicates significant differences between sham and OVX groups.
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Fig 4.4 Ovarian E2 and P4 plasma levels in BIG strains.
The data represent the mean (± SEM) for plasma (A) 17p-estradiol (E2) levels 
and (B) progesterone (P4) levels of the BIG1 and BIG2 strains. **(p < 0.001) and ***(p < 0.0001) 
indicates significant differences between sham and OVX groups. ###(p < 0.0001) indicate 
significant differences between replicate strains.
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Fig 4.5 E2 administration in OVX mice.
The data represent the mean (± SEM) for (A) nesting score in grams, (B) number of marbles 
buried, (C) time in center in open field, (D) time spent on open arms in elevated plus maze 
and (E) RI in novel object recognition of the BIG1 and BIG2 strains. **(p < 0.001) and ***(p < 
0.0001) indicates significant differences between vehicle and E2 treatment groups. #(p < 0.05) 
and ###(p < 0 .0 0 0 1 ) indicate significant differences between replicate strains.
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Fig 4.6 P4 administration in OVX mice.
The data represent the mean (± SEM) for (A) nesting score in grams between 0-1 h, (B) nesting 
score in grams between 0-24 h, (C) number of marbles buried, (D) time in center in open 
field, (E) time spent on open arms in elevated plus maze and (F) RI in novel object recognition 
of the BIG1 and BIG2 strains. *(p < 0.05) and ***(p < 0.0001) indicates significant differences 
between vehicle and P4 treatment groups. #(p < 0.05) indicate significant differences between 
replicate strains.
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Chapter 5: Postpartum Lactation-Mediated Behavioral Outcomes in a Spontaneous Mouse 
Model of OCD is Partly Regulated by Oxytocinergic Mechanisms.4
5.1 Abstract
Using a spontaneous mouse model of obsessive-compulsive disorder (OCD), we 
investigated the compulsive-, anxiety- and depression-like behavioral responses among 
lactating, non-lactating and nulliparous females. Compulsive-like lactating mice were less 
compulsive-like in nest building and marble burying and showed enhanced responsiveness to 
fluoxetine (50 mg/kg) in comparison to compulsive-like non-lactating and nulliparous females. 
Lactating mice were however, more anxiety-like in the open field test compared to the 
nulliparous females, while chronic fluoxetine reduced anxiety-likes behaviors. Blocking the 
oxytocin receptor with L368-899 (5 mg/kg) in the lactating mice exacerbated the compulsive-like 
and depression-like behaviors. The dopamine D2 receptor (D2R) agonist bromocriptine (10 
mg/kg) suppressed marble burying, nest building and central entries in the open field, but 
because it also suppressed overall locomotion in the open field, activation of the D2R receptor 
may have inhibited overall activity nonspecifically. Lactation- and fluoxetine-mediated behavioral 
outcomes in compulsive-like mice, therefore, appear to be partly regulated by oxytocinergic 
mechanisms. Serotonin immunoreactivity and serum levels were higher in lactating compulsive­
like mice compared to non-lactating and nulliparous compulsive-like females. Together, these 
results suggest that the role of lactation in symptom expression and SSRI effectiveness in OCD 
patients requires further investigation.
4 Submitted as Mitra, S.; Sweeney, M.; Owen, S.; Bult-Ito, A., Postpartum Lactation-Mediated Behavioral 
Outcomes in a Spontaneous Mouse Model of OCD is Partly Regulated by Oxytocinergic Mechanisms. 
ACS Chem Neuroscience.
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5.2 Introduction
Obsessive compulsive disorder (OCD) is one of the most prevalent neuropsychiatric 
disorders that affects 1-3% of the population1. OCD causes significant interference with quality 
of life which leads to functional impairments2, disability, increased use of healthcare services 
and financial difficulties3'3, b. Mood alterations and psychopathology in the postpartum condition 
can adversely impact both the mother and the child4. In females, the onset and exacerbation of 
obsessive-compulsive disorder (OCD) symptoms are associated with the premenstruum, 
pregnancy and postpartum periods5^  b c d e f g. In addition, mood disorders and depression, 
which are often co-morbid conditions in OCD6, precipitate during the postpartum phase in 
females7a, b. Sex differences also contribute to the phenotypic expression, heterogeneity, and 
drug response variations in OCD8a, b, c which may be partially due to physiological states 
influencing the expression of OCD and related symptoms in females. Hence, a spontaneous 
mouse model of OCD93, b c d is employed to explore this potential explanation.
The brain undergoes dramatic changes in neuronal mechanisms during pregnancy to 
accommodate parturition and lactation10^  b. Secretion of the hormone prolactin, which stimulates 
milk production, from the pituitary gland lactotrophs is regulated by tuberoinfundibular neurons 
of the arcuate nucleus (TIDA) in the hypothalamus that secrete dopamine11. Dopamine secreted 
from the TIDA neurons acts on the D2 (dopamine type 2) receptor (D2R) on lactotrophs causing 
inhibition of prolactin secretion12. Oxytocin is produced and released in the posterior pituitary 
gland in response to suckling. Suckling leads to stimulation of the paraventricular nucleus (PVN) 
and supraoptic nucleus (SON) regions of the hypothalamus, which in turn signal more oxytocin 
production and release13^  b c. Oxytocin facilitates contraction of the cells surrounding the alveoli 
in the mammary glands by binding to its receptor (OXTR) causing milk flow through the duct 
system14^  b.
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In addition, a novel serotonergic biosynthetic system in the mammary glands has been 
shown to be up-regulated during late pregnancy and lactation15. This is consistent with higher 
serum levels of serotonin in lactating female C57BL6/J mice16. Lactation also resulted in lower 
serotonin reactive serotonergic neurons in the dorsal raphe nucleus (DRN) of the brain, while 
behavioral responsiveness to SSRIs for anxiety-like and depression-like behaviors in lactating 
C57BL6/J females was enhanced when compared to virgin females16. Therefore, a possible 
interaction between the central and peripheral serotonin systems that results in modulation of 
behavior has been proposed16. Moreover, serotonergic system has also been shown to 
influence prolactin secretion17'3, b. These findings suggest that hormones that regulate pregnancy 
and postpartum also affect serotonergic systems, which play a role in the expression of 
compulsive-like behaviors9^  18.
These unique neuroendocrinological events as a result of lactation is known to produce 
profound effects on healthy lactating mothers which include reduced stress, positive mood 
states and less anxiety19^  b c d e f. However, it is currently not well understood if a similar 
behavioral repertoire is observed in patients with predisposition to psychiatric conditions such 
as, OCD. Studies in rodents have indicated that postpartum phase contributes to a variety of 
maternal care and intruder based aggression behaviors20a, b, c, d. Assessments of anxiety-like 
behaviors, however, are contradictory as some studies have shown the postpartum phase to 
increase these behaviors16, 21 while others have shown the opposite22^  b or no effect 16, 21-23a, b. 
Studies on depression-like and compulsive-like behaviors are limited, where lactation has been 
shown to abolish induced compulsive-like behaviors18 and reduce depression-like behaviors16.
The dopaminergic and the serotonergic system on the other hand has garnered 
substantial support in relation to their role in OCD (reviewed in:24a b ^ d) anxiety (reviewed in:25a 
b) and depression (reviewed in:26a b). Drugs that target serotonin transporters, such as selective 
serotonin reuptake inhibitors (SSRIs), have been effective in treating both OCD and postpartum
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depression27^  b c, e, f, g. Both oxytocin and prolactin which are typically upregulated in lactation 
has been implicated in increasing maternal care and aggression, while decreasing anxiety and 
depression in human28 and animal studies28^  b-29a b c d e f g, h. However, their role in obsessions 
and compulsions remains inconclusive in human studies. Some studies have linked central30 
and peripheral31 oxytocin levels to OCD, while others found no significant correlation among 
endogenous oxytocin levels32 or exogenous administration of oxytocin on OCD 
symptomology33a, b. Plasma prolactin levels in response to serotonin 5HT2C receptor agonist 
mCPP among OCD patients has been contradictory with one study showing higher levels30-34^  b 
and another study finding the opposite34a. Interestingly, 8-OHDPAT-induced compulsive-like 
spontaneous alternation was abolished in the postpartum lactation phase of rats18. Hence, 
probing the neuropeptide/transmitter modulation during the postpartum phase in compulsive-like 
female mice can unravel critical neurobiological mechanisms that drive differential behavioral 
responses during various physiological states in a compulsive-like phenotype.
In the current study, within the context provided above, we hypothesized that in 
spontaneously compulsive-like female mice lactation enhances responsiveness to SSRIs and 
protects against excessive behavioral responses, which are mediated by dopamine and 
oxytocin receptor mediated pathways. We predicted that lactating females display less 
compulsive-like, anxiety-like and depression-like behaviors compared to non-lactating and 
nulliparous compulsive-like female mice. We also predicted that the compulsive-like lactating 
mice exhibit enhanced responsiveness to the SSRI fluoxetine in all these behaviors compared 
to the other experimental groups. Finally, we predicted that blocking of D2Rs decreases, while 
blocking of OXTRs increases compulsive-like, anxiety-like, and depression-like behaviors in 
lactating compulsive-like females.
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5.3 Results and Discussion
5.3.1 Postpartum Lactating Compulsive-Like Female Mice Were Less Compulsive When 
Compared to the Non-lactating and Nulliparous Females and Exhibited Trait Specific Enhanced 
Responsiveness to Fluoxetine.
Lactating females buried significantly less marbles in weeks 1, 2 and 3 (Fig 5.1) when 
compared to the non-lactating and the nulliparous female mice (F2,66 = 99.80, p<0.001). The 
fluoxetine treatment effect was also significant (F166 = 204.70, p<0.001). In the presence of 
fluoxetine, attenuation in marble burying was observed for lactating females in weeks 1 (t22= 
4.651, p<0.001), 2 (t22= 8.001, p<0.001) and 3 (t22= 22.84, p<0.001). The non-lactating and 
nulliparous females showed no attenuation effect due to fluoxetine in week 1 (Fig 5.1a). Non- 
lactating females showed a decrease in marble burying in weeks 2 (t22= 2.830, p<0.001) (Fig 
5.1b) and 3 (t22= 7.210, p<0.001) (Fig 5.1c), while nulliparous females showed a response to 
fluoxetine only in week 3 (t22= 10.41, p<0.001) (Fig 5.1c). This accounted for the physiological 
status of the female by treatment interaction effect (F2,66 = 34.29, p<0.001), indicating that 
lactating females had higher responsiveness to fluoxetine for marble burying when compared to 
non-lactating and nulliparous females.
For the compulsive-like nest building behavior (Fig 5.3), lactating females had 
significantly lower nesting scores in comparison to the non-lactating and the nulliparous females 
(F2,66 = 125.62, p<0.001). The fluoxetine treatment effect was also significant (F166 = 74.53, 
p<0.001). Lactating females in the fluoxetine group had lower nesting scores in weeks 1 (t22= 
4.473, p<0.001), 2 (t22= 4.247, p<0.001) and 3 (t22= 4.479, p<0.001) when compared to the 
vehicle group (Fig 5.3a, b, c). The non-lactating (t22= 3.113 p<0.01) and the nulliparous (t22= 
4.280, p<0.001) females showed a treatment effect against the respective vehicle groups only in 
week 3 (Fig 5.3c). Though there was a strong trend in enhanced responsiveness to fluoxetine
177
by the lactating females, the physiological status of the female by treatment interaction effect 
was not significant (F2,66 = 2.53, p>0.05).
The reduced compulsive-like marble burying and nest-building in lactating compulsive­
like mice aligns with a prior study in rats where 8-OHDPAT-mediated compulsive-like 
spontaneous alternation in T maze was abolished in the lactation phase18. Chronic fluoxetine 
treatment resulted in a greater attenuation of compulsive-like marble burying behavior in the 
lactating females in comparison to the non-lactating and nulliparous females. This greater 
responsiveness to fluoxetine observed in compulsive-like marble burying behavior also showed 
a trend in the compulsive-like nest-building behavior, though not statistically significant. This is 
an interesting finding since an unpublished study from our lab has shown that the compulsive­
like mouse strain can exhibit trait specific responses to SSRI treatment. Hence, a trait specific 
enhanced responsiveness to fluoxetine cannot be ruled out where lactation was anti-compulsive 
for both marble burying and nesting (in absence of fluoxetine), but the fluoxetine response 
varied between the two compulsive-like behaviors. Whether enhanced responsiveness to SSRI 
treatment in the compulsive-like mice for one trait over the other represents clinical 
heterogeneity in postpartum OCD patients remains to be elucidated. The non-lactating females 
on the other hand did not exhibit an enhanced responsiveness to fluoxetine in compulsive-like 
behaviors, indicating that compulsive-like behaviors and drug efficacy in the postpartum phases 
can be influenced by the state of lactation and not pregnancy per se16. A study comparing 
postpartum OCD patients and normal postpartum females revealed that rates of breastfeeding 
was lower in OCD patients which was concomitant with precipitation of marital distress, 
depression and lack of social interactions35. Though this study35 did not assess the effect of 
breastfeeding on expressions of OCD and co-morbid symptomology, it is plausible that 
breastfeeding can improve clinical OCD symptoms as seen with other studies on post natal 
anxiety where breastfeeding has been implicated as an anti-anxiety factor36.
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Various neurobiological possibilities may be contributing to this enhanced 
responsiveness. SSRIs are known to increase oxytocin release in humans37, which along with 
the oxytocin surge due to suckling action, might provide a possible explanation for greater 
responsiveness to fluoxetine by lactating females16. Alternatively, it has been postulated that 5- 
HT1A autoreceptors are desensitized both by SSRIs383, b and lactation specific modulation of 
oxytocinergic or prolactinergic systems393, b. Hence, a concerted action of lactation specific 
events and SSRI-mediated modulation of the serotonergic system might explain the enhanced 
responsiveness of lactating females when compared to non-lactating and nulliparous females.
The reduced compulsive-like behavior is contrary to a previous study in which lactating 
wild type C57BL6/J females treated with daily vehicle injections exhibited more marble burying 
behavior than nulliparous females16. Considering the low number of marbles buried, i.e., about 3 
in nulliparous and about 7 in lactating females on average in lactating females during the 20-min 
test16, C57BL6/J mice can be considered non-compulsive-like mice9a. May be the lower rates of 
marble burying reflect anxiety-like behavior while higher rates of digging better reflect a 
compulsive-like phenotype as seen in our mouse strains93, b c d. Alternatively, the contradictory 
effect of lactation on compulsive-like digging may indicate a strain effect due to genetic 
differences as a result of selection for expression of compulsive-like phenotype or different 
genetic correlation structures due to founder effects or random genetic drift40. Hence, the results 
provide insight into how genetic variability among healthy and OCD patients could produce 
differential outcomes in compulsive-like behavior during postpartum.
5.3.2 Administration of OXTR Antagonist Exacerbated Compulsive-Like Behaviors in 
Lactating Compulsive-Like Female Mice.
Administration of OXTR antagonist, L368-899 increased compulsive-like marble burying 
(F2,28 = 76.74, p<0.001) in the lactating females when compared to the vehicle (t18= 5.305, 
p<0.001) and D2 agonist, bromocriptine (t19= 12.33, p<0.001) treated lactating females (Fig 5.2).
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For compulsive-like nest-building behavior there was an overall treatment effect for 
hours 1 (F 2,31 = 117.42, p<0.001), 2 (F2,31 = 52.54, p<0.001), 3 (F2,31 = 14.05, p<0.001), 5 (F2,31 = 
9.36, p<0.001) and 24 (F231 = 66.56, p<0.001) (Fig 5.4a, b). The drug effect in hours 1 and 2 
was due to lactating females treated with L368-899 showing higher nesting scores than the 
lactating females treated with vehicle (t21= 6.260, p<0.001; t21= 5.102, p<0.001) or bromocriptine 
(t21= 7.307, p<0.001 ; t21= 7.603, p<0.001). Significantly higher nesting scores for vehicle (t20= 
5.528, p<0.001) and L368-899 (t20= 4.509, p<0.001) treated lactating females when compared 
to bromocriptine treated females accounted for the drug effect in hour 3. Drug effect in hour 5 
was due to an increase in the nesting scores of bromocriptine treated animals in comparison to 
vehicle (t20= 4.173, p<0.001) and L368-899 (t21= 4.081, p<0.001) treated females. After 24 
hours the overall nesting scores were significantly higher in L368-899 treated lactating females 
in comparison to the vehicle (t21= 5.579, p<0.001) or bromocriptine (t21= 4.473, p<0.001) treated 
ones (Fig 5.4b).
The current data indicates that blocking OXTR during lactation in compulsive-like mice 
can significantly exacerbate compulsive-like behaviors. The neuropeptide oxytocin has been 
investigated in connection to OCD in clinical studies30-33. However, the association of oxytocin 
and OCD has been contradictory30-33^  b. OXTR on the other hand, is widely distributed in various 
brain regions14b,41a, b, which is suggestive of its wide range of effects in the CNS29f. A study 
comparing human OCD patients with controls linked OXTR epigenetic modulation to OCD 
severity42.
The current finding of the role of oxytocinergic modulation during postpartum lactation in 
animal models that exhibit compulsive-like phenotype is novel. Emerging evidence from rodent 
studies suggest that oxytocinergic and serotonergic systems interact with each other to regulate 
behavioral responses in a context dependent manner2^  43a, b c. For example, oxytocin produced 
anxiolytic effects in mice by regulating serotonin transmission through OXTR expressed on
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raphe neurons29f. This serotonin release and anxiolytic response was positively regulated by 5- 
HT2A/2C receptors29f. OXTR deletion on raphe neurons influenced aggression in a sex 
dependent fashion with male mice exhibiting enhanced aggression and females exhibiting no 
changes in aggression433. This oxytocinergic and serotonergic interaction has also been 
reported during lactation39 in addition to the lactation specific extensive neuro-glia remodeling of 
the oxytocinergic systems103, 16. Moreover, spontaneous alternation due to activation of 5-HT1A 
receptor by 8OH-DPAT was abolished during lactation in rats18. One of the likely explanations 
that the authors proposed for this response was desensitization of the 5-HT1A receptor due to 
oxytocinergic or prolactinergic modulation specific to lactation18, 39, 44a b. The current result from 
our study is suggestive of a possible interaction of oxytocinergic and serotonergic systems to 
exhibit behavioral modulation in compulsive-like mice during postpartum lactation. However, to 
what extent this interaction is involved in regulating spontaneous compulsive-like behavior 
remains to be determined.
Attenuation of marble burying and nesting behavior observed in bromocriptine treated 
lactating females was most likely due to the overall behavioral suppression as locomotion was 
suppressed in the open field (see below). This was unexpected, since we selected a dose which 
was used in a prior study with mice and did not influence motor behaviors45, which suggests that 
compulsive-like may be more sensitive to bromocriptine. Further, in another study, a 
bromocriptine dose of 32 mg/kg evoked climbing behavior in mice46. It should be considered 
that the acute effect of dopamine agonists on locomotory functions is biphasic with initial 
depression followed by excitation47a, b, which the lactating compulsive-like mice also displayed 
for nest-building behavior. The behavioral depression due to bromocriptine in the compulsive­
like lactating females could be attributed to the stimulation of the presynaptic dopamine D2Rs48a 
b in brain regions implicated in motor functions such as dorsal striatum and nucleus 
accumbens49.
181
5.3.3 Postpartum Lactating and Non-Lactating Compulsive-like Female Mice Exhibited Anxiety­
Like Behavior in the Open Field when Compared to Nulliparous Females.
For the anxiety-like behavior in the open field, significant physiological status and 
fluoxetine treatment effects on the central zone entries were observed (F2,64 = 8.52, p<0.01 and 
F2,64 = 22.03, p<0.001, respectively) (Fig 5.5a). Compulsive-like lactating females had 
significantly lower central zone entries when compared to nulliparous females in the vehicle 
group (t22= 2.591, p<0.05, respectively). In the fluoxetine treated groups, the lactating females 
showed less number of central entries (t21= 3.213, p<0.001) when compared to the nulliparous 
females. The significant treatment effect was due to the improvement in the central square 
entries for fluoxetine treated lactating (t21= 2.532, p>0.05) and nulliparous (t22= 3.307, p>0.05) 
females when compared to their vehicle treated counterparts. This was not seen for the non- 
lactating females. There was no significant effect of physiological status (F2,64 = 1.72, p=0.18), 
treatment (F164 = 2.59, p=0.11) and physiological status by treatment interaction F2,64 = 1.12, 
p=0.33) effects on locomotor activity, measured as total distance traveled (Fig 5.5b).
Contrary to our hypothesis, the data indicates that lactating compulsive-like mice were 
more anxiety-like in comparison to nulliparous ones. Lower levels of anxiety during postpartum 
is considered to be a maternal adaptation due to neuroendocrine modulation50^  b, which 
facilitates social bonding and offspring acceptance51^  b. However, the component of emotionality 
can be perceived very differently by lactating females as evaluated through behavioral tests. For 
example, evaluation of anxiety behavior between postpartum and virgin mice and rats in the 
anxiety-like light-dark test revealed no differences23^  b, while locomotion was reduced in 
lactating rats when compared to virgin ones52. Further, when isolated from pups lactating wild 
type C57BL/6 mice were found to be more anxious in marble burying behavior16. It is interesting 
to note that though lactating females were more anxiety-like, locomotory activity among vehicle 
treated lactating, non-lactating and nulliparous compulsive-like females were not different, which
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supports that the anxiety-like differences were not due to activity level differences. Hence, 
motivation to explore novel environment was not affected in the lactation phase. Alternatively, 
selective breeding for compulsive-like phenotype could have resulted in greater anxiety in our 
mouse strains during the postpartum lactating phase. It could be due to a genetic correlation 
between genes that affect compulsivity and postpartum anxiety or different genetic correlation 
structures due to founder effects or random genetic drift40. Further, strain specific anxiety-like 
behavioral differences have been observed in rodents53a, b.
Though improvement in the number of central entries was observed in lactating and 
nulliparous females following fluoxetine treatment, no significant effect was seen for the non- 
lactating females (although it trended in the same direction). It points towards a lesser response 
to fluoxetine in the compulsive-like non-lactating mice. This is interesting since, the state of 
lactation or the presence of pups has been proposed to be an important factor in influencing 
SSRI responsiveness in a study with C57BL6/J16. The fact that both lactating and nulliparous 
compulsive-like mice responded to fluoxetine, indicates that the state of lactation is not the only 
factor that drives SSRI responsiveness for anxiety-like behavior. However, we believe that 
removal of pups and therefore cessation of lactation can result in reduced responsiveness to 
SSRIs for anxiety-like behaviors. The current data could provide enhanced understanding as to 
how OCD patients might vary in their emotional responses during postpartum with potentially 
greater vulnerability for lactating females and poor response to SSRI for non-lactating ones.
5.3.4 Blocking OXTR Did Not Affect Anxiety-Like Open Field Behaviors, While Activating D2 
Receptors Through Bromocriptine Increased Anxiety-Like Behavior and Suppressed Overall 
Activity in Lactating Compulsive-Like Females.
A significant treatment effect was observed for the number of central entries (F2,29 = 7.60, 
p<0.01) (Fig 5.6a) and total locomotion (F2,29 = 12.43, p<0.001) (Fig 5.6b) in the anxiety-like 
open field measure. This was mainly due to the suppression of total locomotion in the
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bromocriptine treated lactating females that also contributed to a lower number of central entries 
when compared to the vehicle (t19= 3.243 p<0.01) and L368-899 (t20= 4.924 p<0.001) treated 
lactating females. No significant differences were observed for number of central entries (t20=
0.0393 p>0.05) and locomotion (t20= 1.722 p>0.05) between vehicle and L368-899 treated 
females.
OXTR did not alter the anxiogenic response of lactating compulsive-like mice. Lack of 
effect on anxiety-like behavior due to blocking of OXTR is in agreement with other rodent 
studies where OXTR antagonists did not cause differences in various anxiety-like 
assessments54^  b. Further, a study with OXTR knockout mice did not reveal significant 
differences in the anxiety-like measures from wild type controls51b. However, it has to be 
considered that these studies were not conducted in the postpartum phases. In fact, a study in 
rats showed that blocking OXTR can produce anxiogenic behaviors in pregnant and lactating 
females when compared to virgin females55. A likely explanation for this differential response 
could be due to low oxytocin system activity during non-reproductive and stress-free events56. 
This indicates that the oxytocinergic system might not maintain basal levels of anxiety-like 
responses but can regulate such behaviors during specific physiological conditions such as 
pregnancy and lactation56. Studies on wild type mice have shown that chronic 
intracerebroventricular infusions or nasal application of oxytocin resulted in downregulation of 
oxytocin receptors in brain regions regulating anxiety57a probably due to OXTR desensitization58. 
Interestingly, chronic oxytocin treatment upregulates vasopressin receptor binding in the lateral 
septum where vasopressin is known to exert anxiogenic effects5715, 59. An oxytocin surge during 
lactation that desensitizes OXTR in specific brain regions could therefore have increased 
anxiogenic behavior in the lactating compulsive-like mice. In that scenario, blocking OXTR 
would not be expected to alter anxiety-like behavior as observed in the compulsive-like lactating 
females indicating no role of OXTR in driving anxiety-like responses during lactation. Though
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oxytocin is known to reduce anxiety-like responses for maternal care60, it could be one of the 
many factors contributing towards these responses61. The anxiogenic behavior observed in 
bromocriptine treated lactating females was predominantly due to the overall suppression of 
locomotory activity as discussed in the context of compulsive-like behavior.
5.3.5 Physiological Status in Fluoxetine Treated Compulsive-Like Female Mice Determined 
Depression-Like Tail Suspension Behavior.
For depression-like tail suspension behavior a significant effect of the physiological status (F2,64 
= 8.38, p<0.001) was found in the compulsive-like mice (Fig 5.7a). There were no significant 
treatment (F164 = 0.14, p=0.71) and physiological status by treatment interaction (F2,64 = 1.60, 
p=0.21) effects. The physiological effect was primarily due to lactating (t20= 3.840, p<0.001) and 
non-lactating (t22= 2.692, p<0.001) females having lower immobility in fluoxetine treated groups 
when compared to fluoxetine treated nulliparous females.
Overall, the data indicates that physiological status of the compulsive-like mice did not 
influence depression-like behavior under normal conditions. However, in the presence of 
fluoxetine, depression-like behavior increased in the nulliparous mice when compared to the 
fluoxetine treated non-lactating and lactating compulsive-like females. The data also shows that 
fluoxetine did not attenuate depression-like behavior in the non-lactating, lactating and 
nulliparous compulsive-like mice. In an inbred mouse strain lactating females exhibited less 
depression-like behavior16. In another study, chronic treatment of fluoxetine (SSRI) in wild type 
mice exposed to chronic stress conditions exacerbated the depression-like behavior when 
compared to mice exposed to enriching conditions which improved performance in depression­
like behavior62. We believe that the responses of the lactating, non-lactating and nulliparous 
compulsive-like mice in the fluoxetine group is probably due to the selective breeding that 
resulted in a higher stress response9c. This might be compounded by physiological events, such 
as postpartum, accounting for lack of antidepressant effect in the presence of fluoxetine. OCD
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patients, especially females and postpartum females, exhibit an enhanced HPA axis and a 
higher baseline stress response63a, b, which could lead to reduced SSRI effectiveness in treating 
depression among postpartum patients.
5.3.6 OXTR Antagonist, L368-899 Increased Depression-Like Behavior in Lactating 
Compulsive-Like Females, While the D2 receptor Agonist Bromocriptine Had No Effect.
An overall treatment effect (F2,64 = 8.38, p<0.001) was observed for lactating females 
undergoing tail suspension behavior (Fig 5.7b). Lactating females administered with L368-899 
had higher immobility in the tail suspension when compared to vehicle (t16= 5.110, p<0.001) and 
bromocriptine (t16= 4.500, p<0.001) administered females.
This data indicates that blocking OXTR increased depression-like behavior in 
compulsive-like lactating females. The antidepressant activity of oxytocin has been established 
in rodent models64'5, b c and is facilitated through OXTR65. Oxytocin is known to control stress 
adaptation by projecting from the paraventricular region of the hypothalamus to areas like the 
amygdala, hippocampus and lateral septum (reviewed in:66). This is also in good agreement 
with the OXTR expression profile in these regions (reviewed in:14b). Hence, blocking OXTR in 
our study decreased immobility time in the tail suspension test.
Interestingly, bromocriptine did not depress mobility in the tail suspension test compared 
to vehicle, although it was measured at the same time after injection as the open field test. 
Bromocriptine reduces immobility of mice in the tail suspension test67'5, b and has been shown to 
have antidepressant effects in preclinical and clinical studies68'5, b c d. Therefore, this anti­
depressant effect of bromocriptine may have compensated for the lower levels of activity 
observed for the bromocriptine treated lactating compulsive-like mice in the marble burying, nest 
building, and open field tests. Alternatively, activation of the D2R by bromocriptine reduced
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compulsive-like behaviors, made the lactating compulsive-like female mice more anxiety-like, 
reduced locomotor activity, but had no effect on depression-like behavior.
5.3.7 Lactating Compulsive-like Females Exhibited Higher DRN Serotonin (5-HT) 
Immunoreactvity and Serum Levels When Compared To Non-lactating and Nulliparous 
Females.
The physiological status effect was significant on the total number of 5-HT positive 
neurons in dorsal raphe nucleus (F2,12 = 15.30, p<0.001). Lactating females had higher 5-HT 
immunoreactivity when compared to the non-lactating (t8= 6.788, p<0.01) and nulliparous (t8= 
6.763, p<0.001) females (Fig 5.8). The serum levels of 5-HT in lactating females were also 
significantly higher (F215 = 5.56, p<0.05) in comparison to the non-lactating (t10= 4.161, p<0.05) 
and nulliparous females (t10= 4.000, p<0.05) (Fig 5.9).
The higher level of serum 5-HT levels in lactating compared to non-lactating compulsive­
like female mice is in agreement with a similar finding in C57BL/6 mice16. Peripheral 5-HT is 
predominantly produced in the enterochromaffin cells of the gut that enter into the blood stream 
from where they get transported into platelets693, b. High peripheral 5-HT levels are typically seen 
during pathologies such as tumors16. lactation is considered to be a unique physiological state16. 
Two probable sources of 5-HT during lactation could account for the observed high serum 5-HT 
levels in lactating females. One source of higher 5-HT could be due to enhanced 5-HT synthesis 
in the mammary glands during lactation15, while another possibility could be due to elevated 
mucosal hyperplasia in the intestine of lactating females16, 70.
The increased DRN 5-HT immunoreactivity in lactating females versus decreased 5-HT 
immunoreactivity in non-lactating and nulliparous females is indicative of altered central 
serotonergic activity during lactation. However, this finding was opposite of what was found in 
c57BL/6 mice, in which lactating females had decreased DRN 5-HT immunoreactivity compared
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to virgin females16. The discrepancy in DRN immunoreactivity could be due to the collection of 
brain tissues at different time points during the lactation period, i.e., 10 days after parturition16 
and 18 days after parturition in our study. Alternatively, selective breeding for compulsive-like 
phenotype might have resulted in higher 5-HT immunoreactivity when compared to nulliparous 
or non-lactating mice. The reduction in DRN 5-HT immunoreactivity in the c57BL/6 lactating 
mice16 could also reflect increased activity of the serotonergic system due to greater release 
accounting for the anxiolytic and antidepressant behaviors. On this premise, the increased DRN 
5-HT immunoreactivity in the compulsive-like lactating females might reflect decreased activity 
of the serotonergic system which aligns with the anxiogenic behaviors exhibited by the lactating 
females. We have shown previously that the compulsive-like mice had lower numbers of 
arginine-vasopressin (AVP) immunoreactive neurons in the suprachiasmatic nucleus (SCN) 
compared to non-compulsive-like mice71. This difference in immunoreactivity was abolished 
when AVP transport and release was blocked by colchicine72. In organotypic SCN cultures, we 
also showed that compulsive-like mice had higher levels of AVP release per AVP neuron 
compared to the non-compulsive-like mice72. Therefore, a lower immunoreactivity of AVP in the 
SCN indicated a more active AVP system, which is similar to what might have been the case 
with serotonergic system in relation to DRN 5-HT immunoreactivity. This concept of higher 
immunoreactivity correlating with lower release and vice versa has been corroborated in other 
studies with neuropeptides73'5, b. Finally, the possibility of higher serotonin immunoreactivity 
could be related to higher serotonin activity at synapses, thereby explaining lower compulsive­
like nest-building and marble burying behaviors in the lactating females when compared to non- 
lactating and nulliparous females. Depleting serotonin in the brain by knocking out tryptophan 
hydroxylase 2, the initial rate-limiting enzyme in serotonin synthesis, increased compulsive-like 
behaviors, including nestlet shredding and marble burying74, compared to wild-type mice, which 
indicates that activation of the serotonergic system is necessary to reduce compulsive-like 
behaviors.
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5.4 Conclusion
The current study provides a novel understanding of the role of physiological status on 
treatment and behavioral outcomes in the female compulsive-like mouse model, in which 
lactation protected compulsive-like female mice from expressing compulsive-like behaviors and 
increased their response to the SSRI fluoxetine in reducing compulsive-like behaviors. This 
study also revealed that the oxytocinergic system during postpartum lactation was at least 
partially responsible for mediating these effects of lactation on mice with a compulsive-like 
phenotype. Considering a pressing need for better understanding of OCD in females during 
physiologically challenging conditions, our data holds clinical importance by providing critical 
insights into SSRI effectiveness, role of breast feeding and comorbid affective disorders in 
postpartum OCD patients.
5.5 Materials and Methods
The University of Alaska Fairbanks Institutional Animal Care and Use Committee 
approved the animal care and experimental procedures (IACUC assurance number 862663).
5.5.1 Animals
For this study we used the compulsive-like BIG male and female mice9. This compulsive­
like mouse model was developed from house mouse strains (Mus musculus) through 
bidirectional selection for nest-building behavior40, 75. The HS/Ibg outbred strain76, which was 
developed through crossing of eight inbred strains (A, AKR, BLB/c, C3H/2, C57BL, DBA/2, Is/Bi, 
and RIII) served as the stock population for the selective breeding75. Bidirectional selection 
resulted in two compulsive-like BIG strains, which consistently exhibit a forty-fold higher level of 
compulsive-like nest-building behavior40, 75 and a three-fold higher level of compulsive-like 
marble burying behavior 9a when compared to the two non-compulsive-like SMALL strains. The 
two randomly-bred control strains express intermediate levels of these behaviors9a, 9c, 40, 75. This 
excessive, repetitive and perseverant otherwise normal, nest-building and marble burying
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behavior by the BIG strains makes them a good model to study compulsive-like phenotypes9. All 
experimental BIG males and females, taken from the one compulsive-like strain that had the 
highest breeding success of about 90% during colony breeding, were housed in polypropylene 
cages (27 cm * 17 cm * 12 cm) with same sex littermates and provided with wood shavings 
under a 12:12 light-dark cycle at 22 ± 1°C with ad libitum food (Purina Mills, Lab Diet Mouse 
Diet #5015, St. Louis, MO) and water. When the animals reached 60 days of age, each BIG 
female was paired with a BIG male in a cage with ad libitum access to high protein rodent chow 
(Masuri Rodent Diet #5663, Purina Mills, LLC, St. Louis, MO, USA) and water.
5.5.2 Experimental Design
The entire study was divided into two main phases. In the first phase of the experiments, 
compulsive-like lactating, non-lactating and nulliparous female mice were tested for compulsive­
like, anxiety-like and depression-like behaviors. For lactating and non-lactating females, the 
males were separated two weeks after pairing. All the females showed signs of pregnancy 
within two weeks of pairing which was confirmed through vaginal plug. All lactating females 
were housed with their pups until the end of all the behavioral assessments. For the non- 
lactating females, pups were removed immediately after birth and the females were housed 
individually in cages until the end of all experimentation. Nulliparous females were housed 
individually in cages after they failed to conceive following pairing with male counterparts for two 
weeks (males were removed after two weeks of pairing). All experimental groups of females 
(lactating, non-lactating and nulliparous) were either treated with fluoxetine (n=12) or vehicle 
(n=12). Animals treated with either fluoxetine or vehicle were subjected to compulsive-like 
marble burying and nest-building behavior once every week for three weeks on days 1, 2, 8, 9, 
15 and 16 of lactation, respectively (day 0 was the day of parturition). Anxiety-like open field and 
depression-like tail suspension tests were conducted only once on days 17 and 18 of lactation, 
respectively.
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Separate groups (n=5 per group) of lactating, non-lactating and nulliparous females that 
did not undergo any behavioral assessments and treatments were subjected to transcardial 
whole body perfusion on day 18 of lactation. Brains were collected for immunohistochemical 
analysis of 5-HT neurons in the dorsal raphe nucleus (DRN). Other separate groups of lactating, 
non-lactating and nulliparous females (n=6 per group) that also were not subjected to any 
behavioral assessments and treatments were used to collect blood samples on day 18 of 
lactation from the trunk of cervically dislocated animals for serum analysis of 5-HT through 
ELISA. Because most of the behavioral assessments (except compulsive-like behaviors, which 
were performed once every week) were performed in the third week, we wanted to evaluate the 
5-HT serum levels and DRN immunoreactivity during the final week of lactation. Day 18 of 
lactation was selected for 5-HT measurements since it is considered to be the peak lactation 
period77a, b.
For phase two of the experiments, only lactating females were used. All lactating 
females were divided into 12 groups. Animals were tested for compulsive-like nest-building and 
marble burying, anxiety-like open field and depression-like tail suspension. For each of four 
behaviors, three main treatment groups were used for a total of 12 experimental groups. For 
each behavior mice were treated with bromocriptine mesylate a dopamine D2 receptor agonist 
78, L368-899 an OXTR antagonist79 or vehicle. All drug or vehicle treated lactating females were 
subjected to a single behavioral assessment, i.e., tested just once for one behavior, on day 18 
of lactation. Exposing animals to multiple behaviors were avoided to minimize stress to the pups 
and the females due to multiple injections. All behavioral assessments were carried out by an 
experimenter blinded to the treatment groups.
5.5.3 Drug Treatment
For phase one of the experiments, all groups (lactating, non-lactating and nulliparous 
females) were treated with either fluoxetine or vehicle. The vehicle animals received sucrose in
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drinking water (2.9 g/L) while the drug groups received 50 mg/kg of fluoxetine in the sucrose 
vehicle as described previously9a. The dosage of 50 mg/kg was used because it shows the most 
consistent suppression of compulsive-like behaviors in our compulsive-like mice9a. The dosage 
of 50 mg/kg was used since it shows the most consistent suppression of compulsive-like 
behaviors in our mice9a. The route of administration was orally in the drinking water. The 
average water consumption was measured for 3-5 days before and after the pups were born in 
lactating and non-lactating females. Treatment for lactating and nonlactating females started on 
the day the pups were born. The amount of drug given was calculated based on the average 
body weight and daily average water consumption of the mice. The water levels were measured 
daily and new water bottles were given every two days. To avoid excess consumption of 
treatment only minimum volumes, determined through measurement of average daily water 
consumption, were provided and animals were checked every 12 hours. For the nulliparous 
females, the same time frame was used for evaluation of drug and vehicle treatments, and 
treatment was started when it was confirmed that they were not pregnant, i.e., three weeks after 
the males were removed. The total duration of treatment was 18 days because after three 
weeks of SSRI treatment maximum fluoxetine effects are obtained in our mouse model of
OCD9a.
In phase two of the experiments, lactating females were divided into three drug 
treatment groups for a total of four behaviors to a total o f 1 2  experimental groups. Each 
behavioral group received 10 mg/kg of D2R agonist bromocriptine mesylate, 5 mg/kg of OXTR 
antagonist L368-899 or vehicle (0.9% sterile saline and 1% Tween) through intraperitoneal (i.p) 
injection one hour before behavioral assessment. The dosage for L368-899 and bromocriptine 
was determined from previous studies in mice and rats78-80a, b, c. The injection volume was 
adjusted proportionally according to the body weight of each animal with a 0.3 ml injection 
volume for a 40g mouse.
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5.5.4 Compulsive-like Behaviors
5.5.4.1 Marble Burying Behavior
The marble-burying test was used to assess compulsive-like behavior9a, 74, 81a, b. All mice 
were individually introduced into a polypropylene cage (37 cm * 21 cm * 14 cm) containing 20 
glass marbles (10 mm in diameter) evenly spaced on 5 cm deep wood shavings firmly pressed 
into a uniform bedding without access to food or water for 10 min. The total number of marbles 
buried at least 2/3 in the 10-min period was quantified as compulsive-like digging behavior9. 
Following the 10-min test, animals were returned to their home cages.
5.5.4.2 Nest-building Behavior
Nest-building behavior was used to assess the compulsive-like phenotype of the female 
mice9a, b, c, d. All mice were housed individually and were allowed to access a pre-weighed cotton 
roll placed in the cage top food hopper. The amount of cotton used by the mice after 1 hour was 
determined by weighing the cotton roll. For phase one of the experiments nest-building was 
performed for 1 hour only. This was mainly to ensure that the lactating females were not 
separated from the pups for too long. The same time frame was followed for non-lactating and 
nulliparous females to have uniform data collection. Nest-building was performed on weeks 1, 2 
and 3 of postpartum for lactating and non-lactating females. A similar time frame was also 
maintained for nulliparous females and was tested thrice on weeks 1, 2 and 3.
For phase two of the experiments all lactating females treated for vehicle, bromocriptine 
or L368-899 were subjected to nest-building for 24 hours only once starting on day 18 of 
lactation. Amounts of cotton used for nesting was measured after 1, 2, 3, 4, 5 and 24 hours after
i.p injection.
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5.5.5 Anxiety-like Open Field Behavior
Anxiety-like behaviors were determined through the open field test82a, b. Mice were 
individually introduced into an open field (40 cm * 40 cm * 35 cm) with a central zone (20 cm * 
20 cm). The apparatus was placed underneath an overhead light illuminating the entire 
apparatus93. The animals were placed in the central zone of the apparatus and their behavior 
was videotaped for 3 min and analyzed with the aid of ANYMazeTM video tracking software 
(Stoelting Co., Wood Dale, IL, USA). The total number of central zone entries (anxiety-like 
measure) and total distance traveled (locomotion) in the entire open field were measured. The 
open field was cleaned before each test with a dilute chlorhexidine solution. Prior experiments9 
with the BIG mice indicate that 3 min duration provides consistent outcomes for assessment of 
locomotor activity and anxiety-like behaviors and therefore considered for the current 
experiment.
5.5.6 Depression-like Tail Suspension Behavior
Depression-like behavior in the compulsive-like mice was assessed through the tail 
suspension test83. Each mouse was individually suspended from a hook of the tail suspension 
apparatus (Stoelting Co., Wood Dale, IL) above the surface of the table by a 15 cm long 
adhesive tape. The tape was placed 5mm from the tip of the tail and the animal was suspended 
60 cm above the base of the apparatus. The immobility duration was recorded sideways for 6 
minutes using a camera. Mice were considered immobile only when they were completely 
motionless without any movement of body parts or front and hind limbs84. The videos were 
analyzed by an experimenter blinded to the outcome of the study.
5.5.7 Serum 5-HT Levels
Trunk blood was collected from females (lactating, non-lactating and nulliparous) on the 
18th day of lactation after cervical dislocation. Blood samples were kept undisturbed at 4 
degrees overnight. This allowed the 5-HT release from platelets16. Serum was then extracted
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from blood samples by centrifugation at 12,000 rpm for 20 minutes (4 degrees). The extracted 
serum was stored at -80 °C until analysis. All serum samples were assayed in duplicates for 5- 
HT levels using an ELISA kit (Kit# ADI: 900-175; Enzo life Sciences) according to the 
manufacturer instructions. The sensitivity for the kit was 0.293 ng/mL
5.5.8 5-HT Immunohistochemistry in DRN
Brains collected through whole body transcardial perfusion (8 mL of 0.01M phosphate 
buffer saline followed by 25mL of 4% paraformaldehyde in PBS) were fixed overnight in 4% 
paraformaldehyde. Fixed brains were transferred to 30% sucrose solution and stored until they 
submerged completely. Brains were then frozen in Tissue-Tek OCT compound in beaker cups 
(VWR International). Frozen brains were sectioned on a freezing microtome at 20qm coronal 
slices -4.84Bregma and -5.02Bregma as per the mouse brain atlas. Brain slices were then 
immunostained for 5-HT on slides (VWR Cat no: 48311-703). Slides containing brain sections 
were first washed in 1X PBS (five 5 min washes). The slides were then incubated in 30% 
hydrogen peroxide in PBS for 30 minutes at room temperature followed by PBS washes (six 5 
min washes). Blocking buffer (1x PBS containing 5% normal goat serum, 2% BSA and 0.4% 
Triton X-100) was then added to the slides for one hour. After one hour, slides were washed in 
1X PBS (three 5 min washes) and incubated with 5-HT primary (Immunostar Cat: 20080; 
1:20,000 in 1X PBS and 0.4% Triton X-100) overnight for 20 hours. On day two, slides were 
washed in PBS (four 5-min washes) and were incubated with secondary antibody (1:600 
biotinylated goat anti-rabbit, Vector labs Cat: BA1000; in PBS and 0.04% Triton X-100) for one 
hour. Sections were finally processed using Vectastain Elite ABC immunoperoxidase system 
(Vector Laboratories) as per the manufacturer instructions and visualized with Ni2+-DAB 
enzyme substrate. For analysis of 5-HT reactive cell bodies in the DRN, ImageJ software (NIH) 
was used. In the threshold mode which was same for all brain section analyzed, the number of 
cell bodies stained positively for 5-HT in the DRN were counted.
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5.5.9 Statistical Analysis
Statistical system software (SAS; Version 9.4 NC Carey) was used for analysis of all the 
results. For the first phase of experiments, a generalized linear model (GLM) repeated 
measures analysis of variance (ANOVA) for physiological status (lactating, non-lactating and 
nulliparous), treatment (vehicle, fluoxetine) and physiological status by treatment interaction 
effects was used to statistically evaluate the nest building and marble burying behaviors. A GLM 
two-way ANOVA for physiological status, treatment and physiological status by treatment 
interaction effects was used to statistically evaluate the open field and tail suspension 
behaviors. For serum and DRN 5-HT levels, a GLM one-way ANOVA was conducted for the 
effect of physiological status. For the second phase of the experiments, a GLM one-way 
ANOVA was performed to test for the effect of treatment (bromocriptine, vehicle and L368-899) 
on each of four behaviors. When significance was found in any of the ANOVA measures, 
appropriate pairwise comparisons were performed using the Studentized Range test. The 
nesting scores were square root transformed to obtain a more normal distribution9, 40, 85a b. All 
data are represented as mean ± standard error of the mean (SEM). A probability level of p<0.05 
was used to determine statistical significance in all cases.
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Fig 5.1 Lactating compulsive-like female mice exhibited less compulsive-like marble burying. 
Compulsive-like marble buying behavior represented as the total number of marbles 2/3rd 
buried among lactating, non-lactating and nulliparous compulsive-like females administered with 
vehicle or fluoxetine in (a) week 1 (b) week 2 and (c) week 3. *** (p<0.001) indicates significant 
differences between fluoxetine and vehicle groups. # (p<0.05), ## (p<0.01) and ### (p<0.001) 
indicate significant differences between lactating and non-lactating females within each 
treatment group. + (p<0.05) and +++ (p<0.001) indicate significant differences between lactating 
and nulliparous females within each treatment group. Data is expressed as the mean ± SEM.
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Fig 5.2 The OXTR antagonist increased compulsive-like marble burying, while the D2R agonist 
decreased marble burying in lactating compulsive-like female mice.
Compulsive-like marble buying behavior represented as the total number of marbles 2/3rd 
buried in lactating females one hour after bromocriptine (n=11), vehicle (n=10) or L368-899 
(n=10) administration. *** (p<0.001) and ### (p<0.001) indicate significant differences between 
L368-899 and vehicle or bromocriptine groups, respectively. +++ (p<0.001) indicates a 
significant difference between vehicle and bromocriptine groups. All data is expressed as the 
mean ± SEM.
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Fig 5.3 Lactating compulsive-like female mice exhibited less compulsive-like nest-building. 
Compulsive-like nest-building behavior represented as the total nesting score in grams among 
lactating, non-lactating and nulliparous compulsive-like mice in (a) week 1 (b) week 2 and (c) 
week 3. ** (p<0.01) and *** (p<0.001) indicate significant differences between fluoxetine and 
vehicle groups. ### (p<0.001) indicates significant differences between lactating and non- 
lactating females within each treatment group. +++ (p<0.001) indicates significant differences 
between lactating and nulliparous females within each treatment group. Data is expressed as 
the mean ± SEM.
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Fig 5.4 The OXTR antagonist increased compulsive-like nest-building in lactating compulsive­
like female mice.
Compulsive-like nest-building behavior expressed as total nesting score in grams in lactating 
compulsive-like female mice (a) 1-5 hours and (b) 0-24 hours after administration with 
bromocriptine (n=11), vehicle (n=11) or L368-899 (n=12). ** (p<0.01) and *** (p<0.001) 
represent significant differences between L368-899 and vehicle groups. ## (p<0.01) and ### 
(p<0.001) represent significant differences between L368-899 and bromocriptine groups. +++ 
(p<0.001) represents significant differences between vehicle and bromocriptine groups. All data 
is expressed as the mean ± SEM.
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Fig 5.5 Lactating compulsive-like female mice exhibited anxiety-like behavior.
Open field behavior represented as (a) anxiety-like total number of central entries among the 
lactating, non-lactating and nulliparous females administered with vehicle or fluoxetine. (b) 
Locomotor activity as the total distance traveled in cm among lactating, non-lactating and 
nulliparous female mice treated with vehicle or fluoxetine. * (p<0.05) and ** (p<0.01) indicate 
significant differences between vehicle and fluoxetine groups. # (p<0.01) and ## (p<0.001) 
indicate significant differences between lactating and nulliparous females within each treatment 
groups. All data is expressed as the mean ± SEM.
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Fig 5.6 The OXTR antagonist had no effect on anxiety-like behavior, while D2R agonist 
suppressed overall locomotion.
Open field behavior represented as (a) total number of central entries and (b) locomotor activity 
in lactating females one hour after bromocriptine (n=10), vehicle (n=11) or L368-899 (n=11) 
administration. ** (p<0.01) and *** (p<0.001) indicate significant differences between L368-899 
and bromocriptine groups. ## (p<0.01) indicates significant differences between vehicle and 
bromocriptine groups.
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Fig 5.7 Depression-like tail suspension behavior in lactating compulsive-like female mice was 
increased by the OXTR antagonist.
The depression-like tail suspension test is represented as total immobility time. (a) Lactating, 
non-lactating and nulliparous females administered with vehicle or fluoxetine. * (p<0.05) 
represents a significant difference between nulliparous and non-lactating females in the 
fluoxetine group. ### (p<0.001) represents a significant difference between nulliparous and 
lactating females in the fluoxetine group. (b) Lactating females administered with bromocriptine 
(n=10), vehicle (n=10) or L368-899 (n=10). *** (p<0.001) represents a significant difference 
between L368-899 and vehicle groups. ### (p<0.001) represents a significant difference 
between L368-899 and bromocriptine groups. All data is expressed as the mean ± SEM.
204
Fig 5.8 Lactating compulsive-like female mice had higher 5-HT immunoreactivity in the dorsal 
raphe nucleus.
5-HT immunoreactivity represented as 5-HT positive cell count in the DRN of naive lactating 
(n=5), non-lactating (n=5) and nulliparous (n=5) compulsive-like female mice. ** (p<0.01) 
represents the significant differences of the 5-HT positive cells in lactating females in 
comparison to both non-lactating and nulliparous females. All data is expressed as the mean ± 
SEM.
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Fig 5.9 Lactating compulsive-like female mice had higher 5-HT levels in serum.
5-HT levels in serum represented as ng/ml in naive lactating (n=6), non-lactating (n=6) and 
nulliparous (n=6) compulsive-like female mice. * (p<0.05) represents the significant differences 
of the 5-HT serum levels in lactating females in comparison to both non-lactating and 
nulliparous females. All data is expressed as the mean ± SEM.
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Chapter 6: Attenuation of Compulsive-Like Behavior Through Positive Allosteric Modulation of 
a4p2 Nicotinic Acetylcholine Receptors in Non-Induced Compulsive-Like Mice.5
6.1 Abstract
Nicotinic a4p2 receptors are the most abundant subtypes of nicotinic acetylcholine 
receptors (nAChRs) expressed in brain regions implicated in obsessive compulsive disorder 
(OCD). These receptors are known to modify normal and addictive behaviors by modulating 
neuronal excitability. Desformylflustrabromine (dFBr) is a novel, positive allosteric modulator 
(PAM) of high acetylcholine sensitivity (HS) and low acetylcholine sensitivity (LS) a4p2 nAChRs. 
The present study tested the hypothesis that positive allosteric modulation of a4p2 receptors by 
dFBr will attenuate compulsive-like behavior in a non-induced compulsive-like mouse model. 
Male mice (Mus musculus) selected for compulsive-like nesting behavior (NB; 48 animals; 12 
per group) received acute (once) and chronic (every day for 32 days) subcutaneous injection of 
dFBr at 2, 4 and 6 mg/kg doses. Saline was used as a control (0 mg/kg). Compulsive-like NB 
was assessed after 1, 2, 3, 4, 5 and 24 h, while compulsive-like marble burying (MB) and 
anxiety-like open field (OF) behaviors were performed 2 h after dFBr administration. In the acute 
administration protocol, dFBr dose dependently attenuated NB and MB. Rapid effects (1-2 h 
after drug administration) of dFBr on MB and NB were observed for the chronic administration 
which was in congruence with the acute study. Chronic administration also revealed sustained 
suppression of NB by dFBr following 5 weeks of treatment. In both the acute and chronic 
regimen dFBr did not modulate OF behaviors. This research demonstrates the novel role of 
positive allosteric modulation of a4p2 nicotinic receptors by dFBr as a translational potential for 
OCD.
5 Published as 5Mitra, S., Mucha, M., Khatri, S. N., Glenon, R., Schulte, M. K., & Bult-Ito, A. (2016b). 
Attenuation of Compulsive-Like Behavior Through Positive Allosteric Modulation of a4p2 Nicotinic 
Acetylcholine Receptors in Non-Induced Compulsive-Like Mice. Frontiers in Behavioral Neuroscience, 10, 
244. '
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6.2 Introduction
Obsessive-compulsive disorder (OCD) is the fourth most common mental disorder 
(Pittenger et al., 2005). It has a lifetime prevalence of 2.3% and a 12-month prevalence of 1.2% 
(Ruscio et al., 2010). Patients suffering from OCD suffer from persistent obsessive thoughts 
causing distress, and perform compulsive repetitive behaviors to alleviate uncomfortable 
feelings resulting from obsessions (Diniz et al., 2012). OCD can have disabling effects 
throughout the patient’s lifespan in both males and females (Attiullah et al., 2000).
Obsessions can be thematic, such as fear of contamination, pathological doubt, or need 
for symmetry/order, or somatic obsessions, like aggression. Repetitive compulsive behaviors 
involve, washing, seeking, counting, sorting, hoarding and searching (Doron and 
Moulding, 2009; Ghimire and Goit, 2014; Pauls et al., 2014). Although recently declassified as 
an anxiety disorder (American Psychiatric Association, 2015), many clinicians conceptualize 
OCD as a spectrum of related disorders (OCRD) sharing common clinical features of 
anxiety/fear and worry (Stein and Lochner, 2006; Storch et al., 2008; Fornaro et al., 2009). 
OCRD encompasses a wide range of diseases which includes somatoform (e.g., 
Hypochondriasis), impulse control (e.g., Trichotillomania, pathological gambling) and tic 
disorders (e.g., Tourette’s syndrome; Fornaro et al., 2009). Selective serotonin reuptake 
inhibitors (SSRIs) and cognitive behavioral therapy or their combination are often used as first 
line treatments. However, a large group of patients remain resistant to treatment either partially 
or completely (Jenike, 2004; Pittenger et al., 2005).
The cholinergic system in the brain is comprised primarily of nicotinic acetylcholine 
receptors (nAChRs; Paterson and Nordberg, 2000; Kalamida et al., 2007) and muscarinic 
acetylcholine receptors (mAChRs; Scarr, 2012; Thiele, 2013), members of the cys-loop 
superfamily of ligand gated ion channels and G protein-coupled receptors, respectively.
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Dysregulation of both mAChRs and nAChRs have been strongly associated with several 
neurological disorders (Janowsky et al., 1972; Freedman et al., 1995; Warpman and 
Nordberg, 1995; Breese et al., 2000; Salamone and Zhou, 2000; Perry et al., 2001; Woodruff- 
Pak and Gould, 2002; Ray et al., 2005; Quik et al., 2007; Scarr, 2012).
The a4p2 nAChR is one of the most prevalent nicotinic subtypes expressed in the brain 
(McGranahan et al., 2011). The a4p2 subtype is expressed in abundance in the dopamine 
pathways in the midbrain that influence the drug-induced reward system, mood disorders, 
stress, movement generation and learning (Wise, 2009; Maskos, 2010). a4p2 nAChRs have 
also been identified in the striatum, thalamus and cortex (Quik et al., 2013), brain areas 
implicated in OCD (Pena-Garijo et al., 2010; Fitzgerald et al., 2011). In the striatum, a4p2 
receptors have also been shown to modulate GABA and dopamine release (McClure-Begley et 
al., 2009; Perez et al., 2012). In particular, a subtype of the a4p2 receptor with high sensitivity to 
acetylcholine (HS a4p2) appears to be involved in striatal dopamine release (Anderson et 
al., 2009). These studies support a modulatory role of a4p2 receptors in neurotransmitter 
release in circuits affected in OCD.
Positive allosteric modulators (PAMs) enhance agonist responses via increased agonist 
potency and/or efficacy. Desformylflustrabromine (dFBr) is a novel PAM capable of potentiating 
acetylcholine-induced whole cell responses by 370% for the HS and 260% for the low sensitivity 
(LS) a4p2 receptors with an EC50 of 40 ^M and 2.5 ^M respectively (Weltzin and 
Schulte, 2010, 2015). It is currently the only selective PAM for a4p2 receptors capable of 
potentiating the HS form of the receptor involved in striatal dopamine release. As dFBr 
increases the efficacy of acetylcholine and does not directly activate receptors, it is postulated 
that its effect in the synapse would be to enhance acetylcholine mediated transmission. 
Application of dFBr, unlike application of exogenous agonists, would thus retain the control of 
synaptic activation via presynaptic release of acetylcholine, albeit with increased stimulation
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(Weltzin and Schulte, 2015). Only one in vivo study has been conducted to examine the effect 
of dFBr potentiation of a4p2 nAChR in an in vivo behavioral model. In this study dFBr was 
shown to attenuate nicotine self-administration in rats (Liu, 2013). The use of HS a4p2 
receptors PAMs for the treatment of OCD has not been previously proposed or tested in any 
animal model. The aim of the current study was to evaluate our hypothesis that acute and 
chronic administration of dFBr, a novel PAM specific for a4p2 nAChRs and active at the HS 
a4p2 subtype, will attenuate compulsive-like and anxiety-like behaviors in our non-induced 
compulsive-like mouse model.
There are few animal models that exhibit consistent and spontaneous differences in 
compulsive-like behaviors. We have previously shown that our mice exhibit face and predictive 
validity as a spontaneous non-induced model for OCD-like behaviors (Greene-Schloesser et 
al., 2011). The current model was achieved by bidirectionally selecting house mice, Mus 
musculus, for nest-building behavior for 56 generations (Lynch, 1980; Bult and Lynch, 2000). 
The stock population for the original selection experiment (Lynch, 1980) was a cross among 
eight inbred strains, i.e., A, AKR, BLB/c, C3H/2, C57BL, DBA/2, Is/Bi and RIII, to yield the 
HS/Ibg outbred strain (McClearn Ge and Meredith, 1970; Lynch, 1980). Bidirectional selection 
resulted in three levels of nesting behavior (NB). All BIG mice exhibit consistent excessive NB 
engaging in rapid and repetitive pulling of cotton through the cage top metal bars amounting to 
6-7 g of cotton on an average in 24 h when compared to normal NB (no significant hyperactivity 
and repetitiveness when introduced to cotton averaging around 0.50-0.70 g in 24 h) by the 
Control strain (non-compulsive) and very little NB (most of them do not indulge in nesting) by 
the SMALL strain (non-compulsive). The Control mice therefore serve as a selection control with 
intermediate levels between compulsive-like BIG and non-compulsive SMALL strains (Bult and 
Lynch, 2000). NB is homologous to hoarding in humans with OCD (Warneke, 1993), which is 
considered to be a measure of compulsive-like phenotype in mice (Greene-Schloesser et
234
al., 2011; Wolmarans De et al., 2016). The BIG mice also uniformly display repetitive marble 
burying (MB) behavior burying on an average 19-20 marbles. Both these behaviors are 
significantly attenuated by SSRIs (e.g., fluoxetine) used to treat OCD but not with normal 
antidepressants (e.g., desipramine; Greene-Schloesser et al., 2011) substantiating the face and 
predictive validity of the NB and MB phenotype of the BIG mice for investigating compulsive 
disorders. Hence in the current context of investigation compulsive-like BIG mice have been 
considered.
6.3 Materials and Methods
6.3.1 Animals
Compulsive-like BIG male mice, Mus musculus, were raised on wood shavings in 
polypropylene cages (27 cm * 17 cm * 12 cm) under controlled temperature (22 ± 1°C) and 
light (12:12 light-dark cycle) with free access to food (Purina Mills, Lab Diet Mouse Diet #5015, 
St. Louis, MO, USA) and water. Animals were 60 days of age at the start of the experiment. The 
University of Alaska Fairbanks Institutional Animal Care and Use Committee approved the 
animal care and experimental procedures (protocol # 675023).
6.3.2 Drug Administration
Deformylflustrabromine hydrochloride (dFBr; Abcam Biochemicals) was dissolved in 
physiological saline (pH = 6.7) to yield final doses of 2 mg/kg (0.27 mg/mL), 4 mg/kg (0.53 
mg/mL) and 6 mg/kg (0.80 mg/mL). Saline was used as a vehicle control (0 mg/kg). A mouse of 
40 g received an injection volume of 0.3 mL. Injection volumes were proportionally adjusted 
according to the body weight of individual animals. All behaviors were performed in the light 
phase of the light:dark cycle. All data were recorded by an individual blinded to the study.
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6.3.3 Acute Study
Male BIG mice were divided into four treatment groups comprising vehicle (sterile 
saline), 2 mg/kg, 4 mg/kg and 6 mg/kg. Animals in each group (n = 12 per group) were tested 
for nesting on day 1, MB on day 3 and open field (OF) on day 5. On the first day of testing 
animals randomly received dFBr or vehicle subcutaneously and in subsequent tests received 
the same dose. Days 2 and 4 were employed to avoid any residual effects of dFBr from 
previous administration. For nesting, data were collected after 1, 2, 3, 4, 5 and 24 h due to the 
progressive nature of the NB (The BIG mice typically get excited and indulge in excessive and 
repetitive NB when introduced to cotton for the first 3-4 h in the light cycle. This excessive and 
repetitive nesting activity resumes again in the dark cycle). MB and OF behavior was performed 
2 h after dFBr administration (Figure 6.1).
6.3.4 Chronic Study
Since the foundation of our animal model was established through effective reversal of 
compulsive-like NB and MB behaviors by chronic fluoxetine treatment (Greene-Schloesser et 
al., 2011) we also conducted a chronic regimen to establish the sustained and long term effects 
of dFBr on NB and MB. Animals belonging to 0, 2, 4 and 6 mg/kg dose group (n = 12 per group) 
received single subcutaneous injection of dFBr or saline daily for 32 days. NB, MB and OF 
behaviors were assessed in the final week (weeks 5) after dFBr administration (NB after 1, 2, 3 
4, 5 and 24 h and MB after 2 h of drug injection). NB was performed on day 30, MB on day 31 
and OF on day 32 (Figure 1).
The dosages and route of administration was determined based on a prior in vivo study 
of dFBr on rats (Liu, 2013). Studies on rats have shown that dFBr penetrates the blood-brain 
barrier and reaches the brain amounting to around 36% in the cerebrospinal fluid after 90 min of 
subcutaneous administration (Liu, 2013).
236
6.3.5 Assessment of Compulsive-Like Behaviors
6.3.5.1 Nest-Building Behavior
Nest-building behavior (NB) was performed to assess compulsive-like behavior in the 
mice (Greene-Schloesser et al., 2011). For both the acute and chronic study, compulsive-like 
male mice were singly housed and provided with a pre-weighed roll of cotton (Mountain Mist 
cotton batting, Troy, Inc., Chicago, IL, USA) in the cage-top food hopper immediately following 
subcutaneous injection of dFBr. The cotton roll was weighed after 1, 2, 3, 4, 5 and 24 h. NB was 
quantified by the grams of cotton used during each testing period (Bult and 
Lynch, 1996, 1997, 2000; Greene-Schloesser et al., 2011).
6.3.5.2 Marble Burying Behavior
The MB test is an effective test for determining compulsive-like behavior in mice 
(Takeuchi et al., 2002; Thomas et al., 2009; Angoa-Perez et al., 2013). Mice generally do not 
interact with the marbles and therefore the MB test measures only digging behavior (personal 
observations). Two hours after dFBr administration, compulsive-like male mice were individually 
introduced to a polypropylene cage (37 cm * 21 cm * 14 cm) containing 20 glass marbles (10 
mm in diameter) evenly spaced on 5 cm deep bedding comprised of wood shavings without 
access to food or water for 20 min (Greene-Schloesser et al., 2011). Testing was carried out in 
the testing room separate from the housing room. The total number of marbles buried at least 
2/3 in the 20-min period was quantified as compulsive-like digging behavior. After the 20-min 
test, the animals were returned to their home cages.6.2.6 Assessment of Locomotory and 
Anxiety-Like Behavior.
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6.3.6 Assessment of Locomotory and Anxiety-Like Behavior
6.3.6.1 Open Field Test
Anxiety-like behaviors were determined in the OF test (Simon et al., 1994; Prut and 
Belzung, 2003). Compulsive-like male mice were individually introduced into an OF (40 cm * 40 
cm * 35 cm) with a central zone (20 cm * 20 cm). The apparatus was placed underneath an 
overhead light illuminating the entire OF (Greene-Schloesser et al., 2011). The animals were 
placed in the center of the OF and their behavior was video taped for 3 min and analyzed with 
the aid of ANYMazeTM video tracking software (Stoelting Co., Wood Dale, IL, USA). The time 
spent in the center (anxiety-like measure) and total distance traveled (locomotion) in the entire 
OF were measured. The OF was cleaned before each test. Prior experiments (Greene- 
Schloesser et al., 2011) with the BIG mice in OF indicate that a 3 min duration provides 
consistent outcomes for assessment of locomotory and anxiety-like behaviors and therefore 
considered for the current experiment.
6.3.7 Statistical Analysis
Statistical analysis was performed in Graphpad Prism (GraphPad Software, Inc.) and 
Statistical Analysis System Software (SAS Version 9.4, Cary, NC, USA). NB (grams of cotton), 
MB (number of marbles at least 2/3 buried) and OF measures (time in center and total distance 
traveled) were expressed as the mean ± standard error of the mean (SEM). The NB data were 
shown in figures as grams of cotton used, whereas the statistical analysis was conducted on the 
square-root transformed nesting scores in order to normalize the data (Bult and Lynch, 2000). 
Nesting scores at different time points, MB and OF results were analyzed by one-way analysis 
of variance (ANOVA) whereas, overall drug and drug by time interaction effect between 0 h and 
5 h was done by two-way repeated ANOVA. Pairwise comparisons for significant differences 
between doses were tested by the post hoc Bonferroni multiple comparison test. A probability 
level of p < 0.05 was used as an index of statistical significance in all cases.
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6.4 Results
6.4.1 dFBr Attenuates Compulsive-Like NB
6.4.1.1 Significant Suppression of Compulsive-Like NB During the First 5 h of Acute dFBr 
Administration (Figure 6.2A)
There was an overall significant drug (F(3,220) = 38.60, p < 0.0001) effect during the first 5 
h, a significant time (F(4,220) = 44.71, p < 0.0001) and drug by time interaction effect (F(12,220) = 
7.08, p < 0.0001) in the compulsive-like NB.
Following a 1 h of dFBr administration, there was no significant attenuation of nesting 
(F(3,44) = 1.276, not significant (NS)). Between 1 and 2 h, dFBr administration resulted in dose- 
dependent and significant reductions in nesting scores (F(3,44) = 26.42, p < 0.0001). Post 
hoc assessment revealed that 4 mg/kg (t22 = 6.210, p < 0.001) and 6 mg/kg (t22 = 6.638, p < 
0.001) doses of dFBr significantly attenuated NB as compared to the control (saline). This effect 
was sustained only by 6 mg/kg dose (t22 = 3.727, p < 0.01) between 2 and 3 h (F(3,44) = 
7.906, p < 0.0005) and both 4 and 6 mg/kg (t22 = 3.305, p < 0.05 and t22 = 4.585, p < 0.001 
respectively) between 3 and 4 h (F(3,44) = 8.094, p < 0.0005). Between 4 and 5 h after dFBr 
administration, nesting scores were not significantly different (F(3,44) = 2.375, NS).
6.4.1.2 dFBr has an Overall Effect on NB Between 0 h and 24 h in the Acute Administration 
(Figure 6.3A)
Twenty four hours (time 0 through 24 h) after dFBr administration, overall nesting scores 
were dose-dependently and significantly reduced (F(3,44) = 7.645, p < 0.001) with the 2 mg/kg 
(t22 = 6.213, p < 0.001), 4 mg/kg (t22 = 9.774, p < 0.001) and 6 mg/kg (t22 = 10.50, p < 0.001) 
groups significantly below the control group.
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6.4.1.3 dFBr has an Overall Effect on NB During the First 5 h in the Chronic Administration 
(Figure 6.2B)
Significant drug (F(3,220) = 4.87, p < 0.01) time (F(4,220) = 177.12, p < 0.0001) and drug by 
time interaction effect (F(12,220) = 2.29, p < 0.01) was observed in the first 5 h of the chronic 
administration.
Between 0 h and 1 h there was an overall suppression of NB (F(3,44) = 6.52, p < 0.01) 
with 4 mg/kg and 6  mg/kg being the most effective doses (t22 = 6.097, p < 0.001 and t22 = 
5.394, p < 0.001 respectively). For 1-2 h the NB declined (F(3,44) = 4.86, p < 0.01) significantly 
with 2 and 6  mg/kg showing the main attenuating effects (t22 = 3.086, p < 0.05 and t22 = 
3.210, p < 0.01 respectively). No significant effect was observed for NB between 2-3 (F(3,44) = 
1.54, NS), 3-4 (F (3,44) = 1.01, NS) and 4-5 ( F ^  = 6.52, NS) h.
6.4.1.4 dFBr has an Overall Effect on NB Between 0 h and 24 h in the Chronic Administration 
(Figure 6.3B)
Twenty four hours (time 0 through 24 h) after dFBr administration, overall nesting scores 
were dose-dependently and significantly reduced (F(3,44) = 8.85, p < 0.0001) with the 2 mg/kg 
(t22 = 4.574, p < 0.05), 4 mg/kg (t22 = 7.149, p < 0.001) and 6  mg/kg (t22 = 4.555, p < 0.05) 
groups significantly below the control group.
6.4.2 dFBr Attenuates Compulsive-Like MB Behavior (Figure 6.4)
6.4.2.1 Acute Administration (Figure 6.4A)
MB behavior were significantly reduced (F(3,44) = 64.62, p < 0.0001) 2 h after dFBr 
administration. The 2 mg/kg, 4 mg/kg and 6  mg/kg doses decreased MB dose-dependently 
compared to the control (t22 = 3.428, p < 0.01; t22 = 12.85, p < 0.001; t22 = 7.667, p < 0.001, 
respectively). The 4 mg/kg and 6  mg/kg doses also attenuated MB behavior more than the 2 
mg/kg dose (t22 = 9.426, p < 0.001 and t22 = 5.332, p < 0.001, respectively).
240
6.4.2.1 Chronic Administration (Figure 6.4B)
dFBr suppressed MB behavior significantly (F(3,44) = 40.03, p < 0.0001) in the fifth week 
of administration. The most effective doses were 4 mg/kg and 6 mg/kg which showed the 
maximum suppression of MB when compared to control (t22 = 8.643, p < 0.001; t22 = 8.554, p < 
0.001, respectively). The 4 and 6 mg/kg doses were also significantly lower than the 2 mg/kg 
dose (t22 = 7.039, p < 0.001; t22 = 6.950, p < 0.001, respectively).
6.4.3 dFBr has no Effect on Anxiety-Like OF Behavior (Figure 6.5)
6.4.3.1 Acute Administration
The total distance traveled which is used to quantify locomotor activity was not different 
among the treatment groups (F(3,44) = 1.213, NS; Figure 6.5A). No significant differences were 
also observed among the treatment groups for the time spent in center of the OF (F(3,44) = 
0.9849, NS; Figure 6.5C).
6.4.3.2 Chronic Administration
For the chronic regimen the total distance (F(3,44) = 0.30, NS) and time in center (F(3,44) = 
0.18, NS) did not differ among treatment groups (Figures 6.5B,D).
6.5 Discussion
Evidence exists for cholinergic involvement in OCD (Lucey et al., 1993; Yankelevitch- 
Yahav and Joel, 2013). Some studies have indicated exacerbation of OCD symptoms induced 
by nicotine (Abramovitch et al., 2015). In contrast to the higher rates of smoking in patients with 
psychiatric disorders, such as schizophrenia, bipolar disorder and ADHD, OCD patients report 
less smoking behavior (Bejerot and Humble, 1999; Bejerot et al., 2000; McCabe et al., 2004; 
Abramovitch et al., 2014). It has been suggested that nicotinic activation of an already 
hyperactivated fronto-striatal circuit worsens OCD symptoms (Abramovitch et al., 2015). 
However, other studies have shown that nicotine augmentation improves clinical symptoms in
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patients with OCD (Carlsson, 2001; Pasquini et al., 2005). Glutamatergic hyperactivity 
associated with OCD may also be due to mediation of glutamate release by nicotinic receptor 
activation. (Araki et al., 2002; Mansvelder et al., 2002; Pasquini et al., 2005). Studies 
investigating cholinergic involvement in glutamatergic hyperactivation suggest that nicotine 
promotes glutamatergic transmission and stabilizes hyperactivity of the neural circuit that 
originates in the orbitofrontal cortex and projects to the cingulate gyrus, the striatum and the 
thalamus (Pasquini et al., 2005). PET and fMRI studies in OCD subjects have shown elevated 
cerebral blood flow, metabolism and activation (indicators of hyperactivity) in the orbitofrontal 
cortex and amygdala in OCD (Busatto et al., 2000; Carlsson, 2000; Menzies et al., 2008). These 
regions receive substantial cholinergic innervations (Mesulam et al., 1986; Carlsson, 2000). 
Based on these prior studies, we investigated the modulatory role of a4p2 nAChRs in 
compulsive-like and anxiety-like behaviors in the compulsive-like mice model.
Administration of the novel a4p2 PAM, dFBr produced a reduction in compulsive-like NB 
and MB, but did not alter anxiety-like and locomotor activity in the OF for the acute study. A very 
similar response to chronic dFBr was observed where the treatment groups showed rapid 
suppression of NB (1 h and 2 h) and MB (2 h) after dFBr administration. OF behaviors however 
remained unaffected by the chronic treatment. These results indicate an apparent selectivity of 
dFBr for compulsive-like behaviors corroborating the hypothesis that potentiation of a4p2 
nAChRs could be an alternative approach for suppressing compulsive-like phenotype thereby 
posing significant translational potential.
In the acute administration, 4 mg/kg and 6 mg/kg dFBr doses had the largest attenuating 
effects on NB 2 h after injection, while for the chronic administration the suppression effects on 
NB was visible after the first hour and endured in the second hour with 6 mg/kg showing a more 
consistent effect. Interestingly, an earlier effect of dFBr (1 h after administration) on NB was 
observed for the chronic study indicating potential sensitization to dFBr due to repeated
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treatment. The attenuating effects gradually decreased during the next 4 h for both the 
treatment, showing that dFBr had a rapid effect. This result is consistent with the finding that 
peak levels of dFBr in the cerebrospinal fluid occur 90 min after administration in rats 
(Liu, 2013). The 2 mg/kg dFBr dose had no immediate attenuating effect on NB. A long term 
effect of this dose was however seen in both acute (after 24 h) and chronic (week 5) 
administration indicating that this dose was effective over a longer time period.
The effects of dFBr, 2 h after injection on MB behavior were generally similar to the 
effects on NB. However, at the 2 h time point in the acute treatment 2 mg/kg moderately and 
significantly reduced MB behavior. This effect was not significant in the chronic regimen. No 
significant effect was observed on NB at the same dose and time point in the acute study but 
had an effect in the chronic study. These different effects of dFBr treatment may indicate subtle 
differences in the brain mechanisms that control NB and MB behavior. Clinical studies have 
shown that some OCD patients with specific types of symptoms do not respond to first line 
therapies in a similar way (McKay et al., 2004). The doses that act to attenuate obsessions and 
compulsions in general OCD patients typically fail to produce results in treatment resistant ones 
(Albert et al., 2013). Moreover, recommended doses for first line treatments might vary 
depending on the severity of the disorder, co-morbid symptoms like anxiety and potential side 
effects (Hanna et al., 2011; Albert et al., 2013). Though, a common agreement on OCD 
subtypes is lacking, therapeutic response and results for each OCD subtype are different 
(Alonso et al., 2001). For example, fluoxetine, a common OCD drug has greater efficacy in 
washers and obsessive thoughts when compared to checkers (Farnam et al., 2008). Therefore, 
the variation in dose response to dFBr of compulsive-like MB and NB behavior adds additional 
heterogeneity to the BIG mouse for assessing drug effects on various compulsive-like 
phenotypes.
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Acute and chronic dFBr regimen failed to modulate anxiety-like (time spent in center) 
and locomotor (total distance traveled) behaviors in the OF test. Previous studies using the BIG 
mice have shown a similar effect of SSRIs like fluoxetine, which failed to reduce overall wheel- 
running locomotion in the compulsive-like BIG mice but significantly attenuated NB and MB 
behavior (Greene-Schloesser et al., 2011). Separate brain regions and signaling pathways 
influencing compulsive-like and anxiety-like symptoms are most likely the explanation for the 
observed lack of a dFBr effect in the OF test. Anxiety is attributed primarily to the amygdala and 
ventral hippocampus (McHugh et al., 2004), whereas compulsions and obsessions have been 
linked to dorsolateral prefrontal cortex (Hirosawa et al., 2013), anterior cingulate cortex 
(Fitzgerald et al., 2005), orbitofrontal cortex (Beucke et al., 2013) and dysregulation of the 
corticostriatal-thalamo-cortical circuitry (CSTC; Ting and Feng, 2011). These regions receive 
projections from the amygdala and hippocampus (McDonald, 1991; Eblen and Graybiel, 1995; 
Welch et al., 2007; Toyoda et al., 2011; Chen and Etkin, 2013) explaining the co-existence of 
anxiety along with OCD, which appears to be specific to anxiety related to compulsive-like 
behaviors rather than more generalized anxiety.
Removal or inhibition by antagonists of a4p2 nAChRs abolishes the anxiolytic effects of 
nicotine, while stimulating these nAChRs receptors with an agonist decreases anxiety-like 
behavior. In contrast, anxiogenic effects of nicotine withdrawal are enhanced by stimulation of 
a7 nAChRs and decreased by inhibition of these nAChRs receptors (Kutlu and Gould, 2015). 
Allosteric modulation of a4p2 nAChRs by dFBr did not affect anxiety-like behavior in the OF test 
in the BIG mice, suggesting that these nAChRs receptors may not be involved in the control of 
anxiety in nicotine-naive mice. A partial agonist of a4p2 nAChRs (ABT-089) caused anxiogenic 
effects in nicotine-naive mice (Yohn et al., 2014). Whether this result contradicts our findings or 
could be due to low affinity of ABT-089 for a7 nAChRs remains to be determined.
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In summary, both acute and chronic dFBr was effective in reversing compulsive-like NB 
and MB, without exerting any influence on anxiety-like and locomotory behaviors. This indicates 
the therapeutic potential of modulation of a4p2 nAChRs by dFBr for compulsive phenotypes. 
Due to the rapid rate of onset (a few hours) of the attenuating effects of dFBr on compulsive-like 
behaviors, this class of specific nicotinic subtype modulators might also provide more immediate 
suppression effects thereby provide a bridging option to other first line therapies (e.g., SSRIs) 
that display longer time courses for onset of effectiveness. dFBr maintained its attenuating 
effects on NB and MB during chronic treatment, and may therefore also represent a novel first 
line treatment. However, the cellular mechanisms leading to such acute and chronic 
suppression of compulsive-like behavior and the role of upstream and downstream targets that 
ultimately modulate phenotypic expression of the behaviors remains to be elucidated. It also 
remains to be determined if this effect of dFBr is consistent across all rodent models of 
compulsive-like phenotype. The current study thereby provides a strong impetus for further 
exploration of these factors in otherwise sparsely explored area of the role of nAChRs in OCD.
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6.7 Figures
Fig 6.1 Schedules for behavioral assessments following Desformylflustrabromine (dFBr) 
administration.
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6.1 continued: Top panel-Acute Study: mice in all experimental groups (0, 2, 4 and 6 mg/kg) 
received subcutaneous administration of vehicle or dFBr on days 1, 3 and 5. On day 1, 
immediately after injections all mice were subjected to nest-building and data were collected 1, 
2, 3, 4, 5 and 24 h after injection (nest building testing schedule). On day 3 and 5 all mice were 
subjected to marble burying (MB) and open field (OF) behaviors, respectively, 2 h after vehicle 
or dFBr injections. On days 2 and 4 mice were not given injections and were not tested. Lower 
panel-Chronic study: for the chronic study mice from all groups (0, 2, 4 and 6 mg/kg) received 
daily single subcutaneous injections of vehicle or dFBr for 32 days. On day 30, immediately 
after injection all mice were subjected to nest-building and data were collected after 1, 2, 3, 4, 5 
and 24 h after injection (nest building testing schedule). On day 31 and 32 all mice were 
subjected to MB and OF behaviors, respectively, 2 h after vehicle or dFBr injections.
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Fig 6.2 Dose-dependent effect of dFBr on compulsive-like NB behavior in compulsive-like BIG 
mice (n = 12 in each group) from 1-5 h of (A) acute and (B) chronic dFBr administration. Data 
are expressed as the mean ± standard error of the mean (SEM) for the amount of cotton used in 
grams. Statistical significance is considered as *p < 0.05, **p < 0.01 ***p < 0.001. All 
comparisons are with respect to control (saline).
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Fig 6.3 Dose-dependent effects of dFBr on overall compulsive-like NB behavior in compulsive­
like BIG mice (n = 12 in each group) 0-24 h after (A) acute and (B) chronic dFBr administration. 
Data are expressed as the mean ± SEM for the amount of cotton used in grams. Statistical 
significance is considered as *p < 0.05 and ***p < 0.001. All comparisons are with respect to 
control (saline)
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Fig 6.4 Dose-dependent effect of dFBr on compulsive-like MB behavior in compulsive-like BIG 
mice (n = 12 in each group) 2 h after (A) acute and (B) chronic dFBr administration.
Data are expressed as the mean ± SEM for the number of marbles that are 2/3 buried. 
Statistical significance is considered as **p < 0.01 and ***p < 0.001. All comparisons are with 
respect to control (saline).
250
Fig 6.5 Effect of dFBr on OF locomotory activity in (A) acute administration and (B) chronic 
administration. Anxiety-like time in center in OF in (C) acute administration and (D) chronic 
administration in compulsive-like BIG mice (n = 12 in each group).
Data are expressed as the mean ± SEM for the total distance traveled in the OF. No statistical 
significance was found.
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Chapter 7: Conclusion and Future Directions
7.1 General overview
Through this thesis work, I have strengthened the face, predictive and construct validity 
of a novel mouse model that exhibits a spontaneous compulsive-like phenotype for studying 
OCD in humans. Due to the complex symptom dimensions of human OCD patients (Leckman et 
al., 2007) it is impossible to create an animal model that recapitulates all neurobiological 
substrates and behavioral correlates of human OCD (Joel, 2006). However, investigating the 
compulsive-like, perseverant and repetitive phenotypes in rodent models can enhance the 
understanding of the compulsive behavior and its corresponding neural mechanisms in humans 
(Alonso et al., 2015). Relatively fewer studies have been performed on spontaneous and 
behaviorally induced models that exhibit phenotypic similarities of repetitiveness and stereotypy 
(Yadin et al., 1991; Joel and Avisar, 2001; Korff et al., 2008; Greene-Schloesser et al., 2011). 
Further, the associated anxiety-like, depression-like and cognitive behaviors have been sparsely 
explored in animal models of OCD (Welch et al., 2007; Shmelkov et al., 2010; Shanahan et al., 
2011). The clinical heterogeneity of the disorder due to factors, such as genetics and sex 
differences (Nestadt et al., 2010; de Mathis et al., 2011; Mas et al., 2014; Mas et al., 2016), also 
warrants studies that compare compulsive-like strains and investigates sex hormonal influence 
for face, predictive and construct validity of phenotypic subtypes and associated affective 
behaviors. Through this research I have attempted to address these factors.
7.2 Interplay of Strain And Sex Modulates Compulsive-Like and Associated Affective Behaviors 
in Spontaneous Compulsive-Like Mouse Strains.
In the experiments described in chapter 2, I evaluated the compulsive-, anxiety-, 
depression- and cognitive-like behaviors of our mouse model based on strain and sex 
differences. Previously, our lab investigated the predictive validity of the mouse model to study 
OCD (Greene-Schloesser et al., 2011). In this study only males of one of the compulsive-like
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and non-compulsive strains were used. The experiments described in chapter 2 were an 
extension of this study that accounted for males and females of replicate strains of compulsive­
like BIG mice (BIG1 and BIG2), randomly bred controls (C1 and C2) and non-compulsive 
SMALL mice (SML1 and SML2). This comparison of both males and females of all the replicate 
strains furthered the understanding of the differences in behavioral phenotypes that were 
influenced by strain and sex. The results from the study indicated that female BIG strains have 
face validity for studying OCD (Mitra et al., 2017). This was not established before. I also 
showed that in the proestrus stage of the estrus cycle when estrogen levels are considered to 
be higher in circulation, the BIG females were less compulsive than males (Mitra et al., 2017). 
One of the most important findings of this study was that sex by genotype interactions influence 
behavioral outcomes in the compulsive-like condition. Replicate, strain and sex effects were 
observed in compulsive-like phenotypes, whereas replicate, strain and sex effects influenced 
anxiety-like open field, elevated plus maze and depression-like forced swim behaviors, 
respectively. Strain differences were also observed in the mouse strains for HPA axis response 
to stress (Mitra et al., 2017). Overall this data indicates that sex and genotype interaction can 
influence obsessive compulsive symptomology in humans and strengthens the validity of our 
mouse model for studying such interactions on treatment, behavioral outcomes and 
neurobiological substrates. This can assist in pinpointing critical neurobiological candidates for 
understanding clinical heterogeneity in human OCD patients.
As a continuation to this study, it would be interesting to assess the behavioral outcomes 
in various estrous stages of BIG females, which were not performed in the current study. It 
would also be interesting to investigate baseline HPA axis response of the strains. A more 
robust cognitive assessment could be included to look for various forms of memory 
consolidation such as spatial and long-term memory.
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7.3 Predictive Validity of BIG Male Mouse Strains for Evaluation of Clinical Heterogeneity in 
OCD
Chapter 3 was a follow up of chapter 2, where I investigated the role of genetic 
background in influencing drug efficacy. Using BIG1 and BIG2 males, I evaluated the strain and 
compulsive-trait differences in response to fluvoxamine, a common first line treatment option for 
OCD patients. Chronic administration of fluvoxamine daily for 18 days resulted in a dose- 
dependent attenuation of compulsive-like nesting behavior for BIG1 male mice one hour after 
drug administration. Surprisingly, I did not observe any effect of the drug on compulsive-like 
nesting for BIG2 male mice. This was an interesting finding since fluvoxamine dose-dependently 
attenuated compulsive-like marble burying behavior in both the BIG1 and BIG2 males. 
Fluvoxamine treatment also did not affect anxiety-like open field and locomotory behaviors in 
BIG1 strain, while in BIG2 strain the effect was observed for a medium dose of 10 mg/kg. This 
data is very interesting since it establishes the predictive validity of our model to study clinical 
heterogeneity associated with OCD. Clinical studies have shown that some OCD patients with 
specific symptoms respond to first line treatment better than patients with a different symptom 
dimension (Farnam et al., 2008). These symptoms categorize patients into OCD subgroups.
Compulsive-like phenotypes in rodents such as nest-building and marble burying is 
considered to be human equivalent of hoarding (Warneke et al., 1993) and 
repetitive/perseveration behaviors (Thomas et al., 2009; Angoa-Perez et al., 2013), respectively, 
as commonly seen in OCD. Hence, these two behaviors can be used to understand two 
separate compulsive facets in humans. The trait specific response of the BIG strains to 
fluvoxamine further corroborates this hypothesis. I showed through chapter 2 that though BIG 
strains were generally less anxious than SMALL strains, within each BIG strain the BIG2 males 
exhibited more anxiety-like behavior than BIG1 strains (Mitra et al., 2017). The BIG2 strains 
responded to the fluvoxamine dose of 10 mg/kg for the time spent in center of the open field.
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This effect was not seen in other measures of anxiety and locomotion such as line crossings 
and latency to leave the center. Hence, behavioral responses to fluvoxamine in the BIG strains 
can be very specific to assessed parameters and type of anxiety-like measure and could vary 
between strains. Results from chapter 3 therefore provide a foundation for using BIG strains in 
further exploration of neurobiological mechanisms of drug resistance that is seen in OCD patient 
subtypes.
For future experimentation inclusion of female BIG strains will be considered. RNA 
sequencing of brain regions implicated in OCD that have been treated with first line drugs such 
as, SSRIs in both sexes is also a future direction. This would provide a gene expression profile 
of candidate genes and would also enable screening of new target genes. Other anxiety-like 
assessments such as elevated plus maze, light-dark chamber tests could be included to 
evaluate strain differences and treatment responses to various forms of emotionality associated 
with compulsive-like behaviors.
7.4 Predictive and Construct Validity of the BIG Compulsive-Like Female Mouse Strains During 
Surgical Menopause
Through chapter 4, I established the predictive and construct validity of the BIG1 and 
BIG2 females on the premise of the possible role of ovarian sex steroids in compulsive 
behaviors. Only few studies have so far evaluated the role of sex hormonal manipulations on 
compulsive-like phenotypes (Fernandez-guasti et al., 2006; Flaisher-Greenberg et al., 2009). 
This is critical since it can provide significant understanding of the role of ovarian sex steroids in 
regulating obsessions and compulsions. My results showed that there was an exacerbation of 
compulsive-like and anxiety-like behaviors in compulsive-like strains (BIG1 and BIG2) only with 
a trait specific variation in compulsive-like behavior among BIG1 and BIG2 females. The BIG1 
sham and ovariectomized females had higher compulsive-like nesting scores when compared to 
BIG2 sham and ovariectomized females (Mitra et al., 2016a). This replicate effect was not seen
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in the nesting scores once the ovariectomized strains were treated with either 17p-estradiol (E2) 
or progesterone (P4). The BIG strains (BIG1 and BIG2) however did not exhibit the same 
replicate effect for compulsive-like marble burying behavior. Acute E2 administration attenuated 
compulsive-like nesting and marble burying, while P4 administration had no effect on these 
behaviors. For the anxiety-like measures there was a strain specific response to E2 and P4 
administration (Mitra et al., 2016a). Overall this data adheres to the clinical heterogeneity 
associated with OCD (Fontenelle et al., 2005; Grados and Riddle, 2008; Leckman et al., 2009) 
and opens future avenues for investigating hormonal therapy for OCD patients undergoing 
surgical menopause. My results also established the construct validity of the BIG females based 
on ovarian sex steroids to study neurobiological substrates and concomitant behavioral 
correlates in OCD during surgical menopause.
A comparison between acute versus chronic ovariectomy in expression of behavioral 
phenotypes in the BIG strains could be a future direction. Also, acute versus chronic hormone 
treatment and a combinational treatment (E2+P4) experiment would be essential to understand 
the scope of hormonal intervention in the compulsive-like condition. This acute versus chronic 
ovariectomy could further elucidate the behavioral outcomes between surgical versus 
progressive menopause in compulsive-like mice. It can lead to better understanding of the 
differential role of surgical and natural menopause in influencing obsessions, compulsions, 
anxiety, depression and cognition in human OCD patients. Deciphering the role of estrogen and 
or progesterone receptor subtypes in mediating these behavioral expressions in OCD implicated 
brain regions would further address the neurobiological mechanisms attributed to these 
hormone challenge stages in compulsive-like female mice and thereby female OCD patients. 
The long term goal would be to facilitate tailor made hormone replacement therapy effective for 
various physiological stages in female OCD patients.
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7.5 Postpartum Lactation-Mediated Modulation of Behavioral Outcomes in Compulsive-Like 
Female Mice is Partly Oxytocin Mediated.
In chapter 5, I investigated the role of postpartum lactation in influencing behavioral 
expression in the compulsive-like mice. The findings indicated that lactating female compulsive­
like mice exhibited less compulsive-like nesting and marble burying when compared to non- 
lactating and nulliparous females. When treated with chronic fluoxetine the attenuation of 
compulsive-like behavior was enhanced for lactating females when compared to non-lactating 
and nulliparous controls for marble burying, but not for nest-building. For anxiety-like behaviors, 
lactating females showed more anxiogenic behavior in comparison to non-lactating and 
nulliparous females. Fluoxetine treatment did not produce an enhanced responsiveness to 
anxiety-like behavior in the non-lactating females. No difference was observed for depression­
like tail suspension behavior. The serum levels of serotonin (5-HT) and dorsal raphe nucleus 
(DRN) 5-HT immunoreactivity were also higher for lactating females. This indicates that there is 
no balancing effect between peripheral and central serotonin signaling during lactation as 
proposed in a prior study with wild type C57BL6/J mice (Jury et al., 2015). It could also mean 
that the serotonin signaling during lactation can vary in normal versus psychiatric condition 
giving rise to differential behavioral outcomes as seen in our mouse model. This however is not 
established in my current study and requires further investigation.
My data also showed that the anti-compulsive effect of lactation was eliminated in 
female mice treated with an oxytocin receptor inhibitor, while suppression of lactation through 
activation of dopaminergic system reduced the overall locomotion of the animals. This 
suppression in locomotory function resulted in less compulsive-like behavior, but more anxiety­
like behavior indicating that these were most likely not drug specific effects. When assessed in 
the depression-like tail suspension test however, the dopamine receptor agonist group of 
lactating female mice showed no difference in immobility. The oxytocin receptor antagonist
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group however had higher immobility indicating more depression-like phenotype. Overall, the 
data indicated the role of oxytocin during postpartum lactation in attenuating compulsive-like 
and depression-like behaviors. Postpartum is associated with precipitation of mood disorders 
and pre-existing psychiatric disorders such as OCD during postpartum has been sparsely 
researched (House et al., 2016; Brandes et al., 2004; Miller et al., 2013). Hence, the current 
study provides valuable insight into the lactation-mediated behavioral modulation during the 
postpartum phase. This can be replicated to human OCD patients for effective treatment 
strategies during postpartum conditions.
Including BIG1 females for strain comparison in lactation-induced behavioral and 
neurobiological outcomes would be an interesting future research objective to replicate the 
results in the BIG2 mice. Also, treating lactating compulsive-like females with fluoxetine along 
with oxytocin receptor antagonist or D2 receptor agonist would be a useful future aim in 
evaluating mechanism of enhanced responsiveness to SSRIs.
7.6 Allosteric Modulation of Nicotinic Receptor Subtype Can Attenuate Compulsive-Like 
Phenotypes.
The role of nicotinic receptor subtypes in modulating compulsive-like behavior was 
explored in the final thesis chapter. The a4p2 subtype of neuronal nicotinic receptors is 
predominantly expressed in brain regions involved in the drug-induced reward system, mood 
disorders, stress and learning (Wise, 2009; Maskos, 2010). These receptor subtypes are also 
expressed in brain regions implicated in OCD (Pena-Garijo et al., 2010; Fitzgerald et al., 2011; 
Quik et al., 2013). Hence, I investigated the modulatory role of these receptors on expression of 
compulsive-like and anxiety-like phenotypes in the compulsive-like mouse model. 
Desformylflustrabromine (dFBr), a novel positive allosteric modulator of a4p2 (Weltzin and 
Schulte, 2010), was used for this study. The results showed a consistent suppression of 
compulsive-like nest-building and marble burying behavior in the BIG1 males treated both
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acutely and chronically with dFBr. dFBr however did not have any modulatory role on 
locomotion and anxiety-like behavior in the open field (Mitra et al., 2016b). The findings from 
this chapter point towards the potential role of nicotinic receptor subtype potentiation in 
attenuating compulsive-like behaviors. This could have significant translational prospect for 
treatment of OCD and OCD related (OCRD) disorders.
Future studies would aim at investigating the neurobiological mechanisms attributing to 
this attenuation of compulsive-like behavior due to dFBr administration.
7.7 Overall Conclusion
Finally, this research does not intend to establish a mouse model that represents all 
aspects of human OCD. This would be impossible, considering the species specific complexity 
that happen in human OCD patients based on personal experiences and events. Through this 
research, I have attempted to understand the complex interplay of sex and strain in influencing 
neuronal building blocks of behavior in a spontaneously compulsive-like mouse model. This 
thesis also highlights the importance of ovarian steroids, postpartum lactation and modulation of 
the cholinergic system in influencing behavioral expression in the compulsive-like mice. This 
can contribute to the understanding of analogous behaviors in human OCD patients and the 
variables such as genetics, sex differences and physiological stages that influence the 
symptomology and neurobiology of the disorder.
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■ Hbnn reaeaitf [fra m e .1 ;iar on1/  actt-S t* cEK.’tteo ,Vn die ^ajTOieJ l^CUC ^ io tc o  san ie  
^ a -tn rn d  Ensure personM' rai-e reeo apgromarieiy iTaVTfd fo ^srtiTTi m&v- dUfes.
■ Se svtare c f sra1^  ifetfier^acic^t; in iFSrfcr w.ti apprusal orfy ejfV.fc as diis menage and 
Tie oocynenrs .l conians; it toes net 'TCiV aoprwa.' for tite rte & lo n i rfn n o v a k  ynu ™ y  t&se 
sormtneo e  r.ie \a c u c  ^ w te tc #
■ B is ie  anrtrai .'esm .t1i m x ™ 1 a<e airarE o ' (Vs- rEporihg pfooefrrzs s r  Jie fator/T-g
Reoeved.
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De® rrte - 3 .2D11 
De® r t f  3 .2C11 
D e ® n t f  3.2E15
"Tls x fo r  is ituded on ;be Decerrser 11. 2C IACUC Agerto.
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